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1.1 Neuropathic pain 
Nociceptive pain is a basic function of the nervous system that functions as an important defense 
mechanism that protects tissue from immediate injury and helps survival of the individual. This is 
evident in congenital SCN9A channelopathy that results in a complete inability to sense pain (Cox et 
al. 2006). The inability to sense pain predisposes the individual to injuries and mutilations early in life 
and has a dramatic effect on life expectancy (Manfredi et al. 1981). 
Neuropathic pain, on the other hand, is a maladaptive form of chronic pain caused by a primary 
injury or lesions in the central or peripheral nervous systems. Cutting and crushing injuries are 
common causes of neuropathic pain, for example after limb amputations or during a slipped disk 
injury respectively. Some diseases like multiple sclerosis, HIV/AIDS and diabetes can result in neural 
degeneration and disrupt the processing of pain signals causing pain. Also neurotoxic chemicals and 
drugs such as those used in cancer chemotherapy (e.g. Cisplatin, Oxaliplatin, and Vincristine) can 
cause pain by damaging neurons. (Boyce-Rustay and Jarvis 2009, Farquhar-Smith 2011, Manas et al. 
2011, Nickel et al. 2012, Windebank and Grisold 2008). The main characteristics of neuropathic pain 
establish themselves in the unpleasant and abnormal sensations such as an increased response to 
painful stimuli (hyperalgesia) and painful response to benign stimulation (allodynia). 
About 7-8 % of the population suffers from chronic neuropathic pain according to epidemiological 
studies. The effects of pain on people’s quality of life can be quite dramatic. The extended symptoms 
of chronic pain include for example decrease in mobility, inability to work, and depression. This is 
exacerbated by the difficulty in treating neuropathic pain properly (Manas et al. 2011, Bouhassira et 
al. 2008, Torrance et al. 2006). 
Since there is currently no proven way to prevent or cure neuropathic pain, treatment for chronic 
neuropathic pain often requires a multifaceted approach of drugs, surgery, rehabilitation and 
psychological treatment. Several classes of drugs (see Table 1) are sometimes effective in treating 
neuropathic pain, however complete relief is very rare. Antidepressants and anticonvulsants are 
most commonly used. NICE guidelines recommend using amitriptyline, a tricyclic antidepressant, or 
pregabalin, an anticonvulsant, as first line treatment, if no contraindications or comorbities prevent 
its use. Switching between amitriptyline and pregabalin or combining them is then considered 






Table 1 Drugs used for the treatment of Neuropathic Pain (Beers and Berkow 2012) 
Class Drugs Comments 
Anticonvulsants Carbamazepine, Gabapentin, 
Phenytoin, Pregabalin, Valproate 
Gabapentin is the most 
widely used, while 
pregabalin is a common 
second choice 





Clonidine, Tizanidine  




Memantine, Dextromethorphan  
Oral Na channel blockers Mexiletine Used only for neuropathic 
pain 
Opioids Butorphanol, Codeine, 
Hydromorphone, Levorphanol, 
Meperidine, Methadone, Morphine, 
Nalbuphine, Oxycodone, 
Oxymorphone, Pentazocine 
Should only be considered as 
third-line treatment 
Topical Capsaicin, EMLA®, Lidocaine   
Other Baclofen, Pamidronate  
 
Opioid analgesics sometimes provide some relief but are less effective than for nociceptive pain, and 
have many and sometimes severe side effects and may lead to abuse and addiction. Opioids should 
only be considered as third-line treatment according to the clinical guidelines of the United 
Kingdom´s National Institute for Health and Clinical Excellence (NICE) (i.e. after amitriptyline and 
pregabalin treatment has failed) (NICE 2010). In the end, the goals of the treatment are to reduce 
the pain as much as possible, delicately balancing the side effects versus pain relief and helping 
patients deal with any residual pain. 
Given the problems with treating neuropathic pain and the consequences to people’s quality of life, 
as well as the high prevalence of the condition it is important to conduct research on this problem, 
in particular novel pathways that could lead to pain relief without the damaging side effects of 
current treatments. 
1.2 Models for neuropathic pain 
Animal models are very important for research into the biological mechanism and potential 
therapies of neuropathic pain. A plethora of models have been reported in the literature. Jaggi et al 





models have many different characteristics and advantages and have made a great contribution to 
the understanding of pain mechanisms. The models are variously induced by physical injury to 
peripheral nerves, disease models such as diabetes-induced neuropathy, or by drugs such as anti-
cancer agents like vincristine or anti HIV drugs like the nucleoside reverse transcriptase inhibitor 
zalcitabine. 
1.2.1 SNI model 
The model applied in this work is the SNI model 
developed by Decosterd et al (Decosterd and Woolf 
2000). In this model two of the terminal branches of 
the sciatic nerve, the tibial and common peroneal 
nerves, are ligated leaving the sural nerve intact (see 
Figure 1). Cutting these two branches produces a 
neuropathic pain like sensation in the paw of the 
mouse. Two variants of this model have been 
developed where the ligation of different nerve 
combinations are used, in one variant the common 
peroneal nerve and sural nerve are ligated leaving the 
tibial nerve intact, and in the other the tibial nerve is 
ligated leaving the sural and common peroneal nerves 
intact. (Decosterd and Woolf 2000, Bourquin et al. 
2006) 
Mechanical and thermal hyperalgesia occur within 24 
hours of the injury showing the greatest effect after 
about one week post injury.  
The SNI is relatively simple to perform compared to many other models for neuropathic pain. After 
anesthesia the skin of the left hind leg of the mouse is shaved and a cut made directly through the 
biceps femoris muscle. The three terminal branches of the sciatic nerve, the tibial, common peroneal 
and sural nerves, now being visible, the tibial and common peroneal nerves are ligated with 5-0 silk 
followed by an axotomy of 2 mm distal nerve. Care must be taken not to touch or stretch the sural 
nerve as this could interfere with the sensitization. (Decosterd and Woolf 2000) 
Figure 1 Schematic overview of the SNI 
Adapted from Decosterd et al 2000. Two of the 
terminal branches of the sciatic nerve, the 
tibial and common peroneal nerves, are ligated 
leaving the sural nerve intact branches 
producing a neuropathic pain like sensation in 





The SNI operation produces consistent, robust, and substantial changes in thermal and mechanical 
sensitivity that closely mimic clinical neuropathic pain and therefore is very useful as an 
experimental model. 
1.3 Role of Nitric oxide in pain 
Nitric Oxide (NO) has emerged as an important pro-nociceptive signaling molecule (Schmidtko, 
Tegeder and Geisslinger 2009) which, however, may also reduce hyperexcitability (Jin et al. 2011). It 
is likely that the effects of NO release depend on the cellular redox status and the amount and site of 
its production by nitric oxide synthases (NOS).  
Reduction or inhibition of neuropathic and inflammatory pain has been achieved with a variety of 
ways that influence nitric oxides effects or production, such as:  
• Chemical inhibition of NOS (Meller et al. 1990, Minami et al. 1995, Aley, McCarter and 
Levine 1998, Schmidtko et al. 2008, Schmidtko et al. 2003). 
• Inhibitors of the NOS-coenzyme tetrahydrobiopterin (Tegeder et al. 2006, Miyamoto et al. 
2009).  
• Deletion of neuronal NOS (Boettger et al. 2007). 
• Deletion of inducible NOS (Guhring et al. 2000). 
However, the intrathecal injection of NO donors has been shown to both increase and decrease 
sensitivity to nociceptive stimuli (Schmidtko et al. 2009, Tegeder et al. 2002).  
NO is known to partly exert its effect in pain via reduction of cGMP production and attenuation of 
protein kinase G activation (Schmidtko et al. 2008, Schmidtko et al. 2003). However, NO is a 
multifaceted molecule and in addition to the activation of soluble guanylylcyclase (sGC) it may also 
modulate enzyme function or protein interactions and transport at various levels by direct protein S-
nitrosylation (SNO) of critical cysteine residues (Matsushita et al. 2003, Whalen et al. 2007, Hara et 
al. 2005, Jaffrey et al. 2001, Yoshida et al. 2006, Nott et al. 2008, Uehara et al. 2006, Tian et al. 2008, 
Gu et al. 2002).  
1.4 S-Nitrosylation (SNO)  
Protein S-Nitrosylation is a post translational covalent addition of nitric oxide to the thiol group of 
cysteine. This reaction is an electrophilic attack of nitrosonium (NO+) equivalent on the sulfur, 
followed by deprotoation. Reactions involving nitroxyl (NO-) equivalents or NO radicals have also 







2 NO + O2     2 NO2 




- + RSH   RSNO + HNO2 
Where O2 acts as an electron acceptor and RSH is the substance to be nitrosylated. Under 
physiological conditions where the concentration of NO is in the nano-molar and oxygen in the 
micro-molar ranges the first reaction proceeds rather slowly and is therefore the rate limiting 
reaction. However it has also been shown that specific proteins can catalyze SNO synthesis. For 
example ceruloplasmin, a plasma protein involved in iron metabolism and an antioxidant, was 
shown to generate low molecular RSNO, in particular S-nitrosoglutathione (GSNO). Type I copper 
servers as the electron acceptor and NO+ is transferred to the thiol of glutathione. (Inoue et al. 
1999) Hemoglobin can also serve to catalyze SNO formation (Gow and Stamler 1998). SNOs are also 
formed by nitric oxide synthase (NOS), either directly through NO-formation or through the 
coproduction of NO and superoxide in the presence of glutathione (Schmidt et al. 1996). Thus under 
physiological conditions S-nitroso-proteins are not produced by a direct reaction between NO and a 
thiol group but requires oxygen, transition metals or other relevant electron acceptors (Lindermayr, 
Sell and Durner 2009). Alterations in the subcellular environment (e.g. changes in pH, hypoxia, or 
other disease related changes) can affect the occurrence and reversibility of S-nitrosylation. 
 
1.4.1 Detection and analysis of SNO 
Detection of SNO modifications of proteins in tissues has proven difficult to achieve (Torta et al. 
2008). Due to low in vivo levels and instability of the S-NO bond, detection of SNO directly from 
complex mixtures by mass spectrometry (MS) is very inefficient. Detection of modifications in 
synthetic or purified recombinant proteins was achieved by electrospray ionization-mass 
spectrometry (Mirza, Chait and Lander 1995, Hao and Gross 2006, Lee et al. 2007).  Although 
application of this approach is limited, it has the advantage to require little sample manipulation and 
therefore may better represent the in vivo situation, by avoiding loss of nitrosylation modifications. 
The simplest methods to detect nitrosylation of proteins are chemoluminescent or colorimetric 
techniques, such as diaminofluorescein fluorometry (Itoh et al. 2000) or the Saville-Griess assay 
(Saville 1958), respectively. These methods can quantify the total content of SNO in samples but do 
not allow identification of the modified proteins. 
The most commonly applied approach to detect and identify SNO modifications is the biotin-switch 
technique (BST) developed by Jaffrey et al. (Jaffrey et al. 2001). In this method, the SNO modification 





exploited in many ways such as: affinity pull down of labeled protein (Jaffrey et al. 2001, Dall'Agnol 
et al. 2006), identification by anti-biotin antibodies (Jaffrey et al. 2001), or direct identification of 
SNO labeling sites by mass spectrometry (Hao et al. 2006, Whalen et al. 2007). The biotin-switch is 
highly specific for SNO modifications. However, the method is technically challenging and laborious. 
Other drawbacks are that acetone precipitation steps can cause loss of sample, and that there is a 
risk of false positives due to endogenous biotinylation and photocatalysed biotinylation of blocked 
thiols.  
The biotin switch with an avidin affinity pulldown step does not discriminate between multiple SNO 
sites on the same protein. This can be a substantial problem as one study found up to 45% of SNO 
proteins to have more than one SNO site (Doulias et al. 2010). To account for this it was part of my 
project to develop an Elisa based detection method. For this approach the nitrosylation sites were 
labeled with biotin followed by sandwich ELSIA purification with target specific antibodies and 
detection of biotinylation with an anti-biotin infrared-labeled (700) fluorescent antibody. The use of 
an anti-biotin antibody allows for more than one SNO site per protein to be detected similar to the 
fluorescent labeling. The method however, does not account for lack of antibody specificity 
(Scheving et al. 2012). 
Further BST-based methodological developments utilize other switch labels of nitrosylation sites. 
His-Tag peptide label has the advantage of binding irreversibly to the modified cysteine and 
identification of the modified site by MS is facilitated by the generation of a diagnostic peptide 
(Camerini et al. 2007).  
Two-dimensional difference gel electrophoresis (2-D DIGE) can be applied if the SNO modifications in 
the samples are labeled with fluorescent dyes (Kettenhofen et al. 2008, Chouchani et al. 2010). 
When two samples (e.g. control vs. disease) are labeled with Cy3 and Cy5 and separated in one 2-D 
gel, relevant in vivo nitrosylation for each condition can be filtered and identified by MS. The 
difference approach also reduces false positive results since they are identically detected in both 
samples and can be excluded from further studies. The main drawbacks of this method are high 
costs and technical challenge. Moreover, this technique tends to identify mainly abundant proteins. 
A recent development of using mass spectrometry to detect and identify SNO-modifications is the 
SNO-Site Identification (SNOSID). The SNOSID method utilizes the Biotin-switch method to label 
SNO-modifications followed by trypsin digestion and affinity purification resulting in enrichment of 
peptides that contain the NO target cysteine (Hao et al. 2006). Purified peptides are then eluted and 
analyzed by mass spectrometry. This potentially allows a high throughput identification of SNO 






The ICAT (isotope-coded affinity tags) method utilizes labeling reagents consisting of a reactive 
group, an isotopically coded linker, and an affinity isolation tag. After labeling the samples with two 
different isotopes, the samples are combined and subjected to protease digestion, affinity pull-
down, and analysis by mass spectrometry. This allows the relative quantification of each analyzed 
protein between the samples, although as with the other methods the sample handling can cause 
loss of sample and mostly abundant proteins can be identified (Gygi et al. 1999). 
Ischiropoulos et al. developed a method where phenylmercury-biotin compounds are used to react 
directly with the S-NO group followed by purification upon capture and subsequent release from 
agarose beads. The proteins or peptides are then sequenced by MS. This method avoids the use of 
ascorbate for the reduction and thus is less likely to falsely identify disulfide bridges or other 
oxidative modification instead of S-nitrosylation (Doulias et al. 2010). 
Using stable isotope labeling by amino acids in cell culture (SILAC) (Ong et al. 2002, Gygi et al. 1999, 
Zhu et al. 2002) it is theoretically possible to simultaneously detect nitrosylated proteins and non 
nitrosylated proteins and calculate the level of nitrosylation as a ratio of expressed proteins. This 
approach could be useful to circumvent many of the disadvantages the currently available methods 
have. SILAC utilizes metabolic incorporation of a given “heavy” form of amino acids into the proteins 
where the amino acids have been incorporated with stable isotopic nuclei (e.g. deuterium, 13C, 
15N). Thus, after growing the target organism (i.e. cells or animals) in “heavy” labeled culture media 
or with heavy diet the “heavy” protein can be extracted. When mixed with extracted proteins from 
any experimental setting with the same or like organism and analyzed by mass spectrometry the 
ratio of heavy and light proteins in each sample can be determined and compared between 
experimental groups. 
By labeling cysteine residues in the standard with iodoacetamide (IAM) and N-ethyl-maleimide 
(NEM) (in a 1:1 ratio) a standard for the detection of SNO modified cysteine can be established. 
When the samples are first dark labeled with either of these cysteine reactive agents, and then after 
precipitation and ascorbate reduction of SNO sites the remaining cysteine are labeled with the 
respective other cysteine reactive agent, and finally mixed with the SILAC standard, the ratio of SNO 
labeled proteins versus the heavy cysteine labeled proteins can be assayed by mass spectrometry 
due to the mass difference of the proteins peptides. The non-nitrosylated portion (i.e. dark labeled) 
of the same protein is then in a similar manner compared with the heavy standard and the ratio of 














The main advantage of this approach is the simultaneous identification of both changes in protein 
expression and the level of nitrosylation. Other prominent advantages are the increased spectrum of 
proteins as this approach is not as limited by the poor resolution of hydrophobic proteins in DIGE, 
and the direct identification of the SNO site as well as a more confident identification of the SNO 
proteins. This approach also allows determination of the level of modifications of different SNO sites 
within the same protein. 
Once the sites of S-Nitrosylation have been determined it is possible to elucidate the effects of the 
nitrosylation by using point mutations of the respective cysteine. For example, by introducing a 
C694S point mutation into NADPH oxidase 5 (Nox5) Qian et al were able to show a dramatically 
lowered Nox5 activity, NO sensitivity, and biotin labeling of Nox5. Other cysteine point mutations in 
Nox5 did not show these effects, suggesting that endogenously produced NO can directly S-
Nitrosylate and inhibit the activity of Nox5 (Qian et al. 2012). Another example can be found from 
Tang et al. They showed how S-Nitrosylation of the Apo2L/Trail Receptor DR4 induced by the NO 
donor nitrosocobolamine promotes cell death. A point mutation in DR4 of cysteine 336 to alanine 
desensitized cells against cell death induced by nitrosocobolamine and reduced biotin labeling of 
DR4. The C336A mutant also displayed a reduced caspase-8 enzymatic activity following 
nitrosocobolamine compared with other mutants, highlighting the importance of S-Nitrosylation on 
the protein’s activity.(Tang et al. 2006) 
Thus there are many methods available for the detection of protein S-nitrosylation (see Table 2), 
though none of them is alone sufficient to provide conclusive evidence for S-nitrosylation. This 
requires the use of multiple methods to triangulate and confirm that the proteins are truly S-
nitrosylated. To then address the functional consequences of SNO of a single protein point 
mutations of the respective cysteine are required and functional assays must be developed and 











Site ID Purification Labeling Reduction 
Direct MS X √ √ X X X 
Organomercuric X √ √ Biotin-Avidin Biotin X 
SNOSID X √ √ Biotin-Avidin  Biotin Ascorbate 
ICAT √ (MS) √ √ Biotin-Avidin  Biotin Ascorbate 
Biotin switch √ (Immuno-
detection) 
√ X Biotin-Avidin  Biotin Ascorbate 
SNO-DIGE √ (Fluroscent 
labeling) 






Diamino fluorescein √ (total) X X X X X 
Saville assay √ (total) X X X X X 
SNO-SILAC √ (MS) √ √ X Thiol reactive agent Ascorbate 
 
1.4.2 S-Nitrosylation in pain 
Presently not many studies have addressed the implications of SNO in pain. Lu et al. published in 
2011 that rapid S-nitrosylation of actin by NO donors was implicated in inhibitory action on 
inhibitory synaptic transmission in the spinal dorsal horn (Lu et al. 2011). However a variety of 
proteins that are known to be involved in pain processing, and neuronal or glial adaptions to ongoing 
nociceptive stimulation or injury have been shown to be targets of S-nitrosylation (see Figure 3). 
Specifically S-nitrosylation affects the functions of: 
• glutamate receptors (Lipton et al. 1993, Kim et al. 1999) 
• receptor trafficking (Huang et al. 2005, Selvakumar, Huganir and Snyder 2009) 
• transcription factors (Choi et al. 2000, Reynaert et al. 2004, Li et al. 2007, Tsang et al. 2009) 
• pro-inflammatory enzymes (Gu et al. 2002) 
• heat-shock proteins (Martinez-Ruiz et al. 2005) 
• proteases (Mannick et al. 2001),  
• cytoskeletal (Lu et al. 2009) and synaptosomal (Palmer et al. 2008) proteins,  
• Ion channels (Evans and Bielefeldt 2000, Yoshida et al. 2006, Jian et al. 2007, Asada, 






Figure 3 Nitric oxide signaling pathways. 
NOS activity depends on the availability of its enzyme cofactor, tetrahydrobiopterin (BH4), which is 
produced in a multistep synthesis cascade initiated by the GTP cyclohydrolase 1 (GCH1). NO 
activates sGC, which produces cGMP, leading to activation of PKG, phosphodiesterases (PDE2 and 
PDE3), CNGs, and HCNs. In neurons, activation of PKG regulates neurite outgrowth and collapse and 
neurotransmitter release. In addition to this classic NO/sGC/PKG signaling pathway, NO modifies 
nociceptor sensitivity and synaptic functions by direct S-nitrosylation of glutamate receptors, 
scaffolding and motor proteins, ion channels, kinases, proteases, and redoxins. AC, adenylyl cyclase; 
Hsp, heat-shock protein; JNK, c-Jun N-terminal kinase; K2P, two-pore potassium channel; Mdm2, 
murine double minute 2; MLC, myosin light chain; NOX, NADPH oxidase; Npr, natriuretic peptide 
receptor; Prx, peroxiredoxin; SERCA, sarco/endoplasmic reticulum Ca2-ATPase; SerR, serine 
racemase; UB E3, ubiquitin 3 ligase; VASP, vasodilator-stimulated phosphoprotein. 
 
 
Although this may seem like quite diverse targets there are three main schemes that emerge from 
this on closer inspection. The three major schemes that potentially modulate pain by SNO are: 
1) Ion channels 
2) Membrane fusion and fission 
3) Proteasome or protease-mediated protein degradation 
Thus NO mediated S-nitrosylation may serve to propagate the nociceptive signals similarly to the 
regulation by phosphorylation and de-phosphorylation, and might have just as much impact on the 





1.4.2.1 Ion channels and membrane fusion and fission proteins 
Although the methods currently available for the identification of S-Nitrosylation are not very 
effective for membrane proteins several important candidates in terms of neuropathic pain have 
been identified as S-Nitrosylated (see Table 3). However, most targets have only been identified in 
cell culture using NO-donors such as NONOate or CysNO, as a result the impact of S-Nitrosylation of 
most of these proteins in vivo remains to be elucidated. 
The best studied example of SNO affecting ion channel gating is the N-Methyl-D-aspartic acid 
(NMDA) glutamate type receptor. Direct S-nitrosylation of the NR2A subunit at cysteine 399 results 
in a change of its channel gating properties that curtail the excessive calcium influx in neurons and in 
protects from excitotoxic insults (Lipton et al. 1993, Kim et al. 1999, Choi et al. 2000). Glutamate is 
one of the most important primary excitatory neurotransmitters and pharmacological experiments 
have shown that blocking the NMDA receptor reduces nociception and prevents nerve injury-evoked 
death of nociceptive neurons in the dorsal horn (Scholz et al. 2005, Laughlin, Kitto and Wilcox 1999). 
This suggests that glutamate excitotoxicity and NMDA receptor hyperexcitability are involved in 
neuronal death and development of neuropathic pain, and that S-nitrosylation may have a 
protective role.  
The NMDA receptor has also been shown to be indirectly controlled by S-nitrosylation of several 
proteins interacting with the receptor. Overstimulation of the NMDA receptor and permanent SNO 
of Dexras1 may cause iron overload and neurotoxicity (Jaffrey, Fang and Snyder 2002, Cheah et al. 
2006). NMDA receptor activation enhances the SNO of astroglial serine racemase (ASR) through 
activation of nNOS that releases NO into the postsynaptic neuron. SNO of ASR in turn increases the 
release of D-serine, a co-agonist of glutamate and leads to the development of long-term 
potentiation (Mustafa et al. 2007, Chiang et al. 2007). Proteomic screening has additionally detected 
SNO in the excitatory amino acid transporter 2 and glutamine synthase (Goerg et al. 2007, 










Table 3 S-Nitrosylation of ion channels and membrane proteins 
Target protein SNO Site Effect of SNO on target 
function 




gated channels  





N.D. Modulation of nNOS and 
GluR6 coupling and 
subsequent activation of 
c-Jun N-terminal kinase 
signaling.  
Increase of nociceptive 
neuron sensitivity 
(Yu et al. 2008) 
KCNQ1 potassium 
channel 
Cys445  Modulation of channel 
function 
Increase of nociceptive 
neuron sensitivity 




N.D. Blocks hKv1.5 channels by 
SNO and by a cyclic GMP-
dependent mechanism 
Increase of nociceptive 
neuron sensitivity 




Cys3635 Reduction of RyR1 open 
channel probability and 
Sarcoplasmic reticulum 
Ca2+ leak 
Modulation of ESPCs in 
lamina II nociceptive 
neurons in spinal cord 
(Sun et al. 2001, 
Salanova et al. 
2008, Bellinger 
et al. 2009, 
Aracena-Parks 
et al. 2006) 
Ryanodine receptor 
2  (RyR2) 
N.D. Sarcoplasmic reticulum 
diastolic calcium leak and 
arrhythmogenesis 
Modulation of ESPCs in 
lamina II nociceptive 
neurons in spinal cord 
(Gonzalez et al. 
2007) 
Transient receptor 





Nitrosylation of native 
TRPC5 upon G protein-
coupled ATP receptor 
stimulation elicits entry of 
Ca2+ into endothelial cells. 
Increase of nociceptive 
neuron sensitivity 




N.D. Increase of calcium influx Increase of nociceptive 
neuron sensitivity 







Inhibition of SNARE 
complex disassembly, 
reduction of synaptic 
vesicle exocytosis, 
increase of membrane 
insertion of AMPA-R  
GluR2 
Decrease of nociceptive 
neuron sensitivity to 
noxious stimuli, decrease 
of LTP at nociceptive 
synapses. 






Cys399   Reduction of calcium 
influx 
Prevention of glutamate 
excitotoxicity and 
hyperexcitability 
(Lipton et al. 






Reduction of calcium 
influx 
Prevention of glutamate 
excitotoxicity and 
hyperexcitability 
(Takahashi et al. 
2007) 
Stargazin Cys302 Increase of AMPA-R 
membrane insertion 
Increase of nociceptive 
neuron sensitivity. 
(Selvakumar et 
al. 2009),  
Syntaxin 1 Cys145 Regulation of synaptic 
vesicle exocytosis 
Prevention of excess 
glutamate or 
neuropeptide release. 




Increase of channel gating 
for calcium entry 
Increase of nociceptive 
neuron sensitivity. 







The ATPase N-ethylmaleimide-sensitive factor (NSF) is a crucial protein for membrane trafficking in 
many cells, including neurons, and functions as a soluble NSF attachment protein receptor (SNARE) 
chaperone that binds to SNARE complexes and uses the energy of ATP hydrolysis to disassemble the 
complex, thus facilitating SNARE recycling. Upon S-nitrosylation of NSF, vesicle exocytosis was 
reduced because SNO-NSF lost the ability to disassemble the SNARE complex, despite maintaining its 
ATPase activity. Nitric oxide also inhibited the dissociation of NSF from the synaptic vesicle protein 
syntaxin which itself is modified by S-nitrosylation and is involved in the regulation of 
neurotransmitter release (Palmer et al. 2008, Huang et al. 2005, Sollner and Sequeira 2003, 
Matsushita et al. 2003). Syntaxin 1a-deficient mice developed enhanced allodynia after peripheral 
nerve injury and dorsal horn excitatory postsynaptic currents were enhanced in both frequency and 
amplitude in these mice (Takasusuki et al. 2007). 
Thus direct S-nitrosylation of one crucial ATPase may modify nociceptive signal transduction at 
multiple sites with variable outcome, depending on the stimulus and the site of NO release and 
being mediated mainly by adaptation of membrane fusion and fission and receptor 
compartmentalization.  
1.4.2.2 Proteasome or protease-mediated protein degradation 
Disruption in protein folding and degradation are the hallmark of many neurodegenerative disorders 
such as Multiple Sclerosis and Alzheimer´s disease. Recent evidence suggests that the disruption of 
these processes can be caused by redox reactions triggered by excessive levels of NO. S-
nitrosylation-mediated targeting of protein degradation pathways including autophagy and 
proteasomal degradation may constitute a general mechanism by which nitric oxide interferes with 
the removal of misfolded proteins and the stability of transcription factors and hence long-term 
adaptations to neuronal stress. S-nitrosylation may also be important for the quality control of 
mitochondria. Under neuronal stress, including that caused by axonal injury, there is an up-
regulation of heat-shock proteins such as the 27-kDa heat-shock protein (Lewis et al. 1999, Benn et 
al. 2002) and protein disulfide isomerase (PDI) (Walker et al. 2010). This adaption helps the neuron 
survive the injury by facilitating protein maturation and transport of unfolded secretory proteins. 
Uehara et al. have shown that the S-nitrosylation of PDI, as well as various chaperones, is linked with 
protein misfolding and neuronal death (Uehara et al. 2006). S-nitrosylation of PDI compromises its 
catalytic chaperone and thiol-disulfide oxidoreductase function, leading to accumulation of 
misfolded proteins and, eventually, cell death. Thus, excessive NO levels may interfere with an 





In addition S-nitrosylation may affect protein stability by modulation of ubiquitination and 
proteasomal degradation, S-nitrosylation has been found to regulate the activity of hypoxia-
inducible factor (Li et al. 2007), tumor suppressor p53, iron response proteins, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and IκB/NF-κB by regulating the degradation of the respective 
S-nitrosylated protein, a regulatory partner, or the ubiquitin E3 ligase. Thus, although the 
mechanism and localization of S-nitrosylation may differ and depend on the close association of NOS 
and the respective targeted protein, S-nitrosylation ultimately affects the ability of the neuron to 
dispose of protein waste which may impact on neuron survival and hence, development and 
maintenance of chronic pain (DiAntonio and Hicke 2004, Bingol and Schuman 2005, Sutton and 
Schuman 2006).  
Table 4 S-Nitrosylation in proteasome or protease-mediated protein degradation 
Target protein SNO 
Site 
Effect of SNO on target 
function 
Presumed consequence of 
SNO in nociception 
Source 
β-arrestin 2 Cys410. Promotion of GPCR 
endocytosis and recycling 
Function of cannabinoid 
and opioid receptors and 
tolerance. 
(Ozawa et al. 
2008) 
GAPDH N.D. Increase of binding to and 
signaling of Siah 
Increase of glutamate 
excitotoxicity 
(Hara et al. 2005, 
Mohr, Stamler 
and Brune 1996) 
GOSPEL Cys47 Facilitation of GAPDH-
GOSPEL binding, and 
neuroprotection by GOSPEL 
Decrease of glutamate 
excitotoxicity 
(Sen et al. 2009) 
NF-κB p50 Cys62 Inhibition of DNA binding 
capacity 
Anti-inflammatory (Kelleher et al. 
2007) 
NF-κB p65 N.D. Inhibition of DNA binding 
capacity 
Anti-inflammatory (Kelleher et al. 
2007) 
Hypoxia-inducible 
factor 1 (HIF-1) 
Cys533 Stabilization and increase of 
transcriptional activity 
Increase of nociceptive 
neuron sensitivity and pro-
inflammatory 
(Li et al. 2007) 
Protein-disulphide 
isomerase (PDI) 
N.D. Inhibition of catalytic 
activity, accumulation of 
polyubiquitinted proteins 
and activation of the 
unfolded protein response 
Increase of ER stress (Uehara et al. 




Rodriguez-Muela et al. recently published a study showing that autophagy and protein degradation 
can promote survival of retinal ganglion cells after optic nerve axatomy in mice (Rodriguez-Muela et 
al. 2012). Neuronal death after axonal injury is believed to be crucial in the development of 
neuropathic pain, and thus any process that interferes or enhances the odds of a neuron recovering 
from injury is likely to attenuate chronic pain. Sarkar et al. were able to show that through inhibition 





overexpression of nNOS, iNOS, or eNOS impaired the formation of autophagosomes. Sarkar et al. 
also showed that inhibition of NOS enhanced the clearance of autophagic substrates and reduced 
neurodegeneration in models of Huntington´s disease, leading to the conclusion that nitrosative-
stress mediated protein aggregation in neurodegenerative diseases may be in part due to inhibition 
of autophagy (Sarkar et al. 2011). 
In light of the increased NO content of neurons after injury and the fact that the cGMP/PKG pathway 
does not fully explain the effects of NO in pain it may be hypothesized that the pro-nociceptive 
effects of NO are also mediated through the direct S-Nitrosylation of proteins. The main mechanisms 
of S-Nitrosylation in adaption to pain signaling are most likely found in ion-channels, receptors, 
mitochondrial quality control, as well as proteins involved in protein recycling. It is thus interesting 
to study the S-nitrosoproteome of the neuropathic pain model to figure out which proteins are 






1.5 Context and problem statement 
With increasing evidence of the pro-nociceptive role of NO in pain, and that the cGMP and PKG 
pathway do not entirely explain NO´s effect, it is important to elucidate the functional role of SNO in 
this context. The limited number of studies into the effects of SNO in pain and autophagy leave 
much room for investigation and contemplation. To address this lack of information I set out to 
investigate the SNO-proteome of the spinal cord after induction of neuropathic pain by SNI 
treatment. It is thus the aim of this study is to identify potential targets of S-Nitrosylation and de-
nitrosylation in neuropathic pain in the mouse spinal cord. However, limits to this investigation are 
noted from the start, mainly as the methods used are expensive and time consuming and all 
underrepresent membrane proteins thus making the exploration of the full membrane SNO-
proteome impossible. With respect to the animal model, I limit the study to the role of S-
Nitrosylations in neuropathic pain induced by the SNI model. Although an investigation into the role 
of other types of chronic pain, such as inflammatory pain, would be interesting other types of pain 
models are nevertheless not covered. The study is also limited to S-Nitrosylations and does not 
investigate any of the other various oxidative modifications of cysteine thiols such as disulfide 
bridges, sulfoxidation, or glutathionylation. The study is also limited to the spinal cord of the mouse, 
although certainly the tissue from the dorsal root ganglia, brain sensory cortex, and the thalamus 
would be interesting as well they are not investigated, in part due to the small amounts of tissue 
recoverable from these parts.  
Emerging from the initial screening as one of the most interesting schemes of potential targets for 
SNO for us, as well as recently being related to pain and pain recovery, a secondary aim of this study 
is to investigate the potential role of NO and SNO in proteasomal degradation and autophagy. Here I 
have limited the scope to autophagy induced by rapamycin (macro autophagy) in a cell culture of 
neuroblastoma cells (SHSY-5Y) overexpressing nNOS or wild type.  




2. Methods and materials  
2.1 Materials 
Chemical Abbreviation Manufacturer 
3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate Chaps Sigma-Aldrich, Seelze 
Acetic acid 100%  
 























Merck KGaA, Darmstadt 









Dimethylsulfoxid  DMSO Sigma-Aldrich, Seelze 
Dithiothreitol DTT  AppliChem GmbH, Darmstadt 
Ethanol 70%  
 






Carl Roth GmbH & Co, Karlsruhe 
Ethylenediaminetetraacetic acid EDTA  Sigma-Aldrich, Seelze 
Glycerol  
 
Carl Roth GmbH & Co, Karlsruhe 
Glycin  
 
Carl Roth GmbH & Co, Karlsruhe 
High Capacity Streptavidin Agarose Resin 
 
Pierce 
Hydrochloric acid HCl Sigma-Aldrich, Seelze 






Abbott GmbH und Co KG, Wiesbaden 
Isopropanol 100%  
 
Carl Roth GmbH & Co, Karlsruhe 
Magnesiumchlorid  MgCl2 Merck KGaA, Darmstadt 
Methanol 100%  
 
Sigma-Aldrich, Seelze 
MyOne Streptavidin Dynabeads 
 
Invitrogen 




Nicotinamide adenine dinucleotide NAD Sigma-Aldrich, Seelze 
Nicotinamide adenine dinucleotide 
phosphate NADPH Sigma-Aldrich, Seelze 
Nω-Nitro-L-arginine methyl ester 
hydrochloride L-NAME Sigma-Aldrich, Seelze 
Odyssey Blocking Puffer  
 
Li-COR Odyssey, Bad Homburg 
PageRuler™ Prestained Protein Ladder 
 
Fermentas 






Roche Diagnostics, Mannheim 
PonceauS 
 
Carl Roth GmbH & Co, Karlsruhe 
Potassium chloride KCl Merck KGaA, Darmstadt 
Precision Plus Protein Dual Color  
 
BioRad Laboratories, California 






Rotiphorese® Gel 30  
 
Carl Roth GmbH & Co, Karlsruhe 
Saccharose 
 
Carl Roth GmbH & Co, Karlsruhe 
Sodium acetate 
 
Carl Roth GmbH & Co, Karlsruhe 
Sodium chloride NaCl Sigma-Aldrich, Seelze 
Sodium citrate 
 
Carl Roth GmbH & Co, Karlsruhe 
Sodium dihydrogen phosphate 
 
Sigma-Aldrich, Seelze 
Sodium dodecyl sulfate SDS Serva Electrophoresis GmbH, Heidelberg 
Sodium hydrogen phosphate 
 
Sigma-Aldrich, Seelze 





Carl Roth GmbH & Co, Karlsruhe 




Tris Base  
 
AppliChem GmbH, Darmstadt 
tris(hydroxymethyl)aminomethane Tris Sigma-Aldrich, Seelze 
TritonX-100  
 







β–Mercaptoethanol βME Merck KGaA, Darmstadt 
   Cell culture chemicals Abbreviation Manufacturer 
RPMI 1640 
 
Gibco, Paisley, Scotland 
Fetal calf serum FCS Gibco, Paisley, Scotland 
Trypsin 
 
Gibco, Paisley, Scotland 
Penicillin G 
 
Gibco, Paisley, Scotland 
Streptomycin 
 
Gibco, Paisley, Scotland 
L-Gluatamie 
 
Gibco, Paisley, Scotland 




SILAC™ Stable Isotopic [13C6]-L-Arginine 
 
Invitrogen, Karlsruhe 
   
Kits  Manufacturer 
Cy3 and Cy5 minimal labeling kit  GE Healthcare 









2.2 General solutions and buffers 
Phosphate buffered saline (PBS): 1.7 M NaCl 
 34 mM Potassium Chloride 
 111 mM Disodium hydrogen phosphate 
 18.4 mM Potassium dihydrogen phosphate 
  pH adjusted to 7.4 
   
Tris buffered saline (TBS) 50 mM Tris 
 150 mM NaCl 
  Adjust pH to 7.6 
   
PBS-T: 0.1% Tween 20 diluted in PBS 
   
SDS Running buffer 25 mM Tris-Base 
 0.2 M Glycin 
 0.1 % SDS 
   
Laemmli buffer (4x) 0.2 M Tris-HCl-buffer (0.5 M, pH 6.8) 
 10 % SDS 
 40 % Glycerol 
 0.004 % Bromphenolblue 
 20 % ß-Mercaptoethanol 
   
Western blot blocking buffer 50 % Odyssey Blocking Puffer  
 50 % PBS 
   
Antibody incubation buffer 50 % Odyssey Blocking Puffer  
 50 % PBS-T 
   
Transfer buffer 48 mM Tris-Base 
 39 mM Glycin 
 20 % Methanol 
 0.0037 % SDS 
   
Ponceau-staining solution 3 % Trichloroacetic acid 
 0.1 % Ponceau S 
   
2.3 Western blot 
2.3.1.1 Western gels (recipe for 2 mini-gels) 





Water 4.16 ml 3.44 ml 2.40 ml 
Tris buffer (1.5 M pH 8,8) 2.46 ml 2.46 ml 1.00 ml 
Acrylamide (Rotiphorse Gel 30) 3.28 ml 3.94 ml 0.50 ml 
SDS 98.40 μl 98.40 μl 40 μl 
APS (10%) 49.20 μl 49.20 μl 40 μl 
Temed 4.92 μl 4.92 μl   4 μl 
 




Separation of protein mixtures and subsequent identification with target specific antibodies was 
performed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting (Burnette 
1981). For the SDS-PAGE a vertical Mini-Protean® 3 electrophoresis system (Bio-Rad, Munich) using 
1 mm thick gels that consisted of a separation gel (10 % or 12 % polyacrylamide, about 5.5 cm tall) 
and a stacking gel (3.75 % polyacrylamide, about 1.5 cm tall). Approximately 30 µg of protein was 
used per sample mixed with Laemmli buffer in a 4:1 ratio and heated to 95°C for 5 minutes before 
being loaded in to the wells of the stacking gel. Each gel also contained in a single well five µl of 
protein weight marker (Precision Plus Protein®, Biorad, Munich). The electrophoretic process was 
generally performed in two separate steps. First, the protein solutions were transferred into the 
stacking gels using a voltage of 80 V and after entry into the separating gel the current is increased 
to 120 V until adequate separation of the proteins was achieved as evident by the separation of the 
molecular weight standard. 
After electrophoretic separation, the proteins were transferred to a Nitrocellulose membrane (0.2 
micron protan, Whatman, Dassel). The gels are placed on top of the blotting paper and briefly 
equilibrated with the Transfer buffer, and then transferred using a Trans-Blot Semi-Dry Transfer Cell 
(Bio-Rad, Munich) under 100 V for 60 minutes. The success of the transfer was confirmed by staining 
the blot with Ponceau solution and after washing away the Ponceau stain with PBS the unspecific 
binding sites of the membrane were blocked using a blocking solution, for 2 hours at room 
temperature or overnight at 4°C. 
2.3.1.2 Target detection with primary antibodies 
For the detection of specific proteins the blots were incubated with primary antibodies according to 
Table 5. 
Table 5 Antibodies used and their dilution 
Protein Gene Dilution Condition Species Producer Product ID 
Protein disulfide-
isomerase 
pdi 1:200 2 h, RT Rabbit Cell Signaling C81H6 
Glutathione synthetase gss 1:200 1.5 h, RT Rabbit abcam ab91591 
Aconitate hydratase 2 aco2 1:200 2 h, RT Rabbit abcam ab83528 
Peroxiredoxin-6 prdx6 1:1000 2 h, RT Mouse abcam ab16947 
Tubulin-α tuba 1:2000 2 h, RT Mouse Upstate 05-829 
Tubulin-β tubb 1:2000 2 h, RT Mouse Promega G7121 
GAPDH gapdh 1:2000 2 h, RT Mouse Ambion AM 4300 
After incubation, the membranes were washed with PBS-T 3 times for 5 – 10 minutes each time, 
followed by incubation with secondary antibody accordingly to the host species of the primary 
antibody.  Secondary antibodies against the target antibodies were used according to Table 6. 




Table 6 Secondary antibodies used and their dilution 
Species Dilution Condition Species Producer Product ID 
α-Rabbit 680  1:1000 1 h, RT Goat LI-COR 926-68071 
α-Rabbit 800  1:1000 1 h, RT Goat LI-COR 926-32211 
α-Mouse 800  1:1000 1 h, RT Goat LI-COR 926-32210 
α-Goat 680  1:1000 1 h, RT Goat LI-COR 926-68074 
α-Sheep 800  1:1000 1 h, RT Rabbit Rockland 713-430-002 
After incubation with the secondary antibody, the membranes were washed again using the same 
procedure and scanned using Odyssey infrared scanner (Licor, Lincoln) and quantified using the 
Odyssey 2.1 software. 
2.4 Animals and treatments 
In this work C57BL/6 mice were used. At the time of operation, they were six to eight weeks old and 
were housed under a 12-h light/dark cycle with lights on at 7 a.m. and off at 7 p.m. with food and 
water ad libitum. The experiments adhered to the guidelines of the Committee for Research and 
Ethical Issues of the International Association for the Study of Pain (IASP), were approved by the 
local Ethics Committee for Animal Research (Darmstadt, Germany) and adhered to the guidelines of 
GV-SOLAS for animal welfare in science.  
2.4.1 Nerve injury model 
Surgery was carried out under 1.5–2 % isoflurane anesthesia. For the spared nerve injury (SNI), two 
of the three peripheral branches of the sciatic nerve, the common peroneal and the tibial nerves, 
were ligated with silk (6–0) and distally transected, leaving the sural nerve intact (Decosterd and 
Woolf 2000). In sham control experiments, the sciatic nerve was exposed but not cut. For the 
animals treated with Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) 30 mg/kg were 
injected intra peritoneal one hour before the SNI surgery and then again 30 minutes before 
sacrificing. 
Mice were sacrificed twenty-four hours or seven days after surgery with isoflurane or CO2, plus 
exsanguination. The L4-L6 lumbar spinal cord, ipsi-lateral to the SNI injury was excised, frozen in 
liquid nitrogen and stored at -80°C.  
2.4.2 Behavioral assessments of nociception  
The sensitivity to mechanical and heat stimulation of the paws ipsi and contralateral to the sciatic 
nerve injury was measured at baseline before surgery, 24h after SNI before drug injection, and at 1h, 
and 4h after intraperitoneal injection of 30 mg/kg of L-NAME or vehicle (PBS).  




After adaptation of the animals to the experimental environment, the latency for paw withdrawal 
was measured using a Dynamic Plantar Aesthesiometer (Ugo Basile, Italy) which assesses the 
sensitivity to pointy mechanical stimulation. The blunt pin-like steel rod was pushed against the 
plantar paw with ascending force (0-5 gram over a 10-second period, 0.2 g/sec) and then maintained 
at 5 gram until the paw was withdrawn. The paw withdrawal latency was calculated as the mean of 
three consecutive trials at ≥ 30 s intervals.   
The sensitivity to painful heat stimuli was assessed by means of the Hargreaves test, which employs 
a radiant heat source placed underneath the respective hind paw. The withdrawal latency to the 
heat stimulus was recorded automatically upon paw withdrawal that turns off the heat beam. Three 
tests were averaged for each testing session. An observer blinded for the treatment assessed 
behavior.  
For statistical analysis data were submitted to analysis of variance for repeated measurements 
(rmANOVA) and subsequent t-tests employing a correction of alpha according to Bonferroni. Eight 
mice were treated per group, P was set to 0.05.  
2.5 Bradford assay 
Protein concentrations determined with the Bradford assay (Marion M 1976) used Bradford reagent 
(Sigma). A protein standard curve using standards ranging from 0-5 µg/µl was prepared using a 
dilution series of a BSA solution. Two hundred microliters of Bradford reagent (Sigma) with 10 µl of 
1:10 diluted protein solution or standard were mixed. After two minutes, the absorption at 595 nm 
was measured using Spectra Fluor Plus ® instrument and XFluor ® software (Tecan, Crailsheim). 
2.6 Lowry assay 
Protein concentrations determined with the Lowry assay (Lowry et al. 1951) used the DC Protein 
Assay (Bio-Rad, Munich). A protein standard curve using standards ranging from 0.0 – 2 µg/µl was 
prepared using a dilution series of a BSA solution. Five microliters of protein sample are incubated 
with 25 µl of Reagent A, followed by 200 µl of Reagent B and incubated at room temperature for 
about 15 minutes and then the absorption at 690 nm was measured using Spectra Fluor Plus® 
instrument and XFluor® software (Tecan, Crailsheim). 
 





2.7.1 Buffers and solutions 
Tissue washing buffer 25 mM NEM in PBS  
   
DIGE buffer (for maleimide labeling) 7 M Urea 
 2 M Thiourea 
 2 % (65 mM) CHAPS 
 30 mM Tris 
 ad 50 ml Water 
 pH adjusted to 7.5 - 8.0 and degased. 
   
Tissue homogenization buffer for SNO-DIGE 1 tablet  Complete Protease inhibitor 
 1 M NEM 
 ad 10 ml DIGE buffer 
   
Ascorbate Stock 200 mM Sodium ascorbate 
 1 ml DIGE buffer 
   
Copper stock 1 mM Copper sulphate x 5 H2O 
 1000 µl  DIGE buffer 
   
10x Reduction stock AC 10 mM  Ascorbate 
 0.01 mM Copper sulphate x 5 H2O 
 1000 µl  DIGE buffer 
   
100x Reduction stock AC 100 mM  Ascorbate 
 0.1 mM Copper sulphate x 5 H2O 
 1000 µl  DIGE buffer 
   
DIGE rehydration buffer 8 M Urea  
 2 % (65 mM) Chaps 
 a.d. 50 ml Water 
 20 mM DTT (add directly before use) 
 0.5 % IPG buffer (add directly before use) 
   
Equilibration buffer 50 mM Tris-HCl pH 8,8 
 6 M Urea 
 30% Glycerol  
 2 % SDS 
 - Bromophenol blue 
 ad 500 ml Water 
   
Equilibration buffer with DTT 10 mg/ml  DTT added directly before use 
   
Equilibration buffer with Iodoacetamide 40 mg/ml IAM added directly before use 
   
   
   
   




SDS running Buffer (10X) 250 mM TRIS 
 2 M Glycin 
 1 % SDS 
 ad 1000 ml Water 
   
2D-Gels 252 ml AB-mix (acrylamide -bisacrylamide; 
49,5% T, 3% C) 
 100 ml 10X SDS Gel buffer Tris-Cl pH 8.8 
 500 µl TEMED                                                                   
 ad 1000ml  Water (degas and precool) 
 4 ml 10% APS 
   
Agarose Sealing buffer 500 mg Agarose   
 20 mg Bromphenolblue 
 ad 100 ml 1x SDS Running buffer 
2.7.2 Tissue homogenization 
Tissue from the mouse was weighed and then briefly washed with ice-cold washing buffer (PBS with 
25 mM NEM). Then 200 µl of tissue homogenization buffer for SNO-DIGE was added to the sample 
for every 5 mg of tissue weight and the tissue homogenized using a potter under argon and low-light 
conditions. After homogenization the tissue was incubated at room temperature for 5 minutes and 
then centrifuged (20.000 x g, 20 minutes, 4°C). The resulting supernatant was then precipitated in 
ice-cold acetone and placed at -20°C for at least one hour, the pellet was discarded. After incubation 
at -20°C the sample was centrifuged again (20.000 x g, 20 minutes, 4°C) and the supernatant 
discarded. The pellet was then dried under argon for about 45 minutes until the pellet was dry.  
After drying the pellet was dissolved in 200 µl DIGE buffer for maleimide labeling for every 5 mg of 
original tissue and the concentration of protein measured using the Bradford assay.  
2.7.3 Labeling 
Pooled Standard 
Five µg from each sample was pipetted into a tube and brought to a final volume of 90 µl with DIGE 
buffer. Ten µl of 10X Reduction stock AC was added and then 20 µl of Cy3 dye. The standard was 
mixed by pipetting, followed by a short spin on a centrifuge. The standard was then incubated for 1 
hour at room temperature in the dark. After incubation, the reaction was quenched with 20µl of 2 
mM cysteine and further incubated for 30 minutes at room temperature in the dark. After 
quenching the standard was frozen at -20°C overnight. After removal from freezer and thawing, 140 
µl of 2X Rehydration buffer (with 2.8 mg DTT and 5 µl Pharmalyte per 1 ml) was added and mixed by 
pipetting. 





Five µg of sample were pipetted to separate tubes and brought to a final volume of 9 µl with DIGE 
buffer. One µl of 10X Reduction stock AC was added and then 2 µl of Cy5 dye. The samples were 
mixed by pipetting, followed by a short spin on a centrifuge. The samples were then incubated for 1 
hour at room temperature in the dark. After incubation the reaction was quenched with 2µl of 2 mM 
cysteine and incubated for 30 minutes at room temperature in the dark. After quenching the 
samples were frozen at -20°C overnight. After removal from freezer and thawing, 14 µl of 2X 
Rehydration buffer (with 2.8 mg DTT and 5 µl Pharmalyte per 1 ml) were added to each sample and 
mixed by pipetting. To each sample 28 µl of the pooled standard was added and mixed by pipetting, 
followed by brief centrifugation. 
2.7.3.2 Preparative gel sample 
Fifty µg from each sample was pipetted into a tube and brought to a final volume of 250 µl with 
DIGE buffer. Ten µl of 100X Reduction stock AC was added and then 20 µl of Cy3 preparative dye. 
The standard was mixed by pipetting, followed by a short spin on a centrifuge. The sample was then 
incubated for 1 hour at room temperature in the dark. After incubation, the reaction was quenched 
with 20µl of 20 mM cysteine and incubated for 30 minutes at room temperature in the dark. After 
quenching 270 µl of 2X Rehydration buffer (with 5.6 mg DTT and 5.5µl Pharmalytes (IPG buffer)) was 
added to the sample and mixed by pipetting, and then centrifuged briefly. 100 µl were removed 
from the sample and stored at -20°C overnight. The rest of the preparative sample (450µl) was 
placed in a rehydration tray with an IEF strip (24cm, 3-10 linear) and allowed to rehydrate the strip 
overnight. 
2.7.4 2D Electrophoresis 
IEF Strips (24 cm, pH 3-10 Linear) are placed on the IEF device manifold and covered with Immobiline 
DryStrip Cover Fluid (GE Healthcare) and the samples loaded using active rehydration at the start of 
the IEF. 
The IEF Program used was as follows: 
Current per strip 75 µA 
Temperature 20°C 
Step 1 step and hold 150V, 3 hours 
Step 2  step and hold 300V, 3 hours 
Step 3 gradient to 1000V, 10 hours 
Step 4 gradient to 8000V, 3 hours 
Step 5 step and hold 8000V, 5 hours 
After the IEF run is complete, the cover fluid was poured off and the IEF strips briefly washed with 
water to wash away any residual cover fluid. The strips were then incubated with Equilibration 




buffer containing DTT for 15 minutes followed by incubation with Equilibration buffer containing 
IAM for 15 minutes. 
For the second dimension, the gel strips were placed on top of 12.5% SDS gels and sealed with a 0.5 
% agarose gel. Before sealing a weight marker was added to the gels anode side (-) side by putting a 
small amount (10 µl) of the weight marker (PageRuler™ Prestained Protein Ladder, Fermentas) on a 
small piece of porous paper and placing it on the anode side after the IEF strip has been loaded. The 
gels were then run at 15W/gel for about 6.5 hours. 
2.7.5 Scanning 
The gels were scanned using a Typhoon using the following settings: 
Fluorescence: Cy3, Cy5. 
PMT: 600V 
Press sample: Yes 
Focus: +3 mm. 
Pixel size: 100 µm. 
DIGE File naming format: Cy3 Standard. 
 
2.7.6 Analysis and Spot picking 
The 2D SNO-DIGE analysis was composed of 10 analytical gels from 10 mice, 5 from each group of 
control and SNI-treated. The pooled standard was used to normalize the spots. Two gels were used 
as preparative gels for spot picking and MS analysis, with either 400 µg or 100 µg of protein. 
For the 2D SNO-DIGE with L-NAME treated animals, samples from three animals of each group 
(naïve, SNI and SNI+L-NAME) were used comprising a DIGE analysis of nine analytical gels and one 
preparative gel. To assess the impact of anesthesia, skin incision, and exposure of the sciatic nerve, 
sham-operated mice were compared with naïve mice. For the sham control experiment, four mice 
were used in each group (naïve vs. sham). 
Gels were scanned using a Typhoon™ 9400 Imager (GE Healthcare). Cy3 fluorescent images, at a 
resolution of 100 µm, were scanned with a 532 nm laser and a 580 nm emission filter and Cy5 
fluorescent images with a 633 nm laser and a 670 nm emission filter. Analysis of the gel images was 
performed with the DeCyder™ software version 6.0 (GE Healthcare) according to the manufacturer’s 
recommendations. The estimated number of spots was set at 2500 per gel and the spots were first 
matched automatically using the batch function, then checked and manually corrected as needed. 
Matched spots were compared across groups according to the standardized abundance and 
considered significantly modified if the average ratio between treated and untreated mice was < -1.2 
or > 1.2, and P < 0.05 (students t-test). Protein spots showing significant changes between treated 




and untreated mice were picked from the gel using an Ettan™ Spot Picker supplied with 2.0 mm 
picker head and placed in perforated 96 well plates (Thermo Scientific).  
2.7.7 Mass spectrometry peptide and protein sequencing 
The in gel digestion with trypsin and peptide extraction were done essentially as described by Collins 
et al. (Collins et al. 2004). Trypsinized peptides were dissolved in 5 % acetonitrile supplied with 0.5 % 
formic acid in water and separated on a 75 µm ID emitter tip (NewObjectives) filled with 3 µm 
C18 Hypersil GOLD reversed phase silica (Thermo Scientific) placed in front of an Orbitrap (Thermo 
Scientific) mass spectrometer. Nano-HPLC runs (60 min for in-gel digests and 90 min for SNO-SID 
samples) with an increasing acetonitrile gradient from 5 % to 50 % containing 0.1 % formic acid were 
performed using Agilent 1200 Nano-HPLC equipment with a flow of 200 nl/min. Eluted peptides 
were submitted online to ESI-MS/MS analysis. The MS data was acquired by a survey scan in a mass 
range of 400 to 1600 m/z followed by CID fragmentation of up to five precursor ions using Data 
Dependent Acquisition (exclusion time 3 min, rejection of singly charged precursor ions). Peak lists 
were generated by Xtract_MSn (Thermo Scientific) and searched using Mascot Server (version 2.2) 
against a database containing 16,327 species specific (Mus musculus) protein sequences 
downloaded from www.uniprot.org. The Mascot search settings were as follows: maximum missed 
cleavages 1, precursor mass tolerance 10 ppm, fragment ion tolerance 0.8 Da and optional 
modifications allowed on methionine (oxidation) and cysteine (modification by NEM and 
carbamidomethylation by iodoacetamide). Only peptides with individual ion scores indicating 
identity (p < 0.05) were considered significant. 
2.7.8 Protein Identification 
As the protein sequencing commonly reveals more than protein in each picked gel spot the selection 
of prime candidate for each spot was done by identifying the molecular mass and calculating the 
theoretical isoelectric point value of the proteins and matching them to the position of the gel as 
well as using indirect quantitative values of quantitation based on the number of sequenced 
peptides, coverage and emPAI values. 
2.8 Identification of SNO sites (SNOSID) 
Trypsin digestion buffer 50 mM  Tris 
 1 mM  CaCl2 
 ad 10 ml Water 
  pH adjusted to 7.8 
   
Washing buffer 5 mM  NH4HCO3 
 10 %  Acetonitrile (MS Grade) 
 ad 10 ml Water (MS Grade) pH adjusted to 8.0 




Ten µg of protein from samples prepared for the SNO-DIGE were reduced with 1 mM ascorbate and 
10 µM CuSO4 in trypsin digestion buffer and labeled with 200 nM Biotin-HPDP (Thermo Scientific). 
After one hour incubation, 500 ng of MS grade trypsin (Promega) and 10 % acetonitrile (Geyer) were 
added and the solution incubated at 37 °C for 16 hours. The trypsinization was stopped with 0.5 mM 
phenylmethanesulfonylfluoride and the biotinylated peptides were purified with MyOne 
Streptavidin Dynabeads (Invitrogen) by incubation for one hour. After washing with MS buffer (5 
mM NH4HCO3, 10 % acetonitrile, pH 8) the peptides were eluted with 5 mM DTT in washing buffer 
and incubated with 20 mM iodoacetamide for 30 minutes at room temperature (Derakhshan, Wille 
and Gross 2007). Protein sequencing of resulting peptides was performed the same as for 
identification of in-gel trypsinized peptides after picking from DIGE gels (see page 28). 
2.9 Prediction of SNO sites 
For the prediction of SNO sites I used the GPS-SNO 1.0 (Group-based Prediction System) algorithm (Xue 
et al. 2010). Protein sequences from Uniprot were used based on the protein identification from Mass 
spectrometry sequencing. Threshold was set at Medium and the sequences run using the Batch version. 
2.10 Biotin switch and immunodetection 
2.10.1 Buffers 
Washing buffer 25 mM  NEM in TBS 
   
Homogenization buffer 2% SDS 
 25 mM NEM 
 100 µM neocuproine 
 1 tablet / 10 ml Complete® mini protease inhibitor 
 ad 10 ml TBS 
   
ELISA coating buffer  100 mM  NaHCO3 
 33 mM  Na2CO3 
 ad 50 ml Water 
  pH adjusted to 9.5 
 
2.10.2 Tissue homogenization 
Tissue for the Biotin-Switch-Technique (BST) and SNO-ELISA was briefly washed with 1 ml of 
Washing buffer, then homogenized in 200 µl of Homogenization buffer and incubated at room 
temperature for 5 minutes, centrifuged (16.000 x g, 4°C for 20 minutes) and the supernatant 
precipitated in ice-cold acetone overnight at -20°C and subsequently centrifuged (16.000 x g, 4°C, 20 
minutes). Proteins were dried, dissolved in 400 µl TBS containing 1 % SDS and the protein 
concentrations determined with a Lowry assay kit (Bio-Rad, Munich). 




2.10.3 Biotin switch 
Fifty µg of protein were reduced with 1 mM ascorbate and 10 µM CuSO4 in TBS and labeled with 200 
nM biotin-HPDP (Thermo Scientific). After one-hour incubation, the solution was precipitated in ice-
cold acetone overnight at -80°C. After overnight precipitation, the samples were centrifuged (16.000 
x g, 4°C, 20 minutes) and the supernatant acetone was removed. The remaining pellet was allowed 
to dry for 30 minutes and then dissolved in 50 µl TBS and incubated with 50 µl of High Capacity 
Streptavidin Agarose Resin (Pierce) beads for 20 minutes. After washing, bound proteins were eluted 
from the beads with 50 µl SDS buffer containing 5 % mercaptoethanol. The solution was then 
concentrated with a vacuum rotator (Eppendorf) and the proteins analyzed by western blotting (see 
page 20).  
2.10.4 Biotin switch ELISA (SNO-ELISA) 
In addition to the Biotin-Switch with Western Blot detection I developed a novel ELISA based 
approach to identify the nitrosylation of the target proteins. Nitrosylation sites were labeled with 
biotin with the biotin switch (above) followed by sandwich ELSIA detection. For this, primary 
antibodies directed against candidate proteins were coated to the surface of a 96-well plate 
overnight at 4°C in ELISA coating buffer. Antibodies were directed against protein disulfide-
isomerase (pdi, 1:500, Cell Signaling, C81H6), glutathione synthetase (gss, 1:500, abcam, ab91591), 
aconitate hydratase 2 (aco2, 1:500, abcam, ab83528), peroxiredoxin-6 (prdx6, 1:1000, abcam, 
ab16947), tubulin-beta (tubb, 1:500, Promega, G7121), and GAPDH (gapdh, 1:500, Ambion, AM 
4300). After washing, 1% BSA in PBS was used to block the plate. Subsequently, 20 µg of the SNO-
site biotinylated proteins in blocking buffer were loaded per well and incubated overnight at 4°C. 
After washing, anti-biotin 700 (1:500, manufacturer, Rockland, 600-130-098) was added to the plate 
and incubated for 2 hours at room temperature. After washing, the plate was then analyzed for the 
infrared fluorescence on an Odyssey Scanning system to determine the extent of protein 
biotinylation, and thus indirectly S-nitrosylation.  
2.11 Cell culture 
Human Neuroblastoma cells (SHSY-4Y) were grown using RPMI 1640 medium supplemented with 
heat-inactivated 10% fetal bovine serum, 1 % Penicillin / streptomycin, and 2 mM glutamine at 37°C 
in 5% CO2 atmosphere at 37°C in a humidified tissue culture incubator. 
2.11.1 SILAC cell culture 
Human Neuroblastoma cells (SHSY-4Y) were grown using SILAC™ Protein ID & Quantitation Media 
Kit Lysine (DMEM-Flex) and SILAC™ Stable Isotopic [13C6]-L-Arginine with heat-inactivated 10% fetal 
bovine serum, 1 % Penicillin / streptomycin, and 2 mM glutamine at 37°C in 5% CO2 atmosphere at 




37°C in a humidified tissue culture incubator. Cells were grown for a minimum of 5 cell cycles before 
harvesting. 
2.11.2 Neuronal NOS-Overexpression 
To produce a stable cell line of nNOS over expressing SHSY-5Y neuroblastoma a lentiviral construct 
was generated using a vector purchased from GeneCopoeia, product ID Mm04153, for mouse Nitric 
oxide synthase 1.  
Lentiviral particles were produced by transient co-transfection of HEK293T cells seeded in 6 cm 
dishes with 10 µg of vector DNA (Mm04153), together with three helper plasmids (5 µg of 
pMDL/RRE, 3 µg of RSV-Rev, and pMD2G-VSVG). The calcium phosphate precipitation method was 
used for transfection according to standard techniques. Cell supernatant containing lentivirus 
particles was harvested at 48 hours after transfection, and passed through a 0.45 µm filter, and 
concentrated by centrifugation for 90 min at 40,000 rpm at 4°C. The virus pellet was suspended in 25 
µl cold 0.1M PBS and the titer was assessed by GFP expression analysis in transduced tumor cells. 
Viral titers were 2–3 x 107 transduction units/ml. 
For transduction, 5 x 105 SHSY-5Y cells were seeded in 10 cm dishes and transduced with the 
respective lentivirus particles at 10 MOI in complete medium. After 3 days the efficiency of virus 
infection was determined by flow cytometry on the basis of eGFP expression. To exclude the non-
infected cells, GFP-positive cells were isolated by the FACSAria Cell sorter (Becton Dickinson, 
Germany). 
2.11.3 Cell stimulation 
To induce autophagy in NOS-overexpressing and wild-type SHSY-5Y, 1x106 cells were seeded in 75 
cm2 culture flasks and grown to c.a. 60% confluence in RPMI medium supplemented with 
GlutaMAXTM. The cells were then stimulated with 1 µM rapamycin added to RPMI culture medium 
supplemented with GlutaMAXTM. Thirty microliters of a 1 mM stock solution of rapamycin dissolved 
in ethanol was used. Ethanol in the same amount was added to the untreated cells (vehicle). NOS 
over-expressing cells were supplemented with 10 µM NAD, 40 µM NADPH, and 100 µM 
tetrahydrobiopterin for NO production by NOS. Each cell type and stimulation was performed and 
analyzed in triplicate. 
After 6 hour stimulation the cells were washed with PBS and then scraped using standard cell 
scraper, collected in a 15 ml tube and centrifuged at 1200 rpm for 3 minutes. After centrifugation 
cells were suspended in PBS and transferred to a 1.5 ml tube, followed by centrifugation and 
removal of PBS. 




2.11.4 Saville-Griess assay 
40 mM NaNO2 2.76 mg NaNO2 
 1 ml Water 
   
40 µM NaNO2 10 µl 40 mM NaNO2 
 10 ml Water 
   
2 N HCl (2 M) 21 ml 37% HCl 
 79 ml Water 
   
0.5% (w/v) ammonium sulfamate 500 mg  ammonium sulfamate  
 100 ml Water 
   
Hg/SN solution  400 mg HgCl2 
 5 g  Sulfanilamide 
 20 ml  2 N HCl 
  ad 100 ml Water 
   
Hg/SN/NEDD solution  20 mg (N-1-(naphthyl)ethylenediamine dihydrochloride) 
 10 ml Hg/SN solution 
NO content of protein was determined with the Saville-Griess assay (Saville 1958) adapted for use 
with microtiter plates. A NO standard curve was prepared with serial dilutions of freshly prepared 40 
μM NaNO2. One hundred micrograms of protein were added to a well and diluted to 100 µl. To each 
well of samples 30 μl of 0.5% ammonium sulfamate (ASM; Aldrich) in water were added followed by 
30 μl of 2 N HCl to all wells and incubated for 1 to 2 minutes. After incubation 40 μl of Hg/SN/NEDD 
solution was added to all wells and incubated for 10 min at room temperature. After incubation, the 
absorption at 595 nm was measured using Spectra Fluor Plus ® instrument and XFluor ® software 
(Tecan, Crailsheim). 
2.12 SNO-SILAC 
2.12.1 Solutions and reagents  
SDT-lysis buffer 4 % (w/v)  SDS 
 100 mM Tris/HCl 
 150 mM  NaCl 
 1 tablet Protease inhibitors per 10 ml 
   
UA buffer 8 M Urea 
 100 mM Tris/HCl 
  pH adjusted to 8.5 
   
UB buffer 8 M Urea 
 100 mM Tris/HCl 
  pH adjusted to 8.0 
   




ASC / IAM solution 8 M Urea 
 100 mM Tris/HCl, pH adjusted to 8.5 
 1 mM  Ascorbate 
 50 mM  Iodoacetamide in UA 
 1 µM CuSO4 
 
2.12.2 Preparation of SILAC Standards 
Cell pellet of cells grown in SILAC medium was homogenized in SDT-Lysis buffer containing 10 mM 
TCEP for 30 minutes and then split in two parts. One part was incubated with 40 mM IAM and the 
other 40 mM NEM. After centrifugation (16.000 g, 20 min, RT) the solutions were precipitated in ice-
cold acetone overnight at -20°C and then solubilized in SDT-Lysis buffer and protein concentration 
measured with GE NanoVue Spectrophotometer. 
2.12.3 Preparation of cells 
Cell pellets were homogenized in SDT-Lysis buffer containing 25 mM NEM and incubated for 5 
minutes at room temperature. After centrifugation (16.000 g, 20 min, RT) the solutions were 
precipitated in ice-cold acetone overnight at -20°C and then solubilized in SDT-Lysis buffer and 
protein concentration measured with a GE NanoVue Spectrophotometer. 
2.12.4 Sample processing 
Twenty microgram of protein sample are added to a FASP column and diluted with 200 µl UA buffer; 
then centrifuged at 14.000 x g for 40 minutes, RT. Then 200 µl UA buffer are added and 
centrifugation repeated. The S-Nitrosylations in the sample are then reduced with 200 µl of ASC / 
IAM solution (1 mM Ascorbate, 50mM IAM, 1 µM CuSO4) and incubated for 45 minutes followed by 
addition 20 µg of SILAC standard and centrifugation (14.000 x g for 40 minutes, RT). Samples were 
washed with with 200 µl UA buffer; then centrifuged at 14.000 x g for 40 minutes, RT. TCEP 10 mM 
was added to the sample after dilution with UA buffer and incubated for 30 minutes followed by 
addition of 40 mM NEM and incubation for 30 minutes. Samples were finally washed twice with 100 
µl of UB buffer and centrifuged (14.000 x g for 30 minutes, RT) after each washing. Filtrate was 
discarded after each centrifugation step as the proteins (> 10 kDa) remain in the FASP filter unit. 
2.12.5 Sample lysis and desalting 
ABC buffer 5 mM  NH4HCO3 
 1 mM  CaCl2 
 ad 10 ml Water (MS Grade) 
  pH adjusted to 8.0 
   
   
   




2 X Acidification buffer 5 mM  NH4HCO3 
 6 % Acetonitrile 
 0.1 % TFA (CF3COOH) 
 ad 10 ml Water (MS Grade) 
  pH adjusted to 8.0 
 
After dilution with UB buffer, endoproteinase Lys-C was added in a 1:50 ratio (800 ng) and mixed by 
shaking for 1 min. Then the samples in the filters were incubated overnight in a wet chamber at 
room temperature.  After overnight incubation 150 µl of ABC buffer containing 400 ng Trypsin (1:100 
ratio to protein) were added to the samples and they mixed by shaking for 1 min, followed by 
incubation at RT for 4 hours. The FASP filters are then centrifuged (14.000 g, 40 minutes, RT) and the 
filtrate collected. After addition of 50 µl 0.5 M NaCl in water, the filter is centrifuged again 
centrifuged (14.000 g, 20 minutes, RT) and the filtrate pooled with the previous filtrate followed by 
acidification with 2 X Acidification buffer in a 1:1 ratio. 
Samples are then desalted on SPE columns. MILI-SPE Extraction disk cartridge (C18-SD) is primed 
with 1 ml of CH3OH and centrifuged (1,500 x g for 1 min), followed by washing with 0.5 ml of 0.1% 
CF3COOH, 70% CH3CN in water and centrifuged, and then 0.5 ml of 0.1% CF3COOH in water and 
centrifuged. Samples were then loaded onto the column and centrifuged at 150 x g for 3 min. 
Samples are washed with 0.5 ml of 0.1% CF3COOH in water and centrifuge at 150 x g for 3 min. SPE 
cartridge is then transferred to a new tube and 0.5 ml of 70% CH3CN in water added to the cartridge 
and centrifuged at 150 x g for 3 min. The resulting elute containing desalted peptides is then 
concentrated in a vacuum centrifuge and solubilized in ABC buffer before injection and analysis in 
mass spectrometer.  
2.13 Western blot for autophagy targets 
Western blot was performed as described on page 20 above and incubated with primary antibodies 
according to Table 7 and appropriate secondary antibodies according to Table 6.  
Table 7 Primary antibodies for autophagy targets 
Target Gene Dilution Conditions Species Producer Product ID 
Ubiquitin ubb 1:1000 1 d, 4°C Mouse Santa-Cruz SC-3936 
β-Actin b-actin 1:1000 1 h, RT Rabbit Sigma N/A 
LC-3β map1lC3b 1:750 2 d, 4°C Rabbit Cell Signaling 2775S 
p62 (SQSTM1) sqstm1 1:200 1 d, 4°C Sheep Abcam ab 31545 
Neuronal-NOS nos1 1:1000 1 d, 4°C Rabbit Santa-Cruz SC-648 







3.1 Effects of L-NAME on pain behavior 
It is fundamental to this study that we see an effect on pain sensation should we inhibit the 
production of nitric oxide in the central nervous system. In fact this can readily be demonstrated. At 
24 hours after an SNI operation, the nerve injury induced hyperalgesia resulted in a paw withdrawal 
latency of 2 and 1.5 seconds in response to mechanical and thermal stimulation, respectively. By the 
peritoneal injection of L-NAME, an unspecific inhibitor of NOS, the withdrawal latencies returned 
back to baseline demonstrating the complete reversal of hyperalgesia. (See Figure 4) 
Figure 4 Effects of L-NAME on pain behaviour 
Paw withdrawal latencies upon mechanical (left) and heat (right) stimulation of the ipsilateral hind 
paw at baseline and after SNI, before and after injection of L-NAME or vehicle (n = 8 per group). The 
asterisks indicate time points which differed significantly between groups (ANOVA for repeated 
measurements, P < 0.05). 
 
Thus preventing the production of nitric oxide in the central and peripheral nervous systems 
reverses the hyperalgesia. This may be in part mediated through inhibition of cGMP signaling and 



























































3.2 2D SNO-DIGE analysis of protein S-nitrosylation in the spinal cord after 
SNI 
3.2.1 Effects of SNI operation 
To explore the potential direct targets of NO that result in S-nitrosylation, I employed the 2D SNO-
DIGE using tissue from spinal cord parts L4-L6 twenty four hours after SNI operation. An analysis of 
spinal cord tissue from SNI treated mice vs. Naïve revealed 57 significantly regulated spots. Spots 
were considered significantly regulated if the relative change +/- 20% and students T-test p < 0.05. 
Out of these 57 spots 31 showed an increase in SNO and 26 spots a decrease in SNO. The 57 spots 
were identified to contain 53 unique proteins, with four of them (aco2, atp5h, dpysl2, and 
serpinb1a) appearing each in two spots that showed consistent SNO regulation. Based on 
information from the Uniprot website the proteins were categorized according to their main known 
function. The functional categorization (see Figure 6) showed that 11 proteins are involved in ATP 
production and mitochondrial function (classifications: energy metabolism and glucose metabolism), 
8 contribute to protein metabolism or folding and 9 regulate neuronal signaling. The functional 
classifications of the identified proteins suggest that mitochondria, ER and pre- and postsynaptic 
densities are major intracellular sites where S-nitrosylation occurs.  
The most profound changes in nitrosylation levels were found in glutathione S-transferase Mu 1 
(gstm1, Ratio SNI vs. Naive: 2.78), malate dehydrogenase, mitochondrial (mdh2, 1.76), and protein 
RUFY3 (rufy3, 1.74) in terms of up-nitrosylation. Neurofilament medium polypeptide (nefm, -4.25), 
ATP synthase subunit d, mitochondrial (atp5h, -3.19), peroxiredoxin-6 (prdx6, -3.05), and aconitate 
hydratase, mitochondrial (aco2, -2.43) showed the strongest decrease in S-nitrosylation. Five of 
these seven proteins (i.e. aco2, mdh2, prdx6, gstm1, and atp5h) are involved in redox regulation or 
energy metabolism. See Table 8. A complete list of identified proteins in the SNO-DIGE after SNI is 
shown in Table 9. 




Name Name Ratio T-test SNOSID Site 
Functional 
classification 
53 gstm1 Glutathione S-transferase Mu 1 +2.78 0.002  Redox regulation 
44 mdh2 Malate dehydrogenase, 
mitochondrial 
+1.76 0.010 89, 93, 212, 
275, 285 
Energy metabolism 
20 rufy3 Protein RUFY3 +1.74 0.016  Signaling 
33 psmc5 26S protease regulatory subunit 8 -2.01 0.012  Protein metabolism 
52 prdx6 Peroxiredoxin-6 -3.05 0.021 47 Redox regulation 
57 atp5h ATP synthase subunit d, 
mitochondrial 
-3.19 0.023 101 Energy metabolism 
1 nefm Neurofilament medium 
polypeptide 










Figure 5 Representative 2D SNO DIGE gel and spot analysis of the spinal cord after SNI 
Representative gel from the analysis of S-nitrosylated proteins in SNI treated vs. naïve mice. Four 
examples of the peak images from the DeCyder analysis are shown for spots 18 (protein disulfide-
isomerase A3 (Pdia3), SNO Ratio -1.29, p: 0.0440), 36 (fructose-bisphosphate aldolase C (Aldoc), 
Ratio 1.55, p: 0.024), 47 (phosphatidylinositol transfer protein alpha isoform (Pitpna), Ratio 1.58, p: 
0.044), and 55 (peroxiredoxin-1 (Prdx1), Ratio 1.65, p: 0.026). The numbers indicate the spots picked 
for and identified by ESI-MS/MS. SNO regulation of these spots is shown in Table 1. In the spot map 
(bottom) proteins with increased S-nitrosylation are shown in blue, those with a decrease in red. The 
size of the spots correlates with the extent of SNO-increase or decrease. The spots are labeled with 
the gene names of the identified proteins. 
 
 
3.2.2 Effects of L-NAME treatment 
In light of the well documented, and previously demonstrated, anti-nociceptive effects of NOS 
inhibitors mice were treated with the NOS inhibitor L-NAME prior to SNI operation and compared 
the SNO proteins between the three groups, i.e. naïve vs. SNI vs. SNI + L-NAME (N = 3). In parallel, 
the effects of L-NAME on nociceptive behavior were assessed. In this experiment 54 unique proteins 
were identified from 69 spots which showed increases or decreases of S-nitrosylation after SNI. A 
complete list of identified proteins is shown in Appendix IV. 
 Up-Nitrosylation 
 Down-Nitrosylation 
Figure 6 Functional categorization of S-Nitrosylated proteins after SNI 
Categories of proteins with significant increases and decreases of S-nitrosylation in the spinal cord 
after sciatic nerve injury as assessed with the 2D SNO-DIGE. Categorization was based on UniProt 






Eight proteins showed an increase in S-nitrosylation (p < 0.05) after SNI. Out of these eight proteins, 
six showed a decrease of SNO modifications in the L-NAME+SNI treated group as compared to SNI 
while two remained unchanged (Figure 7 a). Effects of L-NAME were strongest for actin related 
protein 3 (actr3) which is part of the Arp2/3 complex and involved in actin branching. L-NAME 
treatment prior to SNI also significantly reduced the constitutive S-nitrosylation of several proteins 
including several mitochondrial proteins, heat shock cognate 71 kDa (hspa8), dynamin-1 (Dnm1) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Figure 7 b) whose nitrosylation and 
denitrosylation has been reported to change its function in the context of NO-mediated 
neurotoxicity.  
Figure 7 S-Nitrosylation after SNI and L-NAME treatment 
Fig A shows all proteins which were significantly up-nitrosylated after nerve injury. Fig. B shows all 





Table 9 Protein modification by S-nitrosylation after Spared Nerve Injury of the sciatic nerve in the mouse spinal cord 
 
Spot 
no. UniProt ID 
Gene 







Functional meaning of 
SNO sites Functional description 
Functional 
classification 
1 NFM_MOUSE nefm Neurofilament medium 
polypeptide 
-4.25 0.0500 95916 4.44 57 24%  None None Involved in the maintenance of neuronal 
caliber. 
Cytoskeleton 
2 ACON_MOUSE aco2 Aconitate hydratase, 
mitochondrial 
-2.43 0.0210 85464 8.02 7 12% 126, 
448, 
451 
410 Metal binding 448, 451 
Iron-sulfur (4Fe-4S) 
Catalyzes the isomerization of citrate to 
isocitrate via cis-aconitate 
Energy 
metabolism 
3 K6PF_MOUSE pfkm 6-phosphofructokinase, muscle 
type  
1.58 0.0205 85269 8.08 63 47%  631 None known Catalytic activity: ATP + D-fructose 6-




4 K6PP_MOUSE pfkp 6-phosphofructokinase type C -1.20 0.0440 85455 7.12 6 8%  80, 111, 342, 
410, 722 
None known (see above) Glucose 
metabolism 
5 ACON_MOUSE aco2 Aconitate hydratase, 
mitochondrial  
-1.32 0.0110 85464 8.02 163 62% 126, 
448, 
451 
410 Metal binding 448, 451 
Iron-sulfur (4Fe-4S) 
Catalyzes the isomerization of citrate to 
isocitrate via cis-aconitate 
Energy 
metabolism 
6 ACBG1_MOUSE acsbg1 Long-chain-fatty-acid--CoA 
ligase ACSBG1  
-1.25 0.0370 80426 5.74 52 47%  10, 500 None Mediates activation of long-chain fatty 
acids for both synthesis of cellular lipids, 
and degradation via beta-oxidation.  
Lipid 
metabolism 
7 HSP7C_MOUSE hspa8 Heat shock cognate 71 kDa 
protein 
-1.61 0.0050 70871 5.17 6 10%  574, 603 Modified residue 601 
N6-acetyllysine 
Chaperone. Protein folding 
8 NDUS1_MOUSE ndufs1 NADH-ubiquinone 
oxidoreductase 75 kDa subunit, 
mitochondrial  
-1.27 0.0025 79749 5.41 134 59%  75, 92, 564, 
710, 727 
Metal binding 75, 92 
Iron-sulfur 1 (2Fe-2S),  
Core subunit of the mitochondrial 
membrane respiratory chain NADH 
dehydrogenase (Complex I). 
Energy 
metabolism 
9 CMC1_MOUSE slc25a12 Calcium-binding mitochondrial 
carrier protein Aralar1  
1.28 0.0215 74570 8.41 82 66%  85, 375, 563 Domain 40 – 85 EF-
hand 1  
Calcium-dependent mitochondrial 
aspartate and glutamate carrier.  
Aminoacid 
Transport 
10 STXB1_MOUSE stxbp1 Syntaxin-binding protein 1 1.53 0.0070 67569 6.96 54 42%  45, 110, 366 None known May regulate synaptic vesicle docking 
and fusion, Essential for 
neurotransmission and binds syntaxin, a 




11 LRC40_MOUSE lrrc40 Leucine-rich repeat-containing 
protein 40 
-1.44 0.0280 68076 6.45 29 53%  227, 329, 438, 
469 
None known #N/A Unknown 
12 STIP1_MOUSE stip1 Stress-induced-phosphoprotein 
1 
-1.26 0.0340 62582 6.39 6 10% 26 26, 403, 461 None known Mediates the association of the 
molecular chaperones HSC70 and HSP90. 
Protein folding 
13 DPYL2_MOUSE dpysl2 Dihydropyrimidinase-related 
protein 2  
1.30 0.0366 62278 6.34 80 65% 248, 
504 
248, 439 Modified residue 431, 
499, 509 
Phosphotyrosine, 
Necessary for signaling by class 3 
semaphorins and cytoskeletal 
remodeling. Plays a role in axon 
guidance, neuronal growth cone collapse 
and cell migration. 
Signaling 
14 DPYL2_MOUSE dpysl2 Dihydropyrimidinase-related 
protein 2 
1.59 0.0260 62278 6.34 12 52% 248, 
504 
248, 439 Modified residue 431, 
499, 509 
Phosphotyrosine,  
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Functional meaning of 
SNO sites Functional description 
Functional 
classification 
15 ASNS_MOUSE asns Asparagine synthetase 
[glutamine-hydrolyzing] 
-1.54 0.0290 64283 6.13 31 39%  2 Active site 2 For 
GATase activity   
Catalytic activity: ATP + L-aspartate + L-
glutamine + H2O = AMP + diphosphate + 
L-asparagine + L-glutamate. 
Biosynthesis 
16 G6PD1_MOUSE g6pdx Glucose-6-phosphate 1-
dehydrogenase X 
1.51 0.0300 59263 6.05 18 38%  13, 269, 294 Active site 263 Proton 
acceptor   
Catalytic activity: D-glucose 6-phosphate 
+ NADP+ = 6-phospho-D-glucono-1,5-
lactone + NADPH. 
Glucose 
metabolism 
17 KPYM_MOUSE pkm2 Pyruvate kinase isozymes 
M1/M2  
1.37 0.0428 57845 7.52 165 84% 49, 152 326, 358, 423, 
474 
Modified residues 45, 
148 Phosphothreonine, 
Binding site 328 
Substrate  
Glycolytic enzyme that catalyzes the 
transfer of a phosphoryl group from 
phosphoenolpyruvate (PEP) to ADP, 
generating ATP. Stimulates POU5F1-
mediated transcriptional activation. 
Glucose 
metabolism 
18 PDIA3_MOUSE pdia3 Protein disulfide-isomerase A3 -1.29 0.0440 56678 5.79 39 56%  5, 60, 406, 
409 
Signal peptide 1 – 24, 
Active sites 60, 406, 
409 Nucleophile,   
Disulfide bonds 57 ↔ 
60, 406 ↔ 409  Redox-
active.  
Catalytic activity: Catalyzes the 
rearrangement of -S-S- bonds in proteins. 
Protein folding 
19 GDIA_MOUSE gdi1 Rab GDP dissociation inhibitor 
alpha 
-1.26 0.0230 50522 4.7 58 75% 202, 
317 
317, 335 Modified residue 333 
Phosphotyr., Modified 
residue 339 
Phosphotyr.   
Regulates the GDP/GTP exchange 
reaction of most Rab proteins by 
inhibiting the dissociation of GDP and 
binding of GTP to them. 
Signaling 
20 RUFY3_MOUSE rufy3 Protein RUFY3 1.74 0.0160 53007 5.16 30 43%  29 None known Implicated in the formation of a single 
axon by developing neurons.  
Signaling 
21 COR1A_MOUSE coro1a Coronin-1A 1.36 0.0103 50989 6.04 54 51%  24, 332 None known May be a crucial component of the 
cytoskeleton of highly motile cells. 
Cytoskeleton 
22 SERA_MOUSE phgdh D-3-phosphoglycerate 
dehydrogenase 
1.37 0.0070 56586 6.51 52 41%  48, 111, 254, 
295, 369 
Active site 265, Active 
site 283 Proton donor, 
Binding site 260 NAD 
Catalytic activity: 3-phospho-D-glycerate 
+ NAD+ = 3-phosphonooxypyruvate + 
NADH. Catalytic activity: 2-
hydroxyglutarate + NAD+ = 2-
oxoglutarate + NADH. 
Biosynthesis 
23 TCPB_MOUSE cct2 T-complex protein 1 subunit 
beta 
-1.28 0.0250 57477 5.97 61 32%  346, 371, 395, 
412 
None known Molecular chaperone; assists folding of 
proteins upon ATP hydrolysis.  
Protein folding 
24 CAP1_MOUSE cap1 Adenylyl cyclase-associated 
protein 1 
-1.29 0.0080 51575 7.23 15 31%  92, 355 Modified residue 80 
N6-acetyllysine   
Directly regulates filament dynamics and 
implicated in a number of complex 
developmental and morphological 
processes, including mRNA localization 
and the establishment of cell polarity  
Cytoskeleton 
25 TBB5_MOUSE tubb5 Tubulin beta-5 chain 1.61 0.0400 49671 4.52 4 12% 12, 354 12, 303, 354 None known Major constituent of microtubules.  Cytoskeleton 
26 HMCS1_MOUSE hmgcs1 Hydroxymethylglutaryl-CoA 
synthase, cytoplasmic 
1.46 0.0115 57569 5.55 44 48%  417 None known Condenses acetyl-CoA with acetoacetyl-
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27 SEPT8_MOUSE sept8 Septin-8 1.33 0.0335 49812 5.88 74 65%  400 Coiled coil 320 – 412 Filament-forming cytoskeletal GTPase. 
May play a role in cytokinesis. May play a 
role in platelet secretion. 
Vesicle 
trafficking 
28 TBA4A_MOUSE tuba4a Tubulin alpha-4A chain 1.31 0.0180 49924 4.7 28 52% 54, 347 4, 295, 347, 
376 
None known Major constituent of microtubules.  Cytoskeleton 
29 GSHB_MOUSE gss Glutathione synthetase 1.32 0.0447 52247 5.54 21 45%  422 Binding site 425 ATP Catalytic activity: ATP + gamma-L-
glutamyl-L-cysteine + glycine = ADP + 
phosphate + glutathione. 
Redox 
regulation 
30 NDUV1_MOUSE ndufv1 NADH dehydrogenase 
[ubiquinone] flavoprotein 1, 
mitochondrial 
1.23 0.0030 50834 7.99 1 2% 187 None None known Core subunit of the mitochondrial 
membrane respiratory chain NADH 
dehydrogenase (Complex I)  
Energy 
metabolism 
31 GDIB_MOUSE gdi2 Rab GDP dissociation inhibitor 
beta 
1.43 0.0392 50537 6.12 76 78%  317, 335 None known Regulates the GDP/GTP exchange 
reaction of most Rab proteins by 
inhibiting the dissociation of GDP and  
binding of GTP to them. 
Signaling 
32 RINI_MOUSE rnh1 Ribonuclease inhibitor 1.27 0.0170 49816 4.39 41 60%  80, 90, 194, 
204, 404, 422 
None known Inhibitor of pancreatic RNase and 
angiogenin. May also function in the 
modulation of cellular activities  
RNA 
metabolism 
33 PRS8_MOUSE psmc5 26S protease regulatory subunit 
8 
-2.01 0.0120 45626 7.29 44 69%  None None Involved in the ATP-dependent 
degradation of ubiquitinated proteins. 
Protein 
metabolism 
34 CN37_MOUSE cnp 2',3'-cyclic-nucleotide 3'-
phosphodiesterase 
1.48 0.0346 47123 9.08 10 15% 111 417 Modified residue 110 
Phosphotyrosine 
Catalytic activity: Nucleoside 2',3'-cyclic 




35 ACTZ_MOUSE actr1a Alpha-centractin 1.65 0.0274 42614 6.62 95 71%  222 None known Component of a multi-subunit complex 
involved in microtubule based vesicle 
motility. It is associated with the 
centrosome. 
Trafficking 
36 ALDOC_MOUSE aldoc Fructose-bisphosphate aldolase 
C 
1.55 0.0240 39395 7.14 23 58% 178 None Active site 188 Proton 
acceptor 
Catalytic activity: D-fructose 1,6-




37 GLNA_MOUSE glul Glutamine synthetase -1.34 0.0240 42120 7.09 12 25% 99, 
346, 
359 
269, 359 None known Essential for proliferation of fetal skin 
fibroblasts. Catalyzes the production of 
glutamine and 4-aminobutanoate. 
Biosynthesis 
38 SPB6_MOUSE serpinb6a Serpin B6  1.57 0.0140 42599 5.35 20 41%  None None Inhibitor of cathepsin G, kallikrein-8 and 
thrombin. May be involved in the 
regulation of serine proteinases present 




39 ILEUA_MOUSE serpinb1a Leukocyte elastase inhibitor A -1.28 0.0375 42575 6.13 33 59%  None None Regulates the activity of the neutrophil 
proteases and thus, forms complexes 
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40 DDAH1_MOUSE ddah1 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 
1.31 0.0061 31381 5.84 25 48%  222 None known Hydrolyzes N(G),N(G)-dimethyl-L-
arginine (ADMA) and N(G)-monomethyl-
L-arginine (MMA) which act as inhibitors 




41 ILEUA_MOUSE serpinb1a Leukocyte elastase inhibitor A -1.34 0.0187 42575 6.13 5 13%  None None Regulates the activity of the neutrophil 
proteases and thus, forms complexes 




42 PP1B_MOUSE ppp1cb Serine/threonine-protein 
phosphatase PP1-beta catalytic 
subunit 
1.25 0.0273 37187 6.07 26 42%  104 None known Protein phosphatase (PP1) is essential for 
cell division, it participates in the 
regulation of glycogen metabolism, 
muscle contractility and protein 
synthesis. Involved in regulation of ionic 
conductances and long-term synaptic 
plasticity. 
Signaling 
43 CNN3_MOUSE cnn3 Calponin-3 1.36 0.0270 36429 5.29 20 42%  None None Implicated in the regulation and 
modulation of smooth muscle 
contraction. It is capable of binding to 
actin, calmodulin, troponin C and 
tropomyosin. The interaction of calponin 
with actin inhibits the actomyosin Mg-
ATPase activity. 
Cytoskeleton 
44 MDHM_MOUSE mdh2 Malate dehydrogenase, 
mitochondrial 




132 Nucleotide binding 140 
– 142 NAD,  
Catalytic activity: (S)-malate + NAD+ = 
oxaloacetate + NADH. 
Energy 
metabolism 
45 CSN6_MOUSE cops6 COP9 signalosome complex 
subunit 6 
-1.32 0.0243 35880 5.56 27 44%  None None Component of the COP9 signalosome 
complex (CSN), a complex involved in 
various cellular and developmental 
processes.  
Signaling 
46 CAPZB_MOUSE capzb F-actin-capping protein subunit 
beta 
1.72 0.0257 31345 5.44 2 7%  8 Modified residue 2 N-
acetylserine 
Binds in a Ca
2+
-independent manner to 
the fast growing ends of actin filaments 
(barbed end) thereby blocking the 
exchange of subunits at these ends.  
Cytoskeleton 
47 PIPNA_MOUSE pitpna Phosphatidylinositol transfer 
protein alpha isoform 




48 F177A_MOUSE fam177a1 Protein FAM177A1 1.59 0.0390 23578 4.22 12 39%  None None N/A Unknown 
49 1433Z_MOUSE ywhaz 14-3-3 protein zeta/delta -1.32 0.0410 27771 4.42 12 44% 94 25, 94 None known Adapter protein implicated in the 
regulation of a large spectrum of both 
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50 PGAM1_MOUSE pgam1 Phosphoglycerate mutase 1 -1.51 0.0072 28832 7.22 23 53% 153 55 Site 62 Interaction with 
carboxyl group of 
phosphoglycerates  
Interconversion of 3- and 2-
phosphoglycerate with 2,3-




51 PSA6_MOUSE psma6 Proteasome subunit alpha type-
6 




52 PRDX6_MOUSE prdx6 Peroxiredoxin-6 -3.05 0.0210 24871 5.58 2 15% 47 47 Active site 47 Cysteine 
sulfenic acid (-SOH) 
intermediate 
Disulfide bond 47 
Interchain; in linked 
form   
Involved in redox regulation of the cell. 
Can reduce H(2)O(2) and short chain 




53 GSTM1_MOUSE gstm1 Glutathione S-transferase Mu 1 2.78 0.0020 25970 7.89 52 72%  None None Conjugation of reduced glutathione to a 
wide number of exogenous and 
endogenous hydrophobic electrophiles. 
Redox 
regulation 
54 RAB14_MOUSE rab14 Ras-related protein Rab-14 -2.02 0.0040 23897 5.79 1 7%  None None May be involved in vesicular trafficking 
and neurotransmitter release. 
Signaling 
55 PRDX1_MOUSE prdx1 Peroxiredoxin-1 1.65 0.0260 22162 8.31 45 63% 173 52, 173 Active site 52 Cysteine 
sulfenic acid (-SOH) 
intermediate, 
Disulfide bond 52-173 
Interchain  
Involved in redox regulation of the cell. 
Reduces peroxides with reducing 
equivalents provided through the 




56 ATP5H_MOUSE atp5h ATP synthase subunit d, 
mitochondrial 
-1.72 0.0440 18749 5.38 8 43% 101 None None Produces ATP from ADP in the presence 
of a proton gradient across the 




57 ATP5H_MOUSE atp5h ATP synthase subunit d, 
mitochondrial 
-3.19 0.0230 18749 5.38 18 69% 101 None None (see above)  Energy 
metabolism 
S-nitrosylation in the dorsal horn of the L4/5 mouse spinal cord was assessed by 2D SNO-DIGE analysis and subsequent identification by electrospray ionization mass 
spectrometry (ESI-MS/MS). SNO Upregulation is shown in blue, SNO down regulation in red. Triplicate 2D gels of naïve and SNI-treated mice were analyzed and statistically 
compared by t-tests, P was set at 0.05. Identification of the modified cysteines was done with the SNO site identification method (SNOSID). SNO site predictions were 





3.2.3 Effects of Sham operation 
To control for the effects of the surgery the SNO-DIGE proteome of Sham operated mice was compared 
to that of Naïve mice. For the sham control mice the sciatic nerve was exposed but not cut. 
In this experiment the SNO-DIGE revealed 18 regulated spots. Out of these, 3 spots showed an increase 
and 15 spots a decrease in S-nitrosylation. The 18 spots contained 15 unique proteins, with 12 of them 
down-nitrosylated and 3 up-nitrosylated in the Sham treated mice (namely etfa, car2 and qdpr). Three 
of the proteins with a reduction of S-nitrosylation were represented each in 2 spots (uqcrc1, mdh1, and 
pgam1) with consistent SNO regulation. Only one protein, phosphoglycerate mutase 1 (Pgam1), showed 
a similar reduction of S-nitrosylation in sham and SNI-treated mice. Two further matching proteins, 
glutamate decarboxylase, (glna) and aldolase 3 (aldoc), showed an increase of S-nitrosylation after SNI 
but a decrease after sham surgery. A complete list of identified proteins is shown in Appendix V. 
3.3 SNO-site identification (SNOSID) 
From the SNO-DIGE information it is not possible to identify which cysteine is nitrosylated in each 
protein. In order to directly identify which cysteines are SNO-modified as well as to compare different 
techniques SNO modifications with SNOSID technique were also screened. The SNOSID employs the 
biotin switch technique on trypsinized proteins, followed by avidin purification of the biotin labeled 
peptides and sequencing by mass spectrometry. In naïve mice SNOSID identified 203 S-nitrosylated 
peptides (Figure 8  a) from 131 unique proteins (Figure 8 b). After SNI 161 SNO-peptides were identified 
from 101 unique proteins. These numbers were reduced in the mice pretreated with L-NAME before 
SNI. In this group only 92 SNO-peptides from 37 proteins were identified. The complete list of SNOSID 
results is shown in Appendix VI. Considering only proteins which were significantly up- or denitrosylated 
after SNI in the 2D SNO-DIGE experiments, SNOSID revealed SNO-modified cysteines in 17 out of the 53 
regulated SNO-proteins in the first experiment including naïve versus SNI treated mice and 14 out of 54 
proteins matched this criterion in the second experiment, which compared naïve versus SNI versus SNI + 
L-NAME treated mice. Six proteins were found in all three experiments, namely aconitate hydratase 
(mitochondrial), fructose-bisphosphate aldolase C, pyruvate kinase isozymes M1/M2, malate 
dehydrogenase (mitochondrial), NADH dehydrogenase [ubiquinone] flavoprotein 1 (mitochondrial), and 






Figure 8 S-nitrosylated peptides and proteins identified by SNOSID 
Venn diagrams of S-nitrosylated peptides and respective proteins identified by SNOSID Fig. A shows the 
number of peptides which had one or more S-nitrosylated cysteines. Fig. B shows the corresponding 
number of individual proteins. The comparison of the treatment groups show that S-nitrosylation sites 
were substantially reduced by L-NAME. 
 
3.4 Confirmation of S-Nitrosylation of selected targets 
3.4.1 Biotin-switch Western Blot analysis of selected proteins  
To confirm the S-nitrosylation of the top hits of potential targets identified by the SNO-DIGE and SNOSID 
I employed the biotin switch technique (BST). For BST, SNO sites were labeled with biotin, followed by 
avidin pull-down and immunoblot analysis with target specific antibodies. The selected targets were 
protein disulfide isomerase (PDI), glutathione S-synthetase (GSS), peroxiredoxin-6 (Prdx6), mitochondrial 
aconitase 2 (Aco2), β−tubulin (Tubb), and α-tubulin (Tuba). The BST confirmed SNO-modifications in the 
selected proteins, but comparisons between naïve and SNI-treated mice did not reveal significant 
changes between naïve and SNI-treated mice (see Figure 9).  
3.4.2 Biotin switch ELISA 
In addition to the Biotin-Switch with Western Blot detection a novel ELISA based approach was 
developed to identify the nitrosylation of the target proteins. Nitrosylation sites were labeled with biotin 
as described above followed by sandwich ELSIA detection as described above. Antibodies were directed 
against protein disulfide-isomerase (pdi, 1:500, Cell Signaling, C81H6), glutathione synthetase (gss, 





1:1000, abcam, ab16947), tubulin-beta (tubb, 1:500, Promega, G7121), and GAPDH (gapdh, 1:500, 
Ambion, AM 4300). 
 
Figure 9 Biotin switch analysis 
Biotin switch analysis of selected proteins which were found to be significantly SNO-modified in the 
spinal cord after sciatic nerve injury in 2D SNO DIGE experiments. SNO-modified proteins were identified 
by biotin labeling, avidin purification and subsequent immunoblot analysis with specific antibodies. 
GAPDH was used a loading control. 
 
3.4.3 Time dependent S-nitrosylation  
To assess whether S-nitrosylation after SNI was a short lasting early event or a longer lasting adaptive 
mechanisms the S-nitrosylation of candidate target proteins (GSS, PDI, GAPDH, TUBB, PRX-6, ACO2) 1 
and 7 days after SNI using the ELISA was assessed as described above. For PDI, GSS and Prdx6 alterations 
of S-nitrosylation which were apparent at 1 day after SNI had normalized at 7 days. Instead for ACO2, S-
nitrosylation was significantly increased at 7 days after SNI, but was almost normal at 1 day suggesting 






Figure 10 Time dependent S-nitrosylation 
Percentage change of protein S-nitrosylation of candidate proteins in the spinal cord 1 and 7 days after 
sciatic nerve injury. Time courses of protein S-nitrosylation of glutathione synthetase, GSS; protein 
disulfide isomerase, PDI; glycerinaldehyde-3-phosphate-dehydrogenase, GAPDH; beta tubulin, TUBB; 
peroxiredoxin-6, PRX-6 and mitochondrial aconitase 2, ACO2 as assessed by a biotin switch ELISA in 
triplicate of n = 4 mice per group. The asterisks indicate significant difference versus naïve control mice, 
P < 0.05.  
 
3.5 Method establishment 
3.5.1 Specificity of ascorbate reduction and CyDye labeling 
To test if reduction with ascorbate was selective for S-nitrosylation the protein homogenate of NIH3T3 
mouse fibroblast, that do no express nitric oxide synthase and thus produce very little nitric oxide, was 
reduced with ascorbate or TCEP. TCEP is a strong reduction agent, reducing all cysteine oxidative 
modifications to free SH, while ascorbate is selective only for the relatively weak SNO bond.  
The protein homogenate was subsequently labeled with Cy3 and Cy5 maleimide dyes and run according 
to the standard 2D PAGE protocol of the 2D SNO-DIGE, and scanned using the Typhoon and analyzed 






Figure 11 Specificty of Ascorbate reduction 
A comparison of the selectivity of ascorbate reduction vs. TCEP reduction in protein homogenate from 
NOS free 3T3 fibroblasts shows that ascorbate reduction and subsequent CyDye labeling is selective for 
nitrosylations. 
 
The scans of the gels show that when proteins are reduced with TCEP the CyDye label is able to react 
with the free thiol groups on the protein. However, when the proteins are reacted with ascorbate the 
labeling does not happen as there are no S-nitrosylations to be reduced to free thiols by ascorbate. 
The results show (see Figure 11) that the labeling is specific, for Cy5, the label used for the labeling of 
samples in the SNO-DIGE while Cy3 was used for the internal standard. 
3.5.2 Interference of ascorbate with CyDye labeling 
To test if reduction with ascorbate was possibly interfering with the CyDye labeling dyes were incubated 
with SHSY-5Y cell protein homogenate treated with the NO donor DEA/NO and either reduced with 
ascorbate first and then labeled with CyDye or reduced and labeled simultaneously. 
The scans of the gels show that the simultaneous reduction and labeling is slightly better, though not 
significantly, than two separate steps. The results also show that the ascorbate does not interfere with 







Figure 12 Separate or simultaneous reduction or labeling 
A test of the effects of separate or simultaneous reduction and labeling steps on the efficiency of 






3.6 S-nitrosylation and autophagy 
In light of the effects of the SNI operation on the S-nitrosylation of proteins involved in protein 
metabolism and folding, the next step was to assess whether and how S-Nitrosylation is involved in 
these processes. For this a cell model of neuroblastoma cells (SHSY-5Y) and induced autophagy by 
stimulation with rapamycin was used. 
3.6.1 nNOS over-expression 
SHSY-5Y neuroblastoma cells were transduced with a Lentiviral vector for mouse neuronal NOS (NOS1, 
nNOS) in which nNOS was under control of the cytomegalo virus (CMV) promoter and transduction 
monitored by eGFP expression under the control of the Ires-2 promoter. A stable cell line was produced 
by cell sorting. Figure 13 shows a western blot for nNOS in wild type and nNOS-overexpressing cells. The 
blot confirmed nNOS overepression. 
 
Figure 13 nNOS over-expression in SHSY-5Y cells 
Western blot for nNOS in the two cell types used: wild type and nNOS over-expressing cells. β-actin was 
used as loading control. 
 
3.6.2 NO production 
NO production of the neuroblastoma cells was measured using the Saville-Griess method adapted for 
microtiterplate. Stimulation with rapamycin did not affect nitric oxide content but NO was found to be 






Figure 14 Nitric oxide content of protein after stimulation with rapamycin 
Nitric oxide content of protein from wild type and nNOS over-expressing SHSY-5Y cells after stimulation 
with rapamycin (1 µM, 6 hours). 
 
3.6.3 Markers for autophagy 
To test the effects of the nNOS over-expression on the autophagy processes, western blots were 
performed for known autophagy markers after stimulation of wild type as well as nNOS over-expressing 
cells with rapamycin (1 µM, 6 hours). 
3.6.3.1 Ratio of LC3-I and LC3-II  
The ratio of LC3-I / LC3-II was significantly increased (+233%, p < 0.05) in the wild type cells after 
stimulation with Rapamycin and dramatically increased (+100%, p < 0.05) after stimulation in nNOS 
over-expressing cells. nNOS over-expressing cells had a higher basal ratio than the wild type (+144%, p < 






Figure 15 LC3-I and LC3-II after rapamycin stimulation western blot 
Total protein homogenate western blot of LC3-I and LC3-II in wild type and nNOS over-expressing SHSY-
5Y cells after stimulation with rapamycin (1 µM, 6 hours). 
 
 
Figure 16 Ratio of LC3-I/LC3-II after rapamycin stimulation 
Ratio of LC3-I/LC3-II after stimulation with rapamycin (1 µM, 6 hours). Average values are normalized to 
Naïve cells = 1. Significance markers: * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
3.6.3.2 Ubiquitination 
Total ubiquitination was significantly reduced (-28%, p < 0.01) in the wild type cells after stimulation 
with rapamycin but was dramatically increased (+99%, p < 0.001) after stimulation in nNOS over-
expressing cells, with no significant basal difference between the two cell types. See Figure 17, Figure 





Figure 17 Ubiquitinylation after rapamycin stimulation western blot 
Total protein homogenate western blot of ubiquitinylation in wild type and nNOS over-expressing SHSY-
5Y cells after stimulation with rapamycin (1 µM, 6 hours). 
 
 
Figure 18 Total ubiquitinylation after rapamycin stimulation 
Total ubiquitinylation in wild type and nNOS over-expressing SHSY-5Y cells after stimulation with 
rapamycin (1 µM, 6 hours). Average values are normalized to Naïve cells = 1. Significance markers: * p < 






The level of HSC-70 was slightly but significantly decreased (-25%, p < 0.01) in the wild type cells after 
stimulation with rapamycin and doubled (+117%, p < 0.001) after stimulation in nNOS over-expressing 
cells. No significant basal difference between the two cell types was observed. See Figure 19, Figure 20, 
and Table 10. 
 
 
Figure 19 HSC70 after rapamycin stimulation western blot 
Total protein homogenate western blot of HSC70 in wild type and nNOS over-expressing SHSY-5Y cells 
after stimulation with rapamycin (1 µM, 6 hours). 
 
 
Figure 20 HSC70 after rapamycin stimulation 
HSC70 expression in wild type and nNOS over-expressing SHSY-5Y cells after stimulation with rapamycin 
(1 µM, 6 hours). Average values are normalized to Naïve cells = 1. Significance markers: * p < 0.05, ** p < 





3.6.3.4 p62 (SQSTM1) 
The level of p62 was significantly increased (+14%, p < 0.05) in the wild type cells after stimulation with 
rapamycin but not significantly modified after stimulation in nNOS over-expressing cells. No significant 
basal difference between the two cell types was observed. See Figure 21, Figure 22, and Table 10. 
 
Figure 21 p62 (SQSTM1) after rapamycin stimulation western blot 
Total protein homogenate western blot of p62 (SQSTM1) in wild type and nNOS over-expressing SHSY-
5Y cells after stimulation with rapamycin (1 µM, 6 hours). 
 
 
Figure 22 p62 (SQSTM1) after rapamycin stimulation 
p62 (SQSTM1) expression in wild type and nNOS over-expressing SHSY-5Y cells after stimulation with 
rapamycin (1 µM, 6 hours). Average values are normalized to Naïve cells = 1. Significance markers: * p < 






Table 10 Autophagy markers after stimulation with rapamycin 
Cell type Treatment Ubiquitin HSC70 p62 LC3-I / LC3-II  
WT 
Naïve 1.00 1.00 1.00 1.00 
Rapamycin 0.72 ** 0.74 ** 1.14 * 3.33 * 
nNOS+ 
Vehicle 0.97 0.85 0.96 2.44 * 
Naïve 1.93 *** 1.85 *** 0.96 4.92 ** 
Autophagy markers in wild type and nNOS over-expressing SHSY-5Y cells after stimulation with 
rapamycin (1 µM, 6 hours). Average values are normalized to Naïve cells = 1. Asterisks indicate 
significance (ANOVA) of change from wild type naïve: * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
3.6.3.5 Loading controls  
To test if the β-actin was possibly regulated by the nNOS overexpression or rapamycin stimulation two 
other separate loading controls were tested, HSP70 and GAPDH. Neither HSP70 nor GAPDH was 
significantly modified by the nNOS overexpression or rapamycin stimulation. See Figure 23 and Figure 
24. 
 
Figure 23 Loading controls HSP70 and GAPDH 
Loading control in wild type and nNOS over-expressing SHSY-5Y cells after stimulation with rapamycin (1 
µM, 6 hours). Neither HSP70 (A) nor GAPDH (B) was significantly modified by the nNOS overexpression 







Figure 24 Loading controls HSP70 and GAPDH blots 
Total protein homogenate western blot of HSP70 and GAPDH in wild type and nNOS over-expressing 
SHSY-5Y cells after stimulation with rapamycin (1 µM, 6 hours). 
 
3.6.4 SNO-DIGE 
To investigate the progress of S-nitrosylation in autophagy a timeline of S-nitrosylation changes was 
made using the SNO-DIGE method after stimulation of nNOS over-expressing cells with rapamycin (0.2 
µM, 0-24 hours).  Twenty two unique proteins in 27 spots were found to show time dependent changes 
in nitrosylation. The greatest changes occurred in the range of 4 and 8 hours after stimulation with 
rapamycin. Based on these results a time point of 6 hours was selected for further investigations. See 
Table 12. 
At the four hour time point the most profound increases in nitrosylation were found to be in the 
proteins WD repeat-containing protein 1 (wdr1, ratio 1.72 after 4 hours compared with naive, 1.34 after 
8 hours), Elongation factor 2 (eef2, 1.66 after 4 hours, 0.98 after 8 hours), and Methionine 
aminopeptidase 1 (metap1, 1.62 after 4 hours, 0.98 after 8 hours). The greatest decrease in nitrosylation 
was found in Heat shock cognate 71 kDa protein (hspa8, 0.46 after 4 hours, 0.42 after 8 hours), 
Calreticulin (calr, 0.67 after 4 hours, 0.65 after 8 hours), and Zyxin (zyx, 0.73 after 4 hours, 0.73 after 8 
hours). 
Heat shock cognate 71 kDa protein and Pyruvate kinase isozymes M1/M2 were also found to be 
nitrosylated after SNI operation. Actin, cytoplasmic 1 (actb), Elongation factor 2 (eef2), Far upstream 
element-binding protein 1 (fubp1), Heat shock cognate 71 kDa protein (hspa8), Pyruvate kinase 
isozymes M1/M2 (pkm2), and T-complex protein 1 subunit epsilon (cct5) were also found in the SNOSID 





Far upstream element-binding protein 1 and Pyruvate kinase isozymes M1/M2 were also found to be 
nitrosylated with the SNO-SILAC method. See below. 
3.6.5 SNO-SILAC and SNOSID 
To investigate the potential targets of S-nitrosylation in autophagy the SNO-SILAC and SNOSID methods 
were employed after stimulation of wild type as well as nNOS over-expressing cells with rapamycin (1 
µM, 6 hours).  
The SNOSID method revealed 27 nitrosylation sites in 17 different proteins. See Table 11. 
Table 11 S-Nitrosylation sites after induction of autophagy with rapamycin in nNOS overexpressing 
SHSY-5Y found by the SNOSID method. 
Protein Name Gene Cysteine Control Rapamycin 
Elongation factor 2 eef2 290 √ √ 
Alpha-enolase eno1 357 √ √ 
Glyceraldehyde-3-phosphate dehydrogenase gapdh 152, 156 √ √ 
Glyceraldehyde-3-phosphate dehydrogenase gapdh 247 √ √ 
Heat shock cognate 71 kDa protein hspa8 17 √ √ 
Phosphoglycerate kinase 1 pgk1 108 √ √ 
Enolase eno3 357 √ √ 
Tubulin alpha-1B chain tuba1b 347 √ √ 
Malate dehydrogenase, mitochondrial mdh2 89 √ X 
GTP-binding nuclear protein Ran ran 112, 120 √ X 
Echinoderm microtubule-ass. protein-like 4 eml4 461 X √ 
Heterogeneous nuclear ribonucleoprotein H hnrnph1 22 X √ 
Pyruvate kinase isozymes M1/M2 pkm2 423, 424 X √ 
Malate dehydrogenase, mitochondrial mdh2 212 X √ 
Polypyrimidine tract-binding protein 1 ptbp1 250, 251 X √ 
40S ribosomal protein S26 rps26 74, 77 X √ 
Superoxide dismutase [Cu-Zn sod1 7 X √ 
Tubulin alpha-1A chain tuba1a 347 X √ 
Tubulin beta chain tubbp2 12 X √ 
Ubiquitin-conjugating enzyme E2 D1 ube2d1 85 X √ 
Several proteins were found in two or three approaches these are listed in Table 14. 
The SNO-SILAC revealed 29 proteins with alteration of S-nitrosylation. A summary of these proteins can 
be found in Table 13 and Figure 26. 
Although few S-nitrosylated proteins were found with this method the SILAC experiment revealed 513 





both. The full list of proteins identified with the SILAC method can be found in Appendix VII. A list of ER-
stress proteins from the silac data can be found in Table 16.  
 
3.6.6 SNO-Elisa 
To confirm the nitrosylation of some targets found in the SNOSID the SNO-Elisa method was employed 
as described above. Antibodies were directed against Glyceraldehyde-3-phosphate dehydrogenase 
(gapdh, 1:1000, Ambion, AM 4300) as loading control and ubiquitin-conjugating enzyme E2-D1 (ube2d1, 
1:1000, abcam, ab76652). Ube2d1 showed a 20% up-nitrosylation after induction of autophagy (p = 
0.029). See Figure 25.  
 
Figure 25 SNO-Elisa of UBE2D1 
SNO-Elisa of Ubiquitin-conjugating enzyme E2-D1 in nNOS over-expressing SHSY-5Y cells after 





Table 12 Protein modification by S-nitrosylation after induction of autophagy by rapamycin stimulation as analyzed by SNO-DIGE 
Spot no. Uniprot ID Protein Name Gene 0 h 0.5 h 4 h 8 h 16 h 24 h Spark plot MW PI SNO sites 
1 CSDE1_HUMAN Cold shock domain-containing protein E1 csde1 1 0.86 0.85 0.96 0.36 0.81 
 
88885 5.82   
2 ZYX_HUMAN Zyxin zyx 1 0.79 0.73 0.73 #N/A 0.67 61277 6.23   
3 UBA1_HUMAN Ubiquitin-like modifier-activating enzyme 1 uba1 1 1.35 1.23 0.88 0.66 0.99 117849 5.33   
4 EF2_HUMAN Elongation factor 2 eef2 1 1.03 1.66 0.98 0.55 #N/A 95338 6.41 290 
5 FUBP1_HUMAN Far upstream element-binding protein 1 fubp1 1 1.21 1.22 1.34 1.06 1.51 67560 7.35 148  
7 XRCC5_HUMAN X-ray repair cross-complementing protein 5 xrcc5 1 1.33 1.32 1.57 #N/A 1.60 82705 5.39   
8 WDR1_HUMAN WD repeat-containing protein 1 wdr1 1 1.34 1.72 1.34 #N/A 1.48 66194 6.21   
9 KPYM_HUMAN Pyruvate kinase isozymes M1/M2 pkm2 1 1.06 0.97 1.12 1.52 0.89 57937 7.60 49, 423, 424 
11 HSP7C_HUMAN Heat shock cognate 71 kDa protein hspa8 1 0.59 0.46 0.42 0.44 0.62 70898 5.12 17  
12 HSP7C_HUMAN Heat shock cognate 71 kDa protein hspa8 1 1.25 1.39 1.28 1.19 1.36 70898 5.12 17  
13 CALR_HUMAN Calreticulin calr 1 0.80 0.67 0.65 0.64 0.93 48142 4.03   
14 ACTB_HUMAN Actin, cytoplasmic 1 actb 1 1.24 1.24 1.72 1.02 1.51 41737 5.07 217, 257, 272 
15 CALR_HUMAN Calreticulin calr 1 1.54 1.43 1.42 #N/A 1.64 48142 4.03   
16 DHE3_HUMAN Glutamate dehydrogenase 1, mitochondrial glud1 1 1.03 1.33 1.00 #N/A 0.83 61398 7.58   
17 TCPE_HUMAN T-complex protein 1 subunit epsilon cct5 1 1.11 1.36 0.90 0.76 0.92 59671 5.24 450  
18 HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K hnrnpk 1 1.31 1.15 0.82 #N/A 0.82 50976 5.14   
19 CTBP2_HUMAN C-terminal-binding protein 2 ctbp2 1 1.26 1.16 1.10 #N/A 1.03 48945 6.51   
20 AMPM1_HUMAN Methionine aminopeptidase 1 metap1 1 1.16 1.62 0.98 1.08 1.01 43215 6.77   
21 NP1L1_HUMAN Nucleosome assembly protein 1-like 1 nap1l1 1 1.30 1.17 1.30 #N/A 1.23 45374 4.08   
22 CALR_HUMAN Calreticulin calr 1 1.38 1.16 1.28 #N/A 1.39 48142 4.03   
23 RUVB2_HUMAN RuvB-like 2 ruvbl2 1 1.05 1.26 1.07 0.80 1.09 51157 5.25   
24 ECH1_HUMAN Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase ech1 1 0.96 0.83 1.01 0.49 1.00 35816 7.80   
25 HSPB1_HUMAN Heat shock protein beta-1 hspb1 1 1.11 1.35 1.09 #N/A 0.94 22783 5.97   
26 HSPB1_HUMAN Heat shock protein beta-1 hspb1 1 1.00 1.22 1.03 0.99 1.07 22783 5.97   
27 RABL3_HUMAN Rab-like protein 3 rabl3 1 1.36 1.15 1.42 1.28 1.81 26423 6.71   
S-nitrosylation after rapamycin stimulation was assessed by 2D SNO-DIGE analysis and subsequent identification by electrospray ionization mass spectrometry 
(ESI-MS/MS). SNO Upregulation is shown in blue, SNO down regulation in red, numbers indicate ratio compared to 0 hour (naïve). Identification of the modified 






Table 13 Protein modification by S-nitrosylation after induction of autophagy with rapamycin in wild type and nNOS overexpressing SHSY-5Y cells as analyzed 
by SNO-SILAC 
Protein ID Protein Gene Cysteine WT WT+R nNOS+ nNOS++R 
ROA2_HUMAN Heterogeneous nuclear ribonucleop. A2/B1 hnrnpa2b1 50 56.3 56.7 51.0 59.5 
HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 hnrnpd 126 53.8 58.8 54.8 41.5 
RTN4_HUMAN Reticulon-4 rtn4 1101 28.3 34.7 
 
32.2 
NHP2_HUMAN H/ACA ribonucleoprotein complex subunit 2 nhp2 18 21.2 29.2 
  DOPO_HUMAN Dopamine beta-hydroxylase dbh 596 5.5 
 
5.8 5.7 
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A ppia 161 3.6 
 
4.3 
 KPYM_HUMAN Pyruvate kinase isozymes M1/M2 pkm2 49 0.8 
  
0.6 
RLA0_HUMAN 60S acidic ribosomal protein P0 rplp0 119 20.8 
   HDGF_HUMAN Hepatoma-derived growth factor hdgf 108 14.1 
   TCPD_HUMAN T-complex protein 1 subunit delta cct4 450 8.3 
   RL7A_HUMAN 60S ribosomal protein L7a rpl7a 199 
 
39.8 32.8 42.4 
NOP58_HUMAN Nucleolar protein 58 nop58 439 
 
26.7 24.4 28.6 
FUBP1_HUMAN Far upstream element-binding protein 1 fubp1 148 
  
10.0 21.8 
CRIP2_HUMAN Cysteine-rich protein 2 crip2 126 
  
9.8 
 VDAC2_HUMAN VDAC-2 vdac2 47 
  
49.4 
 RS3_HUMAN 40S ribosomal protein S3 rps3 97 
   
20.9 
RL30_HUMAN 60S ribosomal protein L30 rpl30 85 
   
40.2 
RL32_HUMAN 60S ribosomal protein L32 rpl32 96 
   
36.6 
ACTB_HUMAN Actin, cytoplasmic 1 actb 217 
   
84.8 
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit prkdc 4061 
   
60.7 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase gapdh 152; 156 
   
0.1 
HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U hnrnpu 497 
   
38.2 
LRC59_HUMAN Leucine-rich repeat-containing protein 59 lrrc59 59 
   
75.5 
KDM5A_HUMAN Lysine-specific demethylase 5A kdm5a 626; 636 
   
32.7 
NDKA_HUMAN Nucleoside diphosphate kinase A nme1 109 
   
5.1 
TBB4B_HUMAN Tubulin beta-4B chain tubb4b 12 
   
22.7 
VDAC3_HUMAN VDAC-3 vdac3 36 
   
35.6 
VIME_HUMAN Vimentin vim 328 
   
41.0 
Nitrosylated cysteins identified by the SNO-SILAC method. WT: Wild type SHSY-5Y cells, nNOS+: nNOS overexpressing SHSY-5Y cells, rapa: Rapamycin stimulation 







Figure 26 Venn diagram of proteins identified by SNO-SILAC 
Venn diagram of nitrosylated proteins identified by SNO-SILAC 
Table 14 Protein S-nitrosylation in multiple methods 




ACTB_HUMAN Actin, cytoplasmic 1 actb 217 √ X √ 
EF2_HUMAN Elongation factor 2 eef2 290 √ √ X 
FUBP1_HUMAN Far upstream element-binding 
protein 1 
fubp1 148 √ X √ 
G3P_HUMAN Glyceraldehyde-3-phosphate 
dehydrogenase 
gapdh 152, 156 X √ √ 
HSP7C_HUMAN Heat shock cognate 71 kDa 
protein 
hspa8 17 √ √ X 
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 pkm2 49, 423, 424 √ √ √ 


















Table 15 Protein expression of proteins found nitrosylated by multiple methods 





EF2_HUMAN Elongation factor 2 eef2 1.00 1.37 1.38 0.57 * 
HSP7C_HUMAN Heat shock cognate 71 kDa protein hspa8 1.00 0.94 0.90 0.89 * 
ACTB_HUMAN Actin, cytoplasmic 1 actb 1.00 1.43 1.32 1.33 
FUBP1_HUMAN Far upstream element-binding protein 1 fubp1 1.00 0.98 0.98 1.15 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase gapdh 1.00 1.06 1.00 0.97 
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 pkm2 1.00 0.60 1.25 0.89 
Whole protein expression after rapamycin stimulation was assessed by SNO-SILAC. WT: Wild type SHSY-
5Y cells, nNOS+: nNOS overexpressing SHSY-5Y cells, rapa: Rapamycin stimulation (1 µM, 6 hours). 
Expression is normalized to wild-type naïve. * Significant Anova p < 0.05. 
 
Table 16 ER-stress proteins from SNO-SILAC data 







GRP78_HUMAN 78 kDa glucose-regulated protein hspa5 1.00 1.27  1.19  1.26  
PDIA1_HUMAN Protein disulfide-isomerase p4hb 1.00 1.20  1.14  1.63 * 
CALX_HUMAN Calnexin canx 1.00 0.92  0.85 * 0.85 
ERO1A_HUMAN ERO1-like protein alpha ero1l 1.00 0.18 0.25 0.29 
Results on four known ER-stress protein markers from the SNO-SILAC method. WT: Wild type SHSY-5Y 
cells, nNOS+: nNOS overexpressing SHSY-5Y cells, Rapa: Rapamycin stimulation (1 µM, 6 hours). * 







4.1 S-nitrosylation in neuropathic pain 
This study shows substantial protein S-nitrosylation and denitrosylation in the spinal cord upon sciatic 
nerve injury in mice on the side ipsilateral to the injury. In addition the results show that the impact of 
sciatic nerve injury on hyperalgesia can be abolished by eliminating nitric oxide production with the 
unspecific NOS inhibitor L-NAME. This suggests that NO-mediated post-translational protein 
modifications contribute to the neuronal and glial adaptations to the damage of the afferent neurons. 
4.1.1 Results of screening for S-nitrosylation 
The initial investigation into the targets of nitric oxide using 2D SNO-DIGE screening revealed 31 proteins 
with increased nitrosylation and 22 with a decrease in SNO. This indicates that there is substantial 
constitutive S-nitrosylation in the spinal cord. In contrast, sham surgery only resulted in SNO-
modifications of 15 proteins out of which only three showed an increase of S-nitrosylation suggesting 
that most of the observed alterations after SNI were elicited by the axonal injury. 
Time course analyses of candidate proteins revealed that some early SNO-modifications observed at one 
day after the injury had returned to baseline at 7 days. This was true for protein disulfide isomerase and 
glutathione synthetase where the SNO had been reduced after one day. On the other hand, S-
nitrosylation of the mitochondrial aconitase 2 was mainly increased at 7 days suggesting that S-
nitrosylation of some targets may impact on the chronic phase. It is conceivable that SNO-modifications 
of mitochondrial targets may outlast cytoplasmic or ER SNO modifications because of the more sustained 
disturbance of the redox balance at the mitochondria.  
In order to confirm the observed S-nitrosylation of some candidate proteins the biotin switch technique 
was applied. The BST was able to confirm that GSS, PDI, Aco2, Tuba, Tubb, and Prdx6 were S-nitrosylated 
after nerve injury.  SNO down-regulation of PDI in BST, though the other proteins did not show a 
significant difference between naïve and SNI-treated mice. Because the quantification of Western Blots 
has limitations an ELISA based version of the BST, called biotin switch ELISA (BSE), was established. This 
technical modification still does not allow for a differentiation between multiple SNO sites in one protein 
and relies on the specificity of the antibody. The quantitative readout however, was suitable to assess 
time courses of SNO modifications of target proteins and may be an advancement of the original 





sequence as well as changes in the number or location of SNO sites, but did not provide quantitative 
data. As shown in Fig. 4, SNOSID identified many SNO sites that were not affected by the sciatic nerve 
injury. SNOSID and 2D SNO-DIGE therefore provided complimentary information of the SNO-proteome. 
However, as for 2D-SNO-DIGE, the SNOSID screen mainly detected SNO-sites in highly abundant cytosolic 
proteins.  
4.1.2 Context of results with current literature 
The current understanding of NO mediated effects in nociceptive and nerve injury models suggests that 
glutamate release from the injured or stimulated afferent neurons activates NMDA receptors of the 
postsynaptic neurons which is linked to activation of neuronal NOS in the postsynaptic density and 
subsequent NO release. NO may then act on several targets in its vicinity (Schmidtko et al. 2009, Tegeder 
et al. 2011). This idea is supported by the observed increase of protein S-nitrosylation after sciatic nerve 
injury which was in part reversible upon treatment with L-NAME and paralleled by L-NAME mediated 
reversal of hyperalgesia. However, the observed decrease of S-nitrosylation of several proteins is not 
readily explained in this context. The decrease may be due to complex changes in the redox status, in 
redoxin functions (Benhar et al. 2008) and intracellular levels of glutathione (Romero and Bizzozero 
2009, Benhar, Forrester and Stamler 2009). The apparent decrease of SNO-sites may also result from 
trans-nitrosylation and formation of disulfide bonds or stronger oxidation of thiol groups to form sulfinic 
and sulfonic acid derivatives of cysteine. Such changes occur upon reaction with hydrogen peroxide (Lim 
et al. 2008, Noh et al. 2009, Burgoyne et al. 2007, Charles et al. 2007, Saurin et al. 2004) which may 
compete with NO for the cysteines. NOS catalytic activity depends on the oxidation-reduction cycle at its 
catalytic site. Redox imbalances lead to uncoupling and production of H2O2 instead of NO (Sun, Druhan 
and Zweier 2008, Landmesser et al. 2003) so that posttranslational reversible S-nitrosylation of critical 
cysteines may shift to irreversible thiol oxidations upon axonal injury.  
Out of the 53 proteins found in the first SNO-DIGE, 19 proteins have been previously reported to be S-
nitrosylated in different contexts. For example, S-nitrosylation of protein disulfide isomerase (PDI) was 
shown to affect its chaperone activity resulting in protein misfolding, accumulation of polyubiquitinated 
proteins, and neurodegeneration (Uehara et al. 2006, Walker et al. 2010). In these experiments PDI was 
denitrosylated after sciatic nerve injury suggesting that this may be a protective adaptive response and 
an attempt to prevent further ER stress. Based on the SNO site predictions and the SNOSID results PDI 
was S-nitrosylated at its active sites at cysteines 57, 60, 406, and 409, sites that are known to be redox 





were identified by SNO-DIGE and SNOSID. Based on the localization of S-nitrosylated cysteines, it is 
conceivable that catalytic functions of glutathione synthetase (GSS), mitochondrial aconitase (ACO2) and 
peroxiredoxin-6 (Prdx6) were changed after nerve injury. GSS has an ATP binding site in glutamic acid 
425 in the vicinity of the SNO site Cys422, which upon its nitrosylation might interfere with ATP binding. 
For Prdx6 cysteine 47 in the catalytic center of the enzyme is a SNO site and hence may affect its 
oxidoreductase activity (Fisher 2011) and S-nitrosylation of Aco2 at Cys448 and Cys541 may compete 
with iron-sulphur binding of these cysteines and lead to mitochondrial iron overload and dysfunctions 
(Cairo et al. 2002, Bulteau et al. 2004). Indeed several of the proteins which were SNO-modified are 
localized in mitochondria and involved in glucose metabolism and ATP synthesis or transport. Synapses 
are enriched with mitochondria to meet the high demand of energy for maintenance of synaptic activity. 
Upon nerve injury axonal transport of mitochondria and the physiological fusion and fission processes 
are strongly impaired suggesting that mitochondrial pathology is reflected by the SNO-modifications of 
mitochondrial proteins (Barsoum et al. 2006, Westermann 2009, Ferrari et al. 2011) and may be 
contributed by S-nitrosylation mediated changes of cytoskeletal dynamics and axonal transport (Lu et al. 
2009, Thom et al. 2008). It is of note that S-nitrosylation of the mitochondrial aconitase 2 was further 
increased 7 days after nerve injury whereas SNO-alterations of the ER localized PDI and the cytosolic GSS 
were normalized suggesting that SNO events at the mitochondria may indeed extend to the chronic 
phase.    
4.1.3 Methodological limitations 
Although the 2D SNO-DIGE revealed many SNO protein modifications the method has limitations in that 
it mostly detects abundant cytosolic proteins while underrepresenting membrane proteins and highly 
hydrophobic proteins. In addition, insufficient protein separation resulting in false positive results and 
the variability of the electrophoretic process may affect results. Further difficulties arise, if 
posttranslational modifications of proteins, such as phosphorylation or protein cleavage impact on their 
isoelectric point and mass so that one protein may be represented in more than one spot. Such double 
representations occurred for dihydropyrimidinase-related protein 2 (spot 13 and 14), which is known to 
be phosphorylated (Sweet et al. 2009), for ATP synthase subunit d and leukocyte elastase inhibitor A (no. 
56 and no. 57, and no. 39 and no. 41 respectively) and mitochondrial aconitase (Aco2) (no. 2 and no. 5). 
S-nitrosylation was consistent for all these double represented proteins so that the result was not 
confounded. Identification of the correct protein from excised gel spots can be precarious. Traces of 





this interference the protein spot location was matched with the mass and theoretical pI as well as the 
emPAI values from the MS data (Ishihama et al. 2005), which gave an estimation of protein abundance. 
Based on these values the prime candidate for each spot was selected. 
The present study did not assess the detailed toponomical aspects of S-nitrosylation or the cell types in 
which these changes occurred. In the spinal cord neuronal NOS is mainly expressed in the terminals of 
primary afferent neurons in laminae I and II and in some interneurons in laminae III, IV and V (Maihofner 
et al. 2000). Glial cells do not express NOS isoenzymes at baseline and 24 hours after SNI, but may 
upregulate inducible NOS at later time points (Maihofner et al. 2000, Zhang et al. 1993). It is therefore 
assumed that most of the observed SNO modifications are localized in neurons in laminae I-V of the 
dorsal horn. However, endothelial NOS may contribute to the SNO-proteome and since NO is a diffusible 
molecule it may also cause S-nitrosylation at neighboring glial cells or of matrix proteins. For detailed 
SNO-toponomics laser microdissection of dorsal horn regions and cell sorting prior to 2D SNO-DIGE may 
answer these questions in the future. Knock-in models are required to assess the functional relevance of 
individual SNO-sites in individual proteins. In order to improve the proteomic analyses the SILAC 
technique could be exploited.  
4.1.4 Conclusion 
Despite the limitations this is the first study showing that S-nitrosylation and denitrosylation in the spinal 
cord contribute to the adaptive post-translational changes after peripheral nerve injury. The observed 
partial L-NAME-mediated reversibility of the SNO-modifications and reversal of hyperalgesia suggest that 
the SNO-modifications contribute to the development of neuropathic pain. This study provides a list of 
potentially interesting candidate targets for S-nitrosylation that may play a role in the development of 
neuronal hyperexcitability. In this context NO apparently acts as a posttranslational modifier that, 
according to the prime candidates revealed by 2D SNO-DIGE and SNOSID, is likely to impact on 







4.2 S-nitrosylation in Autophagy 
In light of the results of the investigation into neuropathic pain that S-nitrosylation was likely to impact 
on protein folding and misfolding the next step was to further investigate the effect of S-nitrosylation on 
these processes. For this a cellular model of neuronal nitric oxide synthase (nNOS) over-expressing 
neuroblastoma cell culture, as well as wild type cells of the same type, stimulated with rapamycin to 
induce the process of autophagy was used. The effects of nNOS overexpression on autophagic processes 
were evaluated by western blotting with antibodies for known markers of autophagy. S-nitrosylation was 
evaluated using a combination of SNO-DIGE, SNOSID, SNO-SILAC, and SNO-ELISA methods. 
4.2.1 Evaluation of Autophagy progression 
An initial analysis of autophagy markers on the effects of rapamycin on the two cell lines revealed that 
there is substantial basal increase (+ 144%, p < 0.05) in the ratio of LC3-I / LC3-II in the nNOS over-
expressing cells compared to the wild type after stimulation with rapamycin. Under stressful conditions 
(e.g. starvation, pharmacological stimulation) LC3-I is converted to LC3-II by conjugation with 
phosphatidylethanolamine and then the conjugate form is recruited to autophagosomal membranes 
(Sou et al. 2006). The autophagosomes then fuse with lysosomes to form autolysosomes, and intra-
autophagosomal components are degraded by lysosomal hydrolases (Sou et al. 2006). At the same time, 
LC3-II in autolysosomal lumen is degraded. Thus an increase in the ratio of LC3-I / LC3-II indicates an 
increased autophagic activity or impairment of lysosomal degradation (Tanida, Ueno and Kominami 
2008, Mizushima and Yoshimori 2007). A lower increase of the LC3-I/LC3-II ratio after stimulation with 
rapamycin in the nNOS over-expressing cells (+233% in WT, +100% in nNOS+) suggests that the 
autophagic activity may be impaired by the increase of NO and possibly by an increase of direct protein 
S-nitrosylation. Alternatively, an increase of NO may also stimulate sGC mediated production of cGMP, 
followed by subsequent activation of protein kinase G (PKG). However, no direct link between autophagy 
and PKG has been reported in the literature, supporting the theory that S-nitrosylation might be the 
main mediator of the effects of NO on autophagy.  
A second important marker for degradation of protein aggregates is the ubiquitination of proteins. 
Ubiquitin is a small protein consisting of 76 amino acids that is covalently bound to lysines of proteins to 
mark them for degradation in a process called ubiquitination. Ubiquitination utilized a cascade of three 
different types of ubiquitin ligases, the E1 ubiquitin-activating enzyme that uses ATP to activate ubiquitin 
for conjugation and transfers it to an E2 ubiquitin-conjugating enzyme. The E2 the enzymes then interact 





lysine residue thus marking the target protein for degradation by targeting them to the proteasome, the 
lysosome, and the autophagosome (Shaid et al. 2013).  
In the nNOS over-expressing cells the total ubiquitination was increased (+100%, p < 0.01) while it was 
decreased (-30%, p < 0.01)) in the wild type cells after rapamycin stimulation. This indicates that the 
targeting or degradation processes may be impaired by the increase in S-nitrosylation of the E1, E2 or E3 
ubiquitin ligases. Indeed these results are consistent with previous results by Sarkar et al. who showed 
that NO inhibits autophagy by two distinct mechanisms. Primarily by S-nitrosylation of JNK1 inhibits the 
formation of autophagosomes by reduced Bcl-2 phosphorylation, leading to an increase in interaction of 
Bcl-2 with Beclin-1, and disrupting Beclin 1–hVps34 association, which is essential to the initiation of 
autophagic processes (Li and Fan 2010, Sarkar et al. 2011). Secondly Sarkar et al showed that NO 
activates the mammalian target of rapamycin receptor 1 (mTORC1) leading to an inhibition of autophagy 
processes (Sarkar et al. 2011). This further supports that the effects of NO on the autophagy process are 
not mediated directly through the sGC and PKG pathway. 
Heat shock cognate 71 kDa protein (HSC70, gene: hspa8) is chaperone that binds to nascent 
polypeptides to facilitate correct protein folding. An increase in HSC70 expression is indicative of 
increased protein misfolding (Liu, Daniels and Cao 2012). Indeed the increase in HSC70 expression 
(+120%, p < 0.001) seen in nNOS over-expressing cells after stimulation with rapamycin, while there was 
a decrease in HSC70 expression in wild type cells after stimulation, suggests that there may be a 
significant increase of misfolding and/or disruption of the targeting of misfolded proteins to degradation 
caused by increased S-nitrosylation or redox stress of newly generated proteins due to S-nitrosylation. 
4.2.2 Targets of S-nitrosylation after autophagy induction 
Thus there are clear effects of the increased nitric oxide production induced by the over-expression of 
nNOS on the processes of protein degradation. The next question that arises is what might be the targets 
of nitric oxide. To screen for targets of S-nitrosylation the same approaches as in the investigation of S-
nitrosylation in neuropathic pain were used, namely SNO-DIGE and SNOSID. Due to the transient nature 
of proteins during a process such as autophagy a SILAC based approach was also assessed to analyze 
protein S-nitrosylation and total protein expression simultaneously. The main drawback of the SNO-DIGE 
approach is the mimicry of nitrosylation events by changes in protein expression. Thus a simultaneous 
down-regulation in the expression of a protein and increase in nitrosylation might be seen as little or no 





degradation and turnover such as autophagy it is essential to obtain protein expression information to 
account for changes that might produce false positive or false negative results. 
To investigate the progress of S-nitrosylation in autophagy a timeline of S-nitrosylation changes was 
made using the SNO-DIGE method after stimulation of nNOS over-expressing cells with rapamycin. 
Twenty two unique proteins in 27 spots were found to show time dependent changes in nitrosylation. 
The greatest changes occurred in the range of 4 and 8 hours after stimulation with rapamycin. Based on 
these results a time point of 6 hours was selected for further investigations of nitrosylation events after 
rapamycin stimulation.  
The results suggested that NO impacts on the autophagy process as indicated by the autophagy markers, 
but this study found only a few direct alterations of autophagy-proteins by S-nitrosylation suggesting 
that NO did not directly interfere with the autophagy processes.  
4.2.3 Context of results with current literature 
Currently only one study assessed the involvement of S-nitrosylation in autophagy. Sarkar et al, showed 
as previously described, that S-nitrosylation of JNK1 inhibits the formation of autophagosomes by 
reduced Bcl-2 phosphorylation (Sarkar et al. 2011). Using an autophagy database published by Homma  
et al. (Homma, Suzuki and Sugawara 2011) and the S-nitrosylation prediction algorithm GPS-SNO (Xue et 
al. 2010), revealed that out of 387 proteins listed (with sufficient information to acquire their sequence) 
259 proteins were predicted to be S-nitrosylated. In fact this study found four proteins listed in the 
autophagy database to be nitrosylated, namely Actin (actb), Pyruvate kinase isozymes M1/M2 (pkm), 
DNA-dependent protein kinase catalytic subunit (prkdc), and Ubiquitin-like modifier-activating enzyme 1 
(uba1). 
The SNO-SILAC revealed that cysteine 217 of Actin is nitrosylated. Right next to this cysteine is a 
phosphorylation site at tyrosine 218 (Rush et al. 2005) indicating that the phosphorylation of that site 
could be affected by S-nitrosylation events, potentially affecting the proteins function. Aguilera et al. 
showed that actin participates in the early events of cytoskeletal autophagosome formation upon 
starvation induced autophagy, and that actin is necessary for starvation-mediated autophagy (Aguilera, 
Beron and Colombo 2012). Also actin S-nitrosylation is believed to influence neurotransmitter release in 
inflammatory pain leading to disinhibition of synaptic transmission in the spinal dorsal horn (Lu et al. 





immediately after neuronal injury through disinhibition of signal transduction as well as long term effects 
through inhibition of autophagosome formation. 
DNA-dependent protein kinase catalytic subunit (PRKDC) is a serine/threonine-protein kinase that acts as 
a molecular sensor for DNA damage and also phosphorylates the autophagy protein JNK1 (Ma et al. 
2004, Soubeyrand et al. 2003, Yavuzer et al. 1998). In this study PRKDC was found to be nitrosylated at 
cysteine 4061 in the SNO-DIGE after rapamycin stimulation of nNOS over-expressing cells though no 
currently known functional site is nearby. Knockdown of PRKDC has been shown to induce massive 
autophagic cell death after ionizing radiation injury of glioblasoma cells, indicating a protective role of 
the protein in response to DNA damage (Zhuang et al. 2011). Recent studies have revealed that S-
nitrosylation of DNA repair proteins may enhance their activity (Tang, Wei and Liu 2012) and that PRKDC 
S-nitrosylation is mediated through GAPDH (Kornberg et al. 2010). The effect of S-nitrosylation on the 
function of PRKDC remains to be determined.  
Ubiquitin-like modifier-activating enzyme 1 (UBA1) is an ubiquitin-activating E1 enzyme. UBA1 activates 
ubiquitin by first adenylating its C-terminal glycine residue with ATP, followed by linking this residue to 
the side chain of a cysteine residue in E1, yielding an ubiquitin-E1 thioester and free AMP. UBA1 has two 
active sites within the E1 molecule, allowing it to accommodate two ubiquitin moieties at a time. S-
nitrosylation of the active thiol could affect the ability of UBA1 to carry out the transfer of ubiquitin to 
the E2 as discussed above. 
The results suggest that S-nitrosylation may regulate protein folding, ubiquitination, and possibly de 
novo protein generation. In this study several proteins have emerged as major candidates for being 
targets of S-nitrosylation and consequentially impacting the autophagic processes, namely Heat shock 
cognate 71 kDa protein (abbreviation: HSC70, gene: hspa8) and Pyruvate kinase isozymes M1/M2 
(PKM2, gene: pkm2), Calreticulin (gene:calr), Ubiquitin-conjugating enzyme E2 D1 (UBE2D1, gene: 
ube2d1), and Elongation factor 2 (EF2, gene: eef2). 
HSC70 and PKM2 were found to be nitrosylated after induction of autophagy by rapamycin as well as in 
mouse spinal cord after SNI operation. These proteins mutually interact and, though the interaction site 
has not been described, nitrosylation of either protein could interfere with their interaction. Acetylation 
of PKM2 at K305 decreases PKM2 enzyme activity and increases PKM2 interaction with HSC70 (Lv et al. 
2011). HSC70 is a chaperone for chaperone-mediated autophagy and through interaction with PKM2 





dependent degradation of PKM2 (Lv et al. 2011). In addition S-nitrosylation of PKM2 cysteines 423 and 
424 could theoretically impact on the proteins ability to bind with D-fructose 1,6-bisphosphate (FBP). 
FBP allosterically activates the M2 isoform while selective binding to tyrosine-phosphorylated peptides 
releases the allosteric activator FBP, leading to inhibition of PKM enzymatic activity (Lv et al. 2011). This 
diverts glucose metabolites from energy production to anabolic processes when cells are stimulated by 
certain growth factors. FBP has allosteric binding sites in region 432 – 437 and region 514 – 521. 
Nitrosylation of nearby cysteines could thus interfere with the binding of FBP and inhibiting the 
activation of PKM2 possibly further influencing the interaction with HSC70 and subsequent chaperone-
mediated autophagy of PKM2. Thus S-nitrosylation of PKM2 and HSC70 may influence the long term 
adaption of neurons to neuronal damage by inhibition of the autophagic processes. 
Calreticulin is a calcium-binding chaperone that promotes folding, oligomeric assembly, and quality 
control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle (Michalak et al. 2009). 
Calreticulin binds to misfolded proteins and prevents them from being exported from the endoplasmic 
reticulum to the Golgi apparatus (Holaska et al. 2001, Nauseef, McCormick and Clark 1995).  
Calreticulin has 3 cysteines (C105, C137, and C163) with C105 and C137 forming a disulfide bridge, 
leaving C163 as the likely candidate for nitrosylation. Nitrosylation of calreticulin has been shown to lead 
to an increase in its externalization from the ER in conjunction with phosphatidylserine (PS) under 
apoptotic stress suggesting that calreticulin acts as a bridging molecule during apoptotic cell clearance 
(Tarr et al. 2010). Although they share many components (e.g. the proteins Becliin-1, p62, and Atg5) and 
appear to be highly connected processes no direct causal relationship has been convincingly shown 
between autophagy and apoptosis (Gump and Thorburn 2011). S-nitrosylation of Calreticulin during 
autophagy could, similarly to its effects in apoptosis, lead to an increased externalization of misfolded 
protein and subsequently their transfer to degradation by the autophagic processes. 
The process of ubiquitination requires an ubiquitin-activating E1 enzyme, an E2 conjugating enzyme and 
an E3 ubiquitin ligase. Following activation of ubiquitin by formation of a thioester bond with the E1 the 
ubiquitin moiety is transferred to the E2. The E2 then transfers the ubiquitin to either an E3 ligase or 
mediates the attachment of ubiquitin to a lysine residue of the substrate protein through a RING or U-
box E3 ligases (Windheim, Peggle and Cohen 2008). UBE2D1 accepts ubiquitin from the E1 complex 
through cysteine 85 and catalyzes its attachment to other proteins. Indeed UBE2D1 was found to be 





ability to ubiquitinylate proteins and thus interfere with targeting of certain proteins to degradation. 
Thus S-nitrosylation might catalyze the reaction in a manner depicted in Figure 27. 
 
Figure 27 Catalysis of E2 ubiquitination by NO 
Figure shows the reaction when ubiquitin is transferred to the E2 ligase by formation of a thioester bond. 
UBE2:E2 ubiquitin conjugating enzyme, Ubi: ubiquitin. 
 
This catalysis might lead to the strong increase in ubiquitination seen in nNOS over-expressing cells, 
compared to a decrease in wild type, after stimulation with rapamycin. This could further indicate that 
although there is increased ubiquitination the proteins are not being transferred to degradation, 
suggesting an impairment of the ubiquitination degradation pathway at another step. However, no 
evaluation of protein aggregates was conducted in this study and this remains to be investigated in 
future studies.  
In addition ubiquitination not only marks proteins for degradation but is also important for regulation of 
receptor presentation at the cell membrane, such as AMPA-R. Therefore, alteration of ubiquitin may also 
affect e.g. glutamate sensitivity which is relevant for pain signaling. 
It is important to note that nNOS itself is regulated by ubiquitination (Clapp et al. 2012, Clapp et al. 2010, 
Oustwani et al. 2011). This could lead to a feedback loop where an increase in NO leads to increased 
ubiquitination of nNOS and subsequent decrease in NO. Also increased activity of the ubiquitin pathway 
possibly decreases NO production and thus limiting the inhibitory effects of NO on protein degradation. 
While Ube2D and Hsc70 control protein stability and quality, EF2 may be a potential NO target involved 
in protein synthesis being an essential factor for protein synthesis. Phosphorylation by EF-2 kinase 
completely inactivates EF-2, and such might also be true of nitrosylation (Hizli et al. 2013). Nitrosylation 
might interfere with the proteins ability to be phosphorylated or its interaction with ribosomes. EF is 
under the control of the mTOR system and rapamycin increases the level of phosphorylated EF2 (Ji et al. 
2009). EF2 was found to be nitrosylated at cysteine 290 and was found nitrosylated in the SNO-DIGE 














after rapamycin stimulation. Nitrosylation of EF2 was increased after 4 hours but then decreased back to 
its initial value after 8 hours, to 55% of its initial value after 16 hours, and was no longer nitrosylated 
after 24 hours.  
From this evidence it appears that NO may use multiple mechanisms to modulate cell survival under 
stress conditions: 
1. Interfering with chaperone mediated autophagy. 
2. Interfering with protein degradation and receptor presentation through ubiquitination. 
3. Control of de novo protein synthesis and regulation of energy/calcium homeostasis. 
 
4.2.4 Methodological limitations 
For the autophagy through rapamycin stimulation part of this study, the disadvantages of SNO-DIGE for 
screening for S-nitrosylation are particularly important. A process such as autophagy involves a high level 
of protein modifications, such as phosphorylation as well as changes in expression and degradation. Such 
changes may mask the changes in nitrosylation events. Identification of the correct protein from each 
excised gel spot is problematic and requires statistical approaches as described above. 
To correct for these changes the usefulness of a SILAC based method for the identification of S-
nitrosylated proteins was assessed. Using this approach it is theoretically possible to simultaneously 
detect nitrosylated proteins and non-nitrosylated proteins and calculate the level of nitrosylation as a 
ratio of expressed proteins. However the approach did reveal only few nitrosylated proteins though total 
protein expression patterns of around 500 proteins were successfully mapped. This information is 
nevertheless helpful to evaluate the true changes in nitrosylation of proteins identified by SNO-DIGE.  
The main limitations of this method revolve around the complexity of samples. The samples are not 
purified for S-nitrosylated proteins and thus contain a high amount of non-nitrosylated proteins leading 
to a difficult evaluation of the sample. Better sample fractionation of the samples, for example by 
cellular components, could reduce the sample complexity. Also improvements in mass spectrometry and 
improved peptide search algorithms may also improve sample analysis. A better SILAC standard could be 
made by mixing naïve SILAC cells and SILAC treated with rapamycin to improve expression profile of 






This study was limited to the use of rapamycin for autophagic stimulation. Rapamycin is a direct inhibitor 
of mTOR. Glucagon is also another inhibitor of mTOR and autophagy induction can also be induced 
independent of mTOR by lithium, sodium valproate and carbamazepine (Sarkar et al. 2011). Thus further 
exploration could include different stimulators of autophagy as well as utilizing proteasome the 
proteasomal inhibitor MG-132. Tamoxifen is also believed to induce autophagy by increasing the 
expression of Beclin-1 (Zhang et al. 2007). A multifaceted approach could possibly better reveal which 
role S-nitrosylation may play in the induction of distinct autophagy pathways. Inhibition of autophagic 
processes would also add another dimension to such studies. Several inhibitors of autophagy are known 
though most of them are not entirely specific. This includes the sequestration inhibitors 3-MA, LY294002, 
and wortmannin; phosphatidylinositol-3-kinase inhibitors such as lime okadaic acid; compounds that 
raise the lysosomal pH like bafilomycin; chloroquine that increases the formation of autophagosomes; 
single gene deletions or RNAi interference (e.g. Atg genes) (Klionsky et al. 2008).  
To evaluate the progression of autophagy this study utilized western blotting for LC3-I/LC3-II ratios, p62, 
HSC70, ubiquitin, as well as SILAC based data of protein expression levels. Several other methods have 
been described to monitor the progression of autophagy. This includes electron microscopy of 
autophagosomes, fluorescence microscopy with GFP tagged LC3, TOR and Atg1 kinase activity assays, 
monitoring of transcriptional regulation of autophagy genes, protein degradation assays, GFP-Atg8/LC3 
lysosomal delivery and proteolysis, autophagosome-lysosome colocalization, and more (Klionsky et al. 
2008). A more varied approach to determine the progress of autophagy would enhance the knowledge 
on how NO, through S-nitrosylation, interferes with the process. 
Using a cellular model may not fully reveal potential changes that occur in vivo upon exposure to certain 
types of stress and the response may be site and tissue specific. This study employed neuroblastoma 
cells which share some features of neuronal cells but do not allow an assessment of the complex 
interplay of neurons, glia, immune and endothelial cells which all contribute to the production and 
scavenging of NO. Although overexpression of nNOS in culture was used to mimic the nerve injury 
evoked induction of nNOS in vivo, the neuroblastoma model cannot mimic the specific functions of nNOS 
at the presynaptic terminal and in the postsynaptic density where modification of protein stability and 
quality may be crucial for synaptic signaling. Nevertheless, the results suggest that NO modifies protein 
folding and ubiquitination through direct S-nitrosylation though the in vivo relevance has to be 






This study provides a list of potentially interesting candidate targets for S-nitrosylation that may play a 
role in the ability of neurons to recover from injury (e.g. SNI) by impairing the cells ability to adapt to the 
stressful situation. Impairment of the injured neuron to adapt to increased stress leads to neuronal 
death, a crucial part of the development of neuropathic pain. Autophagy may be an important protective 
adaptive response which, by promoting the removal of protein waste in injured neurons, may enhance 
the likelihood for neuronal survival. Further studies may reveal whether alteration of direct protein S-
nitrosylation of target proteins in autophagy pathways improves the outcome in terms of neuronal 
survival and neuropathic pain. Thus the results suggest that NO, in addition to its known regulation of 
cGMP signaling, may contribute to the fine tuning of protein folding and degradation which are key 







Neuropathic pain is a maladaptive form of chronic pain caused by a primary injury or lesions in the 
central or peripheral nervous systems. Recently nitric oxide (NO) has emerged as important pro-
nociceptive signaling molecule in pain signaling and processing. Chemical inhibiton or deletion of Nitric 
oxide synthase (NOS), as well and inhibition of the NOS-coenzyme tetrahydrobiopterin is known to 
reduce or inhibit neuropathic pain. NO exert its influence through two major pathways: by stimulation of 
sGC and by direct S-nitrosylation (SNO) of target proteins. This study assessed in the spinal cord the SNO-
proteome with two methods, two-dimensional S-nitrosothiol difference gel electrophoresis (2D SNO-
DIGE) and SNO-site identification (SNOSID) at baseline and 24 h after sciatic nerve injury with/without 
pretreatment with the nitric oxide synthase inhibitor L-NAME. At 24h after nerve injury, SNO-DIGE 
revealed 30 proteins with increased S-nitrosylation and 23 proteins with decreased S-nitrosylation. SNO-
sites were identified for 17 out of these 53 proteins. L-NAME pretreatment substantially reduced both 
constitutive and nerve injury evoked up-S-nitrosylation. For the top candidates S-nitrosylation was 
confirmed with the biotin switch technique and time course analyses at 1 and 7 days after nerve injury 
showed that SNO modifications of protein disulfide isomerase (PDI), glutathione synthase (GSS) and  
peroxiredoxin-6 (Prdx6) had returned to baseline within 7 days whereas S-nitrosylation of mitochondrial 
aconitase 2 (Aco2) was further increased.  The identified SNO modified proteins are primarily involved in 
mitochondrial function, protein folding and transport, synaptic signaling and redox control.  
Several targets, including PDI, Heat shock cognate 71 kDa protein, and Serpin B6,  indicated that NO 
might play a role in protein quality control, metabolism, and folding. Subsequently an investigation into 
the potential role of NO and SNO in proteasomal degradation and autophagy was performed. Autophagy 
is a basic catabolic mechanism involving the degradation of unnecessary or dysfunctional cellular 
components through the lysosomal machinery and is an important factor in the recovery of neurons 
after injury. A cellular model of neuronal nitric oxide synthase (nNOS) over-expressing neuroblastoma 
cell culture stimulated with rapamycin to induce autophagy was used. The effects of nNOS 
overexpression on autophagic processes were evaluated by western blotting with antibodies for known 
markers of autophagy. S-nitrosylation was evaluated using a combination of SNO-DIGE, SNOSID, SNO-
SILAC, and SNO-ELISA methods. Increased (+ 144%, p < 0.05) LC3-I / LC3-II ratio in the nNOS over-
expressing cells compared to the wild type after stimulation with rapamycin  suggested that the 
autophagic activity may be impaired by the increase of NO and possibly by an increase of direct protein 





0.01) while it was decreased (-30%, p < 0.01)) in the wild type cells after rapamycin stimulation. This 
indicates that the targeting or degradation processes may be impaired by the increase in S-nitrosylation 
of the E1, E2 or E3 ubiquitin ligases. The results suggest that S-nitrosylation may regulate protein folding, 
ubiquitination, and possibly de novo protein generation. In this study several proteins have emerged as 
major candidates for being targets of S-nitrosylation and consequentially may affect the autophagic 
processes, namely heat shock cognate 71 kDa protein and pyruvate kinase isozymes M1/M2, calreticulin, 
ubiquitin-conjugating enzyme E2 D1, and elongation factor 2. 
The results suggest that NO, in addition to its known regulation of cGMP signaling, may contribute to the 
fine tuning of protein folding and degradation which are key mechanisms for allowing neurons to 
recover stability after axonal injury.    
  




6. Zusammenfassung auf Deutch 
Neuropathischer Schmerz ist eine Form von chronischem Schmerz, verursacht durch eine Verletzung 
oder Läsion im zentralen oder peripheren Nervensystem. Schneiden oder Quetschen sind häufige 
Ursachen von neuropathischen Schmerzen, z.B. nach Amputation einer Extremität oder einem 
Bandscheibenvorfall. Einige Krankheiten wie Multiple Sklerose, HIV/AIDS und Diabetes können 
Nervendegeneration verursachen und die Verarbeitung von Schmerzsignalen stören, was zu Schmerzen 
führt. Ebenso können neurotoxische Chemikalien und Medikamente, wie Beispielsweise die in der 
Chemotherapie bei Krebs eingesetzten (z.B. Cisplatin, Oxaliplatin, and Vincristine), Schmerzen durch 
Schädigung von Neuronen. Die Hauptmerkmale von neuropathischem Schmerz  sind unangenehmen und 
anormalen Gefühle, wie erhöhte Antwort auf schmerzhafte Stimuli (Hyperalgesie) und schmerzhafte 
Antwort auf benigne Stimulation (Allodynie). 
Es hat sich gezeigt, dass NO ein wichtiges pro-nozizeptives Signalmolekül ist, NO entfaltet seine 
Wirkungen teilweise , indem es durch Stimulation der löslichen Guanylylcyclase die Produktion von 
cGMP steigert. NO moduliert zudem Enzymfunktionen oder Protein-Interaktionen und –Transport durch 
direkte Protein S-Nitrosylierung (SNO) von entscheidenden Cysteinresten. SNO ist eine post-
translationale kovalente Addition von Stickoxid zur Thiol-Gruppe des Cysteins. Die Funktion direkter S-
Nitrosylierungen für die Entstehung chronischer Schmerzen ist weitestgehend unbekannt. In dieser 
Studie wurde daher untersucht. 
Daher kann die NO vermittelte S-Nitrosylierung der Übertragung von Schmerzsignalen dienen, ähnlich 
wie die Regulation durch Phosphorylierung und De-Phosphorylierung und kann Einfluß auf die 
nozizeptive Antwort und Adaptation von lang anhaltenden Verletzungen, wie axonale Verletzungen 
haben. 
Angesichts des erhöhten NO-Gehalt von Neuronen nach einer Verletzung und der Tatsache das der 
cGMP/PKG-Signalweg nicht komplett den Effekt von NO im Schmerz erklärt, lässt es vermuten das die 
pro-nozizeptiven Effekte von NO auch durch direkte S-Nitrosylierung von Proteinen vermittelt wird. Der 
Hauptmechanismus der S-Nitrosylierung in der Adaptation auf Schmerzsignale begründet sich sehr 
wahrscheinlich in Ionenkanälen, Rezeptoren, mitochondrialer Qualitätskontrolle, sowie bei Proteinen 
welche beim Protein-Recycling beteiligt sind. Daher ist es interessant das S-Nitrosoproteom des 




neuropathischen Schmerzmodels zu untersuchen, um herauszufinden welche Proteine wichtige Ziele der 
SNO sind. 
Diese Studie zeigt eine beachtliche Protein S-Nitrosylierung und De-Nitrosylierung im Rückenmark nach 
SNI in Mäusen auf der ipsilateralen Seite der Verletzung. Zusätzlich zeigen die Ergebnisse das der Einfluss 
der SNI auf Hyperalgesie durch Unterdrückung der Stickoxid-Produktion, durch den unspezifischen NOS-
Inhibitor L-NAME beseitigt werden kann. Daraus lässt sich schließen, dass die NO-vermittelte post-
translationalen Proteinmodifikationen zu neuronale und gliale Adaptationen, nach Schädigung der 
afferenten Neuronen, beitragen.  
Die anfänglichen Untersuchungen auf die Ziele des Stickoxids mittels 2D SNO-DIGE Screening zeigen 31 
Proteine mit erhöhter Nitrosylierung und 22 mit einer Abnahme in der SNO. Dies zeigt, dass es eine 
beachtliche konstitutive S-Nitrosylierung im Rückenmark gibt. Im Gegensatz dazu kommt es bei Schein-
Operationen zur Modifikation von 15 Proteinen, von denen nur drei eine erhöhte S-Nitrosylierung 
aufweisen, was nahelegt, dass die meisten Änderungen nach SNI durch die axonale Verletzung ausgelöst 
werden.  
Um die beobachtete S-Nitrosylierung von einigen beteiligten Proteinen zu bestätigen, wurde die Biotin-
Switch-Technik (BST) angewandt. Diese zeigte, dass Aconitate hydratase, mitochondrial (Aco2), 
Glutathione synthetase (Gss), Peroxiredoxin-6 (Prdx6), Protein disulfide-isomerase A3 (PDI), Tubulin 
alpha-4A chain (Tuba), und Tubulin beta-5 chain (Tubb) nach Nervenläsion S-nitrosyliert werden. Zur 
besseren Quantifizierung wurde eine ELISA basierte Version des BST etabliert, der Biotin-Switch ELISA. 
Um zu untersuchen ob S-Nitrosylierung nach SNI eine kurzlebige frühe Erscheinung ist oder einen 
langlebigen Anpassungsmechanismus darstellt, überprüften wir S-Nitrosylierungen von bekannten 
Zielgenen (GSS, PDI, GAPDH, TUBB, PRX-6, ACO2) ein und sieben Tage nach SNI unter Verwendung des 
zuvor beschriebenen ELISAs. Für PDI, GSS und PRX6 normalisierten sich die S-Nitrosylierungen, die nach 
einem Tag sichtbar waren, nach sieben Tagen wieder. Im Gegensatz dazu war bei ACO2 die S-
Nitrosylierung nach einem Tag noch unverändert aber sieben Tage nach SNI signifikant erhöht, was 
vermuten lässt, dass ACO2 S-Nitrosylierung eine chronische Modifikation darstellt. 
Die SNOSID-Methode liefert Informationen über das modifizierte Cystein sowie Änderungen in der Zahl 
oder Lokalisation der SNO-Stelle. SNOSID liefert jedoch keine quantitativen Daten. Die Hauptziele von 
SNOSID beinhalten die Akonitat-Hydratase (mitochondriales Protein), die Fruktose-Bisphosphat-Aldolase 




C, das Pyruvatkinase-Isoenzym M1/M2, die Malatdehydrogenase (mitochondriales Protein), das NADH-
Dehydroganse-(Ubiquinon)-Flavoprotein 1 (mitochondriales Protein) und Phosphoglyceratmutase 1. 
Die Untersuchungen zeigen, dass S-Nitrosylierung und Denitrosylierung bei den adaptiven post-
translationalen Änderungen im Rückenmark nach Nervenläsion mitwirken. Die beobachtete partielle L-
NAME-vermittelte Reversibilität der SNO-Modifikationen und die Umkehr der Hyperalgesie legen nahe, 
dass die SNO-Modifikationen zur Entstehung von neuropathischem Schmerz beitragen könnten. NO 
könnte hierbei durch die direkte posttranslationale Modifikation verschiedene Anpassungsprozesse 
modulieren. Bei den Haupt-SNO Kandidaten handelte es sich um Protein der Mitochondrien, des 
Zytoskeletts, Chaperone und am Proteinabbau beteiligte Proteine sowie einige Enyzme. Die Ergebnissen 
deuten darauf hin, dass NO für die Qualitätskontrolle von Proteinen und Mitochondrien bedeutsam sein 
könnte.  
Da die Ergebnisse der Untersuchungen neuropathischer Schmerzen vermuten ließen, dass S- 
Nitrosylierung Proteinfaltung positiv als auch negativ beeinflussen könnte, wurde anschließend der 
Effekt der S-Nitrosylierung auf Autophagie-Prozesse untersucht. Die Autophagie ist neben einer 
Proteasom-vermittelten Proteindegradation ein wesentlicher Proteinabbauweg. Hierzu wurde eine 
neuronale Stickstoffmonoxid-Synthase (nNOS) überexprimierende Neuroblastom Zelllinie, als auch 
wildtypische Zellen des gleichen Zelltyps, mit Rapamycin stimuliert, um den Vorgang der Autophagie zu 
induzieren. Die Auswirkungen der nNOS- Überexprimierung auf autophagische Vorgänge wurden unter 
Verwendung einer Kombination von SNO-DIGE, SNOSID, SNO-ELISA, und SNO-SILACMethoden eruiert. 
SNO-SILAC nutzt den Einbau einer zugeführten „schweren“ Form von Aminosäuren in Proteine mit 
stabilen isotopischen Nuklei (z.B. Deuterium, 13C, 15N). Nach dem Wachstum der Zielorganismen in 
„schwerem“ Nährmedium wird das „schwere“ Protein extrahiert. Durch das Vermischen mit 
extrahiertem Protein aus dem gleichen oder ähnlichen Organismus aus irgendeinem anderen 
expermimentellen Versuchsaufbau, wird ein interner Standard gewonnen. Nach 
massenspektrometrischer Analyse kann der Quotient aus schweren und leichten Proteinen je Probe 
berechnet und innerhalb der experimentellen Gruppen verglichen werden. Durch das Kennzeichnen der 
Cysteine mit Thiolreaktiven Markern kann der Quotient für unterschiedlich gekennzeichnete Cysteine 
reduziert und dadurch der Grad der Nitrosylierungen oder Redox-Modifikationen unterschiedlicher 
Proben verglichen werden. 




Erste Analysen des Effektes von Rapamyzin mittels Markern für Autophagie ergaben, dass eine starke 
basale Zunahme (+144 %, p < 0,05) des LC3-I / LC3-II Quotienten in den nNOS überexprimierenden Zellen 
im Vergleich zur wildtypischen Kontrolle nach Stimulation mit Rapamycin besteht. Die Zunahme des LC3-
I / LC3-II Quotienten weist auf eine Zunahme der autophagischen Aktivität oder auf eine 
Beeinträchtigung des lysosomalen Abbaus hin. Ein verminderter Anstieg des LC3-I / LC3-II Quotienten 
nach Stimulation mit Rapamycin in nNOS überexprimierenden Zellen (+233 % in WT, + 100 % in nNOS+) 
deutete an, dass die autophagische Aktivität aufgrund der NO-Überproduktionund vermutlich durch die 
Zunahme direkter Protein S-Nitrosylierung beeinträchtigt sein könnte. 
Ein weiterer wichtiger Marker für die Degradierung von Proteinaggregaten ist die Ubiquitinylierung von 
Proteinen. Ubiquitin ist ein kleines Protein bestehend aus 76 Aminosäuren. Während der sogenannten 
Ubiquitinylierung wird es kovalent an Lysin-Reste der Proteine gebunden, um diese für die Degradierung 
zu kennzeichnen. In den nNOS überexprimierenden Zellen war die Summe der Ubiquitinylierungen 
erhöht (+100 %, p < 0,01), während sie in den wildtypischen Zellen nach Stimulation mit Rapamyzin 
reduziert war (-30 %, p < 0,01). Dies lässt vermuten, dass die Markierungs- bzw. Degradierungsvorgänge 
durch die vermehrte S-Nitrosylierung der Ubiquitin Ligasen verändert sein könnten. 
Heat shock cognate 71 kDa proteinm (HSC70, hspa8) ist ein Chaperon, dass an wachsende 
Polypeptidketten bindet, um eine fehlerfreie Proteinfaltung zu gewährleisten. Es konnte eine erhöhte 
HSC70 Expression (+120 %, p < 0,001) in nNOS überexprimierenden Zellen nach Stimulation mit 
Rapamycin beobachtet werden, während in wildtypischen Zellen HSC70 nach Stimulation abnahm. Dies 
impliziert, dass die Fehlfaltung von Proteinen signifikant steigt und / oder die Markierung fehlgefalteter 
Proteine zur Degradierung gestört ist, was wiederum durch die vermehrte S-Nitrosylierung oder durch 
Redox-Stress von neu- synthetisierten Proteinen aufgrund von S-Nitrosylierungen ausgelöst wird. 
Um Targets für S-Nitrosylierungen zu identifizieren, wurde die gleiche Herangehensweise wie bei der 
Untersuchung von S-Nitrosylierungen während neuropathischer Schmerzen verwendet: SNO-DIGE und 
SNOSID. Aufgrund der transienten Natur der Proteine während Vorgängen wie Autophagie, wurde eine 
SILAC-basierte Methode herangezogen, um die Protein S-Nitrosylierung und die Gesamtheit der 
Proteinexpression simultan zu analysieren. 
Zur Untersuchung des Fortschreitens der S-Nitrosylierung nach Induktion von Autophagy wurde unter 
Verwendung der SNO-DIGE Methode eine Zeitreihe über die Veränderungen von S-Nitrosylierungen nach 
Stimulation von nNOS überexprimierenden Zellen mit Rapamycin erstellt. 22 unterschiedliche Proteine in 




27 ‚spots‘ wurden gefunden, die zeitabhängige Veränderungen der Nitrosylierungen zeigten. Die 
bedeutendsten Modifikationen ereigneten sich zwischen 4 und 8 Stunden nach Stimulation mit 
Rapamycin.  
Die SNO-SILACUntersuchung ergab nur wenige nitrosylierte Proteine, obgleich die Gesamtheit der 
Proteinexpressionsmuster von etwa 500 Proteinen identifiert werden konnte. Die Resultate implizieren, 
dass NO autophagische Vorgänge beeinflusst, wie durch die Autophagie-Marker aufgezeigt werden 
konnte. Allerdings wurden in dieser Studie nur wenige direkte Modifikationen von Autophagie-Proteinen 
durch S-Nitrosylierungen gefunden, was darauf hindeutet, dass NO eher indirekt in die Vorgänge der 
Autophagie eingreift. Die S-Nitrosylierung reguliert womöglich die Proteinfaltung, Ubiquitinierung und 
wahrscheinlich auch die de novo Proteinsynthese. In dieser Studie konnten einige Proteine als 
Hauptkandidaten für die S-Nitrosylierung identifiziert werden, die autophagische Vorgänge beeinflussen. 
Zu ihnen zählen HSC70, das Pyruvat-Kinase-Isoenzym M1/M2 (PKM2, Gen:pkm2), Calreticulin (Gen: calr), 
das Ubiquitin-konjugierende Enzym E2 D1 (UBE2D1, Gen: ube2d1) und der Elongationsfaktor 2 (EF2, Gen: 
eef2). 
Die Untersuchungen zeigen eine direkteS-Nitrosylierung verschiedener  Proteine im Rückenmark nach 
Schädigung des Ischiasnerven. Diese posttranslationale NO-vermittelte Modifikation könnte für die 
Anpassungen der Neuronen an die axonale Schädigung, insbesondere im Hinblick auf die 
Wiederherstellung neuronaler Stabilität und damit fürdie Entstehung neuropathischer Schmerzen von 
Bedeutung sein. . Weitere Studien könnten aufklären, ob spezifische SNO-Targetproteine hierbei eine 
herausragende Rolle spielen und therapeutisch beeinflussbar sind. 
  




7. List of Abbreviations 
2-D DIGE Two-dimensional difference gel electrophoresis  
ACO2 Aconitate hydratase 2 (mitochondrial) 
ACTB Actin, cytoplasmic 1  
ACTR3 actin related protein 3  
ALDOC Fructose-bisphosphate aldolase C  
ANOVA Analyis of Variance 
ASM Ammonium sulfamate  
ASR astroglial serine racemase  
ATP5H ATP synthase subunit d, mitochondrial  
BH4 tetrahydrobiopterin  
BSE Biotin switch ELISA  
BST Biotin-Switch-Technique  
CALR Calreticulin  
CCT5 T-complex protein 1 subunit epsilon  
CMV Cytomegalo virus  
CYS cysteine  
DIGE Difference gel electrophoresis  
DNM1 dynamin-1  
EF2 Elongation factor 2  
ER Endoplasmic reticulum  
ESI-MS/MS electrospray ionization mass spectrometry  
FBP D-fructose 1,6-bisphosphate  
FUBP1 Far upstream element-binding protein 1  
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
GCH1 GTP cyclohydrolase 1  
GPS-SNO Group-based Prediction System  
GSNO S-nitrosoglutathione  
GSS Glutathione S-synthetase  
GSTM1 Glutathione S-transferase Mu 1  
HIF-1 Hypoxia-inducible factor 1  
HSC70 Heat shock cognate 71 kDa protein  
HSPA8 Heat shock cognate 71 kDa protein  
IAM iodoacetamide  
IASP International Association for the Study of Pain  
ICAT  isotope-coded affinity tags 
L-NAME Nω-Nitro-L-arginine methyl ester hydrochloride  
MDH2 Malate dehydrogenase, mitochondrial  
METAP1 Methionine aminopeptidase 1  
MS mass spectrometry  
mTORC1 mammalian target of rapamycin receptor 1  
NEFM Neurofilament medium polypeptide  




NEM N-ethyl-maleimide  
NICE National Institute for Health and Clinical Excellence  
NMDA N-Methyl-D-aspartic acid  
nNOS Neuronal nitric oxide synthase  
NO Nitric Oxide  
NOS Nitric oxide synthase  
Nox5 NADPH oxidase 5  
NSF N-ethylmaleimide-sensitive factor  
PBS Phosphate buffered saline  
PDI Protein disulfide isomerase  
PITPNA Phosphatidylinositol transfer protein alpha isoform  
PKG Protein kinase G  
PKM2 Pyruvate kinase isozymes M1/M2  
PRDX1 Peroxiredoxin-1  
PRDX6 Peroxiredoxin-6  
PRKDC DNA-dependent protein kinase catalytic subunit  
PS phosphatidylserine  
SDS-PAGE SDS-polyacrylamide gel electrophoresis  
sGC soluble guanylylcyclase  
SHSY-4Y Human Neuroblastoma cells  
SILAC stable isotope labeling by amino acids in cell culture  
SNARE soluble NSF attachment protein receptor  
SNI, spared nerve injury  
SNO S-Nitrosylation  
SNO-ELISA Biotin switch ELISA  
SNOSID SNO-Site Identification  
TBS Tris buffered saline  
TUBB Tubulin-beta  
UBA1 Ubiquitin-like modifier-activating enzyme 1  
UBE2D1 Ubiquitin-conjugating enzyme E2 D1  
WDR1 WD repeat-containing protein 1  









Aguilera, M. O., W. Beron & M. I. Colombo (2012) The actin cytoskeleton participates in the early events 
of autophagosome formation upon starvation induced autophagy. Autophagy, 8, 1590-1603. 
Aley, K. O., G. McCarter & J. D. Levine (1998) Nitric oxide signaling in pain and nociceptor sensitization in 
the rat. J Neurosci, 18, 7008-14. 
Aracena-Parks, P., S. A. Goonasekera, C. P. Gilman, R. T. Dirksen, C. Hidalgo & S. L. Hamilton (2006) 
Identification of cysteines involved in S-nitrosylation, S-glutathionylation, and oxidation to 
disulfides in ryanodine receptor type 1. Journal of Biological Chemistry, 281, 40354-40368. 
Asada, K., J. Kurokawa & T. Furukawa (2009) Redox- and Calmodulin-dependent S-Nitrosylation of the 
KCNQ1 Channel. Journal of Biological Chemistry, 284, 6014-6020. 
Barsoum, M. J., H. Yuan, A. A. Gerencser, G. Liot, Y. Kushnareva, S. Graber, I. Kovacs, W. D. Lee, J. 
Waggoner, J. Cui, A. D. White, B. Bossy, J. C. Martinou, R. J. Youle, S. A. Lipton, M. H. Ellisman, G. 
A. Perkins & E. Bossy-Wetzel (2006) Nitric oxide-induced mitochondrial fission is regulated by 
dynamin-related GTPases in neurons. Embo J, 25, 3900-11. 
Beers, M. H. & R. Berkow. 2012. The Merck Manual for Professionals [Internet]. In Neurologic Disorders - 
Pain, eds. B. MH, J. TV, B. M, K. JL & P. R. Whitehouse Station (NJ): Merck Research Laboratories. 
Bellinger, A. M., S. Reiken, C. Carlson, M. Mongillo, X. P. Liu, L. Rothman, S. Matecki, A. Lacampagne & A. 
R. Marks (2009) Hypernitrosylated ryanodine receptor calcium release channels are leaky in 
dystrophic muscle. Nature Medicine, 15, 325-330. 
Benhar, M., M. T. Forrester, D. T. Hess & J. S. Stamler (2008) Regulated protein denitrosylation by 
cytosolic and mitochondrial thioredoxins. Science, 320, 1050-4. 
Benhar, M., M. T. Forrester & J. S. Stamler (2009) Protein denitrosylation: enzymatic mechanisms and 
cellular functions. Nat Rev Mol Cell Biol, 10, 721-32. 
Benn, S. C., D. Perrelet, A. C. Kato, J. Scholz, I. Decosterd, R. J. Mannion, J. C. Bakowska & C. J. Woolf 
(2002) Hsp27 upregulation and phosphorylation is required for injured sensory and motor 
neuron survival. Neuron, 36, 45-56. 
Bingol, B. & E. M. Schuman (2005) Synaptic protein degradation by the ubiquitin proteasome system. 
Current Opinion in Neurobiology, 15, 536-541. 
Boettger, M. K., N. Uceyler, M. Zelenka, A. Schmitt, A. Reif, Y. Chen & C. Sommer (2007) Differences in 
inflammatory pain in nNOS-, iNOS- and eNOS-deficient mice. Eur J Pain, 11, 810-8. 
Bouhassira, D., M. Lanteri-Minet, N. Attal, B. Laurent & C. Touboul (2008) Prevalence of chronic pain with 
neuropathic characteristics in the general population. Pain, 136, 380-387. 
Bourquin, A.-F., M. Suveges, M. Pertin, N. Gilliard, S. Sardy, A. C. Davison, D. R. Spahn & I. Decosterd 
(2006) Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve 
injury (SNI) in the mouse. Pain, 122, 14.e1-14. 
Boyce-Rustay, J. M. & M. F. Jarvis (2009) Neuropathic Pain: Models and Mechanisms. Current 
Pharmaceutical Design, 15, 1711-1716. 
Broillet, M. C. (2000) A single intracellular cysteine residue is responsible for the activation of the 
olfactory cyclic nucleotide-gated channel by NO. Journal of Biological Chemistry, 275, 15135-
15141. 
Bulteau, A. L., H. A. O'Neill, M. C. Kennedy, M. Ikeda-Saito, G. Isaya & L. I. Szweda (2004) Frataxin acts as 
an iron chaperone protein to modulate mitochondrial aconitase activity. Science, 305, 242-5. 
Burgoyne, J. R., M. Madhani, F. Cuello, R. L. Charles, J. P. Brennan, E. Schroder, D. D. Browning & P. Eaton 





Burnette, W. N. (1981) WESTERN BLOTTING - ELECTROPHORETIC TRANSFER OF PROTEINS FROM 
SODIUM DODECYL SULFATE-POLYACRYLAMIDE GELS TO UNMODIFIED NITROCELLULOSE AND 
RADIOGRAPHIC DETECTION WITH ANTIBODY AND RADIOIODINATED PROTEIN-A. Analytical 
Biochemistry, 112, 195-203. 
Butterfield, D. A., A. Gnjec, H. F. Poon, A. Castegna, W. M. Pierce, J. B. Klein & R. N. Martins (2006) Redox 
proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: 
An initial assessment. Journal of Alzheimers Disease, 10, 391-397. 
Cairo, G., R. Ronchi, S. Recalcati, A. Campanella & G. Minotti (2002) Nitric oxide and peroxynitrite 
activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S 
cluster of cytoplasmic aconitase. Biochemistry, 41, 7435-42. 
Camerini, S., M. L. Polci, U. Restuccia, V. Usuelli, A. Malgaroli & A. Bachi (2007) A novel approach to 
identify proteins modified by nitric oxide: the HIS-TAG switch method. Journal of Proteome 
Research, 6, 3224-3231. 
Charles, R. L., E. Schroder, G. May, P. Free, P. R. Gaffney, R. Wait, S. Begum, R. J. Heads & P. Eaton (2007) 
Protein sulfenation as a redox sensor: proteomics studies using a novel biotinylated dimedone 
analogue. Mol Cell Proteomics, 6, 1473-84. 
Cheah, J. H., S. F. Kim, L. D. Hester, K. W. Clancy, S. E. Patterson, V. Papadopoulos & S. H. Snyder (2006) 
NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase 
Dexras1. Neuron, 51, 431-440. 
Chiang, C. Y., J. Wang, Y. F. Xie, S. Zhang, J. W. Hu, J. O. Dostrovsky & B. J. Sessle (2007) Astroglial 
glutamate-glutamine shuttle is involved in central sensitization of nociceptive neurons in rat 
medullary dorsal horn. Journal of Neuroscience, 27, 9068-9076. 
Choi, Y. B., L. Tenneti, D. A. Le, J. Ortiz, G. Bai, H. S. V. Chen & S. A. Lipton (2000) Molecular basis of 
NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nature Neuroscience, 3, 15-
21. 
Chouchani, E. T., T. R. Hurd, S. M. Nadtochiy, P. S. Brookes, I. M. Fearnley, K. S. Lilley, R. A. J. Smith & M. 
P. Murphy (2010) Identification of S-nitrosated mitochondrial proteins by S-nitrosothiol 
difference in gel electrophoresis (SNO-DIGE): implications for the regulation of mitochondrial 
function by reversible S-nitrosation. Biochemical Journal, 430, 49-59. 
Clapp, K. M., H.-M. Peng, G. J. Jenkins, M. J. Ford, Y. Morishima, M. Lau & Y. Osawa (2012) Ubiquitination 
of Neuronal Nitric-oxide Synthase in the Calmodulin-binding Site Triggers Proteasomal 
Degradation of the Protein. Journal of Biological Chemistry, 287, 42601-42610. 
Clapp, K. M., H. M. Peng, Y. Morishima, M. Lau, V. J. Walker, W. B. Pratt & Y. Osawa (2010) C331A 
Mutant of Neuronal Nitric-oxide Synthase Is Labilized for Hsp70/CHIP (C Terminus of HSC70-
interacting Protein)-dependent Ubiquitination. Journal of Biological Chemistry, 285, 33642-
33651. 
Collins, P. J., G. McMahon, P. O'Brien & B. O'Connor (2004) Purification, identification and 
characterisation of seprase from bovine serum. Int J Biochem Cell Biol, 36, 2320-33. 
Cox, J. J., F. Reimann, A. K. Nicholas, G. Thornton, E. Roberts, K. Springell, G. Karbani, H. Jafri, J. Mannan, 
Y. Raashid, L. Al-Gazali, H. Hamamy, E. M. Valente, S. Gorman, R. Williams, D. P. McHale, J. N. 
Wood, F. M. Gribble & C. G. Woods (2006) An SCN9A channelopathy causes congenital inability 
to experience pain. Nature., 444, 894-8. 
Dall'Agnol, M., C. Bernstein, H. Bernstein, H. Garewal & C. M. Payne (2006) Identification of S-
nitrosylated proteins after chronic exposure of colon epithelial cells to deoxycholate. Proteomics, 
6, 1654-1662. 
Decosterd, I. & C. J. Woolf (2000) Spared nerve injury: an animal model of persistent peripheral 





Derakhshan, B., P. C. Wille & S. S. Gross (2007) Unbiased identification of cysteine S-nitrosylation sites on 
proteins. Nature Protocols, 2, 1685-1691. 
DiAntonio, A. & L. Hicke (2004) Ubiquitin-dependent regulation of the synapse. Annual Review of 
Neuroscience, 27, 223-246. 
Doulias, P. T., J. L. Greene, T. M. Greco, M. Tenopoulou, S. H. Seeholzer, R. L. Dunbrack & H. Ischiropoulos 
(2010) Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that 
accommodate diverse mechanisms for protein S-nitrosylation. Proceedings of the National 
Academy of Sciences of the United States of America, 107, 16958-16963. 
Evans, J. R. & K. Bielefeldt (2000) Regulation of sodium currents through oxidation and reduction of thiol 
residues. Neuroscience, 101, 229-236. 
Farquhar-Smith, P. (2011) Chemotherapy-induced neuropathic pain. Current opinion in supportive and 
palliative care, 5, 1-7. 
Ferrari, L. F., A. Chum, O. Bogen, D. B. Reichling & J. D. Levine (2011) Role of Drp1, a key mitochondrial 
fission protein, in neuropathic pain. J Neurosci, 31, 11404-10. 
Fisher, A. B. (2011) Peroxiredoxin 6: A Bifunctional Enzyme with Glutathione Peroxidase and 
Phospholipase A(2) Activities. Antioxidants & Redox Signaling, 15, 831-844. 
Goerg, B., N. Qvartskhava, P. Voss, T. Grune, D. Haeussinger & F. Schliess (2007) Reversible inhibition of 
mammalian glutamine synthetase by tyrosine nitration. Febs Letters, 581, 84-90. 
Gonzalez, D. R., F. Beigi, A. V. Treuer & J. M. Hare (2007) Deficient ryanodine receptor S-nitrosylation 
increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes. 
Proceedings of the National Academy of Sciences of the United States of America, 104, 20612-
20617. 
Gow, A. J. & J. S. Stamler (1998) Reactions between nitric oxide and haemoglobin under physiological 
conditions. Nature, 391, 169-173. 
Gu, Z. Z., M. Kaul, B. X. Yan, S. J. Kridel, J. K. Cui, A. Strongin, J. W. Smith, R. C. Liddington & S. A. Lipton 
(2002) S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death. 
Science, 297, 1186-1190. 
Guhring, H., M. Gorig, M. Ates, O. Coste, H. U. Zeilhofer, A. Pahl, K. Rehse & K. Brune (2000) Suppressed 
injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia 
in iNOS-deficient mice. J Neurosci, 20, 6714-20. 
Gump, J. M. & A. Thorburn (2011) Autophagy and apoptosis: what is the connection? Trends in Cell 
Biology, 21, 387-392. 
Gygi, S. P., B. Rist, S. A. Gerber, F. Turecek, M. H. Gelb & R. Aebersold (1999) Quantitative analysis of 
complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology, 17, 994-999. 
Hao, G., B. Derakhshan, L. Shi, F. Campagne & S. S. Gross (2006) SNOSID, a proteomic method for 
identification of cysteine S-nitrosylation sites in complex protein mixtures. Proceedings of the 
National Academy of Sciences of the United States of America, 103, 1012-1017. 
Hao, G. & S. S. Gross (2006) Electrospray tandem mass spectrometry analysis of S- and N-
nitrosopeptides: Facile loss of NO and radical-induced fragmentation. Journal of the American 
Society for Mass Spectrometry, 17, 1725-1730. 
Hara, M. R., N. Agrawal, S. F. Kim, M. B. Cascio, M. Fujimuro, Y. Ozeki, M. Takahashi, J. H. Cheah, S. K. 
Tankou, L. D. Hester, C. D. Ferris, S. D. Hayward, S. H. Snyder & A. Sawa (2005) S-nitrosylated 
GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nature Cell 
Biology, 7, 665-U40. 
Hizli, A. A., Y. Chi, J. Swanger, J. H. Carter, Y. Liao, M. Welcker, A. G. Ryazanov & B. E. Clurman (2013) 
Phosphorylation of Eukaryotic Elongation Factor 2 (eEF2) by Cyclin A-Cyclin-Dependent Kinase 2 





Holaska, J. M., B. E. Black, D. C. Love, J. A. Hanover, J. Leszyk & B. M. Paschal (2001) Calreticulin is a 
receptor for nuclear export. Journal of Cell Biology, 152, 127-140. 
Homma, K., K. Suzuki & H. Sugawara (2011) The Autophagy Database: an all-inclusive information 
resource on autophagy that provides nourishment for research. Nucleic Acids Research, 39, 
D986-D990. 
Huang, Y., H. Y. Man, Y. Sekine-Aizawa, Y. F. Han, K. Juluri, H. B. Luo, J. Cheah, C. Lowenstein, R. L. 
Huganir & S. H. Snyder (2005) S-nitrosylation of N-ethylmaleimide sensitive factor mediates 
surface expression of AMPA receptors. Neuron, 46, 533-540. 
Inoue, K., T. Akaike, Y. Miyamoto, T. Okamoto, T. Sawa, M. Otagiri, S. Suzuki, T. Yoshimura & H. Maeda 
(1999) Nitrosothiol formation catalyzed by ceruloplasmin - Implication for cytoprotective 
mechanism in vivo. Journal of Biological Chemistry, 274, 27069-27075. 
Ishihama, Y., Y. Oda, T. Tabata, T. Sato, T. Nagasu, J. Rappsilber & M. Mann (2005) Exponentially modified 
protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by 
the number of sequenced peptides per protein. Molecular & Cellular Proteomics, 4, 1265-1272. 
Itoh, Y., F. H. Ma, H. Hoshi, M. Oka, K. Noda, Y. Ukai, H. Kojima, T. Nagano & N. Toda (2000) 
Determination and bioimaging method for nitric oxide in biological specimens by 
diaminofluorescein fluorometry. Analytical Biochemistry, 287, 203-209. 
Jaffrey, S. R., H. Erdjument-Bromage, C. D. Ferris, P. Tempst & S. H. Snyder (2001) Protein S-nitrosylation: 
a physiological signal for neuronal nitric oxide. Nature Cell Biology, 3, 193-197. 
Jaffrey, S. R., M. Fang & S. H. Snyder (2002) Nitrosopeptide mapping: A novel methodology reveals S-
nitrosylation of Dexras1 on a single cysteine residue. Chemistry &amp; Biology, 9, 1329-1335. 
Jaggi, A. S., V. Jain & N. Singh (2011) Animal models of neuropathic pain. Fundamental & Clinical 
Pharmacology, 25, 1-28. 
Ji, W. T., L. Wang, R. C. Lin, W. R. Huang & H. J. Liu (2009) Avian reovirus influences phosphorylation of 
several factors involved in host protein translation including eukaryotic translation elongation 
factor 2 (eEF2) in Vero cells. Biochemical and Biophysical Research Communications, 384, 301-
305. 
Jian, K. H., M. Chen, X. Cao, X. H. Zhu, M. L. Fung & T. M. Gao (2007) Nitric oxide modulation of voltage-
gated calcium current by S-nitrosylation and cGMP pathway in cultured rat hippocampal 
neurons. Biochemical and Biophysical Research Communications, 359, 481-485. 
Jin, X. G., S. R. Chen, X. H. Cao, L. Li & H. L. Pan (2011) Nitric oxide inhibits nociceptive transmission by 
differentially regulating glutamate and glycine release to spinal dorsal horn neurons. J Biol Chem, 
286, 33190-202. 
Kelleher, Z. T., A. Matsumoto, J. S. Stamler & H. E. Marshall (2007) NOS2 regulation of NF-kappa B by S-
nitrosylation of p65. Journal of Biological Chemistry, 282, 30667-30672. 
Kettenhofen, N. J., X. Wang, M. T. Gladwin & N. Hogg. 2008. In[hyphen (true graphic)]Gel Detection of 
S[hyphen (true graphic)]Nitrosated Proteins Using Fluorescence Methods. In Methods in 
Enzymology, ed. P. Enrique Cadenas and Lester, 53-71. Academic Press. 
Kim, W. K., Y. B. Choi, P. V. Rayudu, P. Das, W. Asaad, D. R. Arnelle, J. S. Stamler & S. A. Lipton (1999) 
Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO. Neuron, 24, 461-
469. 
Klionsky, D. J., H. Abeliovich, P. Agostinis, D. K. Agrawal, G. Aliev, D. S. Askew, M. Baba, E. H. Baehrecke, 
B. A. Bahr, A. Ballabio, B. A. Bamber, D. C. Bassham, E. Bergamini, X. N. Bi, M. Biard-Piechaczyk, J. 
S. Blum, D. E. Breclesen, J. L. Brodsky, J. H. Brumell, U. T. Brunk, W. Bursch, N. Camougrand, E. 
Cebollero, F. Cecconi, Y. Y. Chen, L. S. Chin, A. Choi, C. T. Chu, J. K. Chung, P. G. H. Clarke, R. S. B. 
Clark, S. G. Clarke, C. Clave, J. L. Cleveland, P. Codogno, M. I. Colombo, A. Coto-Montes, J. M. 





Devenish, F. Di Sano, J. F. Dice, M. DiFiglia, S. Dinesh-Kumar, C. W. Distelhorst, M. Djavaheri-
Mergny, F. C. Dorsey, W. Droge, M. Dron, W. A. Dunn, M. Duszenko, N. T. Eissa, Z. Elazar, A. 
Esclatine, E. L. Eskelinen, L. Fesues, K. D. Finley, J. M. Fuentes, J. Fueyo, K. Fujisaki, B. Galliot, F. B. 
Gao, D. A. Gewirtz, S. B. Gibson, A. Gohla, A. L. Goldberg, R. Gonzalez, C. Gonzalez-Estevez, S. 
Gorski, R. A. Gottlieb, D. Haussinger, Y. W. He, K. Heidenreich, J. A. Hill, M. Hoyer-Hansen, X. Hu, 
W. P. Huang, A. Iwasaki, M. Jaattela, W. T. Jackson, X. Jiang, S. K. Jin, T. Johansen, J. U. Jung, M. 
Kadowaki, C. Kang, A. Kelekar, D. H. Kessel, J. Kiel, H. P. Kim, A. Kimchi, T. J. Kinsella, K. Kiselyov, 
K. Kitamoto, E. Knecht, et al. (2008) Guidelines for the use and interpretation of assays for 
monitoring autophagy in higher eukaryotes. Autophagy, 4, 151-175. 
Kornberg, M. D., N. Sen, M. R. Hara, K. R. Juluri, J. V. K. Nguyen, A. M. Snowman, L. Law, L. D. Hester & S. 
H. Snyder (2010) GAPDH mediates nitrosylation of nuclear proteins. Nature Cell Biology, 12, 
1094-U89. 
Landmesser, U., S. Dikalov, S. R. Price, L. McCann, T. Fukai, S. M. Holland, W. E. Mitch & D. G. Harrison 
(2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide 
synthase in hypertension. J Clin Invest, 111, 1201-9. 
Laughlin, T. M., K. F. Kitto & G. L. Wilcox (1999) Redox manipulation of NMDA receptors in vivo: 
alteration of acute pain transmission and dynorphin-induced allodynia. Pain, 80, 37-43. 
Lee, S. J., J. R. Lee, Y. H. Kim, Y. S. Park, S. I. Park, H. S. Park & K. P. Kim (2007) Investigation of tyrosine 
nitration and nitrosylation of angiotensin II and bovine serum albumin with electrospray 
ionization mass spectrometry. Rapid Communications in Mass Spectrometry, 21, 2797-2804. 
Lewis, S. E., R. J. Mannion, F. A. White, R. E. Coggeshall, S. Beggs, M. Costigan, J. L. Martin, W. H. Dillmann 
& C. J. Woolf (1999) A role for HSP27 in sensory neuron survival. Journal of Neuroscience, 19, 
8945-8953. 
Li, F., P. Sonveaux, Z. N. Rabbani, S. L. Liu, B. Yan, Q. Huang, Z. Vujaskovic, M. W. Dewhirst & C. Y. Li 
(2007) Regulation of HIF-1 alpha stability through S-nitrosylation. Molecular Cell, 26, 63-74. 
Li, X. Q. & Z. Fan (2010) The Epidermal Growth Factor Receptor Antibody Cetuximab Induces Autophagy 
in Cancer Cells by Downregulating HIF-1 alpha and Bcl-2 and Activating the Beclin 1/hVps34 
Complex. Cancer Research, 70, 5942-5952. 
Lim, J. C., H. I. Choi, Y. S. Park, H. W. Nam, H. A. Woo, K. S. Kwon, Y. S. Kim, S. G. Rhee, K. Kim & H. Z. Chae 
(2008) Irreversible oxidation of the active-site cysteine of peroxiredoxin to cysteine sulfonic acid 
for enhanced molecular chaperone activity. J Biol Chem, 283, 28873-80. 
Lindermayr, C., S. Sell & J. Durner (2009) Generation and detection of S-nitrosothiols. Methods in 
molecular biology (Clifton, N.J.), 476, 210-22. 
Lipton, S. A., Y. B. Choi, Z. H. Pan, S. Z. Z. Lei, H. S. V. Chen, N. J. Sucher, J. Loscalzo, D. J. Singel & J. S. 
Stamler (1993) A REDOX-BASED MECHANISM FOR THE NEUROPROTECTIVE AND 
NEURODESTRUCTIVE EFFECTS OF NITRIC-OXIDE AND RELATED NITROSO-COMPOUNDS. Nature, 
364, 626-632. 
Liu, T., C. K. Daniels & S. S. Cao (2012) Comprehensive review on the HSC70 functions, interactions with 
related molecules and involvement in clinical diseases and therapeutic potential. Pharmacology 
& Therapeutics, 136, 354-374. 
Lowry, O. H., N. J. Rosebrough, A. L. Farr & R. J. Randall (1951) PROTEIN MEASUREMENT WITH THE FOLIN 
PHENOL REAGENT. Journal of Biological Chemistry, 193, 265-275. 
Lu, J. S., T. Katano, E. Okuda-Ashitaka, Y. Oishi, Y. Urade & S. Ito (2009) Involvement of S-nitrosylation of 
actin in inhibition of neurotransmitter release by nitric oxide. Molecular Pain, 5, 12. 
Lu, J. S., T. Katano, D. Uta, H. Furue & S. Ito (2011) Rapid S-nitrosylation of actin by NO-generating donors 





Lv, L., D. Li, D. Zhao, R. T. Lin, Y. J. Chu, H. Zhang, Z. Y. Zha, Y. Liu, Z. Li, Y. P. Xu, G. Wang, Y. R. Huang, Y. 
Xiong, K. L. Guan & Q. Y. Lei (2011) Acetylation Targets the M2 Isoform of Pyruvate Kinase for 
Degradation through Chaperone-Mediated Autophagy and Promotes Tumor Growth. Molecular 
Cell, 42, 719-730. 
Ma, Y. M., H. H. Lu, B. Tippin, M. F. Goodman, N. Shimazaki, O. Koiwai, C. L. Hsieh, K. Schwarz & M. R. 
Lieber (2004) A biochemically defined system for mammalian nonhomologous DNA end joining. 
Molecular Cell, 16, 701-713. 
Maattanen, P., G. Kozlov, K. Gehring & D. Y. Thomas (2006) ERp57 and PDI: multifunctional protein 
disulfide isomerases with similar domain architectures but differing substrate-partner 
associations. Biochem Cell Biol, 84, 881-9. 
Maihofner, C., C. Euchenhofer, I. Tegeder, K. F. Beck, J. Pfeilschifter & G. Geisslinger (2000) Regulation 
and immunhistochemical localization of nitric oxide synthases and soluble guanylyl cyclase in 
mouse spinal cord following nociceptive stimulation. Neurosci Lett, 290, 71-5. 
Manas, A., J. L. Monroy, A. A. Ramos, C. Cano, V. Lopez-Gomez, X. Masramon, M. Perez & T. c. s. group 
(2011) Prevalence of neuropathic pain in radiotherapy oncology units. International journal of 
radiation oncology, biology, physics, 81, 511-20. 
Manfredi, M., G. Bini, G. Cruccu, N. Accornero, A. Berardelli & L. Medolago (1981) CONGENITAL ABSENCE 
OF PAIN. Archives of Neurology, 38, 507-511. 
Mannick, J. B., C. Schonhoff, N. Papeta, P. Ghafourifar, M. Szibor, K. Z. Fang & B. Gaston (2001) S-
nitrosylation of mitochondrial caspases. Journal of Cell Biology, 154, 1111-1116. 
Marion M, B. (1976) A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254. 
Martinez-Ruiz, A., L. Villanueva, C. G. de Orduna, D. Lopez-Ferrer, M. A. Higueras, C. Tarin, I. Rodriguez-
Crespo, J. Vazquez & S. Lamas (2005) S-nitrosylation of Hsp90 promotes the inhibition of its 
ATPase and endothelial nitric oxide synthase regulatory activities. Proceedings of the National 
Academy of Sciences of the United States of America, 102, 8525-8530. 
Matsushita, K., C. N. Morrell, B. Cambien, S. X. Yang, M. Yamakuchi, C. Bao, M. R. Hara, R. A. Quick, W. 
Cao, B. O'Rourke, J. M. Lowenstein, J. Pevsner, D. D. Wagner & C. J. Lowenstein (2003) Nitric 
oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell, 115, 139-
50. 
Meller, S. T., S. J. Lewis, J. N. Bates, M. J. Brody & G. F. Gebhart (1990) Is there a role for an endothelium-
derived relaxing factor in nociception? Brain Res, 531, 342-5. 
Michalak, M., J. Groenendyk, E. Szabo, L. I. Gold & M. Opas (2009) Calreticulin, a multi-process calcium-
buffering chaperone of the endoplasmic reticulum. Biochemical Journal, 417, 651-666. 
Minami, T., M. Onaka, E. Okuda-Ashitaka, H. Mori, S. Ito & O. Hayaishi (1995) L-NAME, an inhibitor of 
nitric oxide synthase, blocks the established allodynia induced by intrathecal administration of 
prostaglandin E2. Neurosci Lett, 201, 239-42. 
Mirza, U. A., B. T. Chait & H. M. Lander (1995) MONITORING REACTIONS OF NITRIC-OXIDE WITH 
PEPTIDES AND PROTEINS BY ELECTROSPRAY-IONIZATION MASS-SPECTROMETRY. Journal of 
Biological Chemistry, 270, 17185-17188. 
Miyamoto, T., A. E. Dubin, M. J. Petrus & A. Patapoutian (2009) TRPV1 and TRPA1 mediate peripheral 
nitric oxide-induced nociception in mice. PLoS ONE, 4, e7596. 
Mizushima, N. & T. Yoshimori (2007) How to interpret LC3 immunoblotting. Autophagy, 3, 542-545. 
Mohr, S., J. S. Stamler & B. Brune (1996) Posttranslational modification of glyceraldehyde-3-phosphate 
dehydrogenase by S-nitrosylation and subsequent NADH attachment. Journal of Biological 





Mustafa, A. K., M. Kumar, B. Selvakumar, G. P. H. Ho, J. T. Ehmsen, R. K. Barrow, L. M. Amzel & S. H. 
Snyder (2007) Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of D-
serine formation. Proceedings of the National Academy of Sciences of the United States of 
America, 104, 2950-2955. 
Nauseef, W. M., S. J. McCormick & R. A. Clark (1995) CALRETICULIN FUNCTIONS AS A MOLECULAR 
CHAPERONE IN THE BIOSYNTHESIS OF MYELOPEROXIDASE. Journal of Biological Chemistry, 270, 
4741-4747. 
NICE. 2010. CG96 Neuropathic pain - pharmacological management: NICE guideline. In 
www.nice.org.uk/cg96, ed. N. I. f. H. a. C. Excellence. London: National Institute for Health and 
Clinical Excellence. 
Nickel, F. T., F. Seifert, S. Lanz & C. Maihofner (2012) Mechanisms of neuropathic pain. European 
Neuropsychopharmacology, 22, 81-91. 
Noh, Y. H., J. Y. Baek, W. Jeong, S. G. Rhee & T. S. Chang (2009) Sulfiredoxin Translocation into 
Mitochondria Plays a Crucial Role in Reducing Hyperoxidized Peroxiredoxin III. J Biol Chem, 284, 
8470-7. 
Nott, A., P. M. Watson, J. D. Robinson, L. Crepaldi & A. Riccio (2008) S-Nitrosylation of histone 
deacetylase 2 induces chromatin remodelling in neurons. Nature, 455, 411-5. 
Nunez, L., M. Vaquero, R. Gomez, R. Caballero, P. Mateos-Caceres, C. Macaya, I. Iriepa, E. Galvez, A. 
Lopez-Farre, J. Tamargo & E. Delpon (2006) Nitric oxide blocks hKv1.5 channels by S-nitrosylation 
and by a cyclic GMP-dependent mechanism. Cardiovascular Research, 72, 80-89. 
Ong, S. E., B. Blagoev, I. Kratchmarova, D. B. Kristensen, H. Steen, A. Pandey & M. Mann (2002) Stable 
isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to 
expression proteomics. Molecular & Cellular Proteomics, 1, 376-386. 
Oustwani, C. S., N. D. Tsihlis, A. K. Vavra, Q. Jiang, J. Martinez & M. R. Kibbe (2011) Nitric Oxide Increases 
Lysine 48-Linked Ubiquitination Following Arterial Injury. Journal of Surgical Research, 170, E169-
E177. 
Ozawa, K., E. J. Whalen, C. D. Nelson, Y. Y. Mu, D. T. Hess, R. J. Lefkowitz & J. S. Stamler (2008) S-
nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking. Molecular Cell, 31, 
395-405. 
Palmer, Z. J., R. R. Duncan, J. R. Johnson, L. Y. Lian, L. V. Mello, D. Booth, J. W. Barclay, M. E. Graham, R. 
D. Burgoyne, I. A. Prior & A. Morgan (2008) S-nitrosylation of syntaxin 1 at Cys(145) is a 
regulatory switch controlling Munc18-1 binding. Biochemical Journal, 413, 479-491. 
Qian, J., F. Chen, Y. Kovalenkov, D. Pandey, M. A. Moseley, M. W. Foster, S. M. Black, R. C. Venema, D. W. 
Stepp & D. J. R. Fulton (2012) Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible 
S-nitrosylation. Free Radical Biology and Medicine, 52, 1806-1819. 
Reynaert, N. L., K. Ckless, S. H. Korn, N. Vos, A. S. Guala, E. F. M. Wouters, A. van der Vliet & Y. M. W. 
Janssen-Heininger (2004) Nitric oxide represses inhibitory kB kinase through S-nitrosylation. 
Proceedings of the National Academy of Sciences of the United States of America, 101, 8945-
8950. 
Rodriguez-Muela, N., F. Germain, G. Marino, P. S. Fitze & P. Boya (2012) Autophagy promotes survival of 
retinal ganglion cells after optic nerve axotomy in mice. Cell Death and Differentiation, 19, 162-
169. 
Romero, J. M. & O. A. Bizzozero (2009) Intracellular glutathione mediates the denitrosylation of protein 
nitrosothiols in the rat spinal cord. J Neurosci Res, 87, 701-9. 
Rush, J., A. Moritz, K. A. Lee, A. Guo, V. L. Goss, E. J. Spek, H. Zhang, X. M. Zha, R. D. Polakiewicz & M. J. 
Comb (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nature 





Salanova, M., G. Schiffl, J. Rittweger, D. Felsenberg & D. Blottner (2008) Ryanodine receptor type-1 
(RyR1) expression and protein S-nitrosylation pattern in human soleus myofibres following bed 
rest and exercise countermeasure. Histochemistry and Cell Biology, 130, 105-118. 
Sarkar, S., V. I. Korolchuk, M. Renna, S. Imarisio, A. Fleming, A. Williams, M. Garcia-Arencibia, C. Rose, S. 
Q. Luo, B. R. Underwood, G. Kroemer, C. J. O'Kane & D. C. Rubinsztein (2011) Complex Inhibitory 
Effects of Nitric Oxide on Autophagy. Molecular Cell, 43, 19-32. 
Saurin, A. T., H. Neubert, J. P. Brennan & P. Eaton (2004) Widespread sulfenic acid formation in tissues in 
response to hydrogen peroxide. Proc Natl Acad Sci U S A, 101, 17982-7. 
Saville, B. (1958) A SCHEME FOR THE COLORIMETRIC DETERMINATION OF MICROGRAM AMOUNTS OF 
THIOLS. Analyst, 83, 670-672. 
Scheving, R., I. Wittig, H. Heide, B. Albuquerque, M. Steger, U. Brandt & I. Tegeder (2012) Protein S-
nitrosylation and denitrosylation in the mouse spinal cord upon injury of the sciatic nerve. 
Journal of Proteomics, 75, 3987-4004. 
Schmidt, H., H. Hofmann, U. Schindler, Z. S. Shutenko, D. D. Cunningham & M. Feelisch (1996) No center 
dot NO from NO synthase. Proceedings of the National Academy of Sciences of the United States 
of America, 93, 14492-14497. 
Schmidtko, A., W. Gao, P. Konig, S. Heine, R. Motterlini, P. Ruth, J. Schlossmann, D. Koesling, E. 
Niederberger, I. Tegeder, A. Friebe & G. Geisslinger (2008) cGMP produced by NO-sensitive 
guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets 
different from cGMP-dependent protein kinase I. J Neurosci, 28, 8568-76. 
Schmidtko, A., P. Ruth, G. Geisslinger & I. Tegeder (2003) Inhibition of cyclic guanosine 5'-
monophosphate-dependent protein kinase I (PKG-I) in lumbar spinal cord reduces formalin-
induced hyperalgesia and PKG upregulation. Nitric Oxide, 8, 89-94. 
Schmidtko, A., I. Tegeder & G. Geisslinger (2009) No NO, no pain? The role of nitric oxide and cGMP in 
spinal pain processing. Trends in Neurosciences, 32, 339-346. 
Scholz, J., D. C. Broom, D. H. Youn, C. D. Mills, T. Kohno, M. R. Suter, K. A. Moore, I. Decosterd, R. E. 
Coggeshall & C. J. Woolf (2005) Blocking caspase activity prevents transsynaptic neuronal 
apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. 
Journal of Neuroscience, 25, 7317-7323. 
Selvakumar, B., R. L. Huganir & S. H. Snyder (2009) S-nitrosylation of stargazin regulates surface 
expression of AMPA-glutamate neurotransmitter receptors. Proceedings of the National 
Academy of Sciences of the United States of America, 106, 16440-16445. 
Sen, N., M. R. Hara, A. S. Ahmad, M. B. Cascio, A. Kamiya, J. T. Ehmsen, N. Aggrawal, L. Hester, S. Dore, S. 
H. Snyder & A. Sawa (2009) GOSPEL: A Neuroprotective Protein that Binds to GAPDH upon S-
Nitrosylation. Neuron, 63, 81-91. 
Shaid, S., C. H. Brandts, H. Serve & I. Dikic (2013) Ubiquitination and selective autophagy. Cell Death and 
Differentiation, 20, 21-30. 
Sollner, T. H. & S. Sequeira (2003) S-nitrosylation of NSF controls membrane trafficking. Cell, 115, 127-
129. 
Sou, Y., I. Tanida, M. Komatsu, T. Ueno & E. Kominami (2006) Phosphatidylserine in addition to 
phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, 
and GATE-16. Journal of Biological Chemistry, 281, 3017-3024. 
Soubeyrand, S., L. Pope, B. Pakuts & R. J. G. Hache (2003) Threonines 2638/2647 in DNA-PK are essential 
for cellular resistance to ionizing radiation. Cancer Research, 63, 1198-1201. 
Sun, J., L. J. Druhan & J. L. Zweier (2008) Dose dependent effects of reactive oxygen and nitrogen species 





Sun, J. H., C. L. Xin, J. P. Eu, J. S. Stamler & G. Meissner (2001) Cysteine-3635 is responsible for skeletal 
muscle ryanodine receptor modulation by NO. Proceedings of the National Academy of Sciences 
of the United States of America, 98, 11158-11162. 
Sutton, M. A. & E. M. Schuman (2006) Dendritic protein synthesis, synaptic plasticity, and memory. Cell, 
127, 49-58. 
Sweet, S. M., C. M. Bailey, D. L. Cunningham, J. K. Heath & H. J. Cooper (2009) Large scale localization of 
protein phosphorylation by use of electron capture dissociation mass spectrometry. Mol Cell 
Proteomics, 8, 904-12. 
Takahashi, H., Y. Shin, S. J. Cho, W. M. Zago, T. Nakamura, Z. Z. Gu, Y. L. Ma, H. Furukawa, R. Liddington, 
D. X. Zhang, G. Tong, H. S. V. Chen & S. A. Lipton (2007) Hypoxia enhances S-nitrosylation-
mediated NMDA receptor inhibition via a thiol oxygen sensor motif. Neuron, 53, 53-64. 
Takasusuki, T., T. Fujiwara, S. Yamaguchi, T. Fukushima, K. Akagawa & Y. Hori (2007) Enhancement of 
synaptic transmission and nociceptive behaviour in HPC-1/syntaxin 1A knockout mice following 
peripheral nerve injury. European Journal of Neuroscience, 26, 2179-2187. 
Tang, C.-H., W. Wei & L. Liu (2012) Regulation of DNA repair by S-nitrosylation. Biochimica Et Biophysica 
Acta-General Subjects, 1820, 730-735. 
Tang, Z., J. A. Bauer, B. Morrison & D. J. Lindner (2006) Nitrosylcobalamin promotes cell death via S 
nitrosylation of Apo2L/TRAIL receptor DR4. Molecular and Cellular Biology, 26, 5588-5594. 
Tanida, I., T. Ueno & E. Kominami (2008) LC3 and Autophagy. Methods in molecular biology (Clifton, N.J.), 
445, 77-88. 
Tarr, J. M., P. J. Young, R. Morse, D. J. Shaw, R. Haigh, P. G. Petrov, S. J. Johnson, P. G. Winyard & P. 
Eggleton (2010) A Mechanism of Release of Calreticulin from Cells During Apoptosis. Journal of 
Molecular Biology, 401, 799-812. 
Tegeder, I., M. Costigan, R. S. Griffin, A. Abele, I. Belfer, H. Schmidt, C. Ehnert, J. Nejim, C. Marian, J. 
Scholz, T. Wu, A. Allchorne, L. Diatchenko, A. M. Binshtok, D. Goldman, J. Adolph, S. Sama, S. J. 
Atlas, W. A. Carlezon, A. Parsegian, J. Lotsch, R. B. Fillingim, W. Maixner, G. Geisslinger, M. B. 
Max & C. J. Woolf (2006) GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity 
and persistence. Nat Med, 12, 1269-1277. 
Tegeder, I., R. Scheving, I. Wittig & G. Geisslinger (2011) SNO-ing at the Nociceptive Synapse? 
Pharmacological Reviews, 63, 366-389. 
Tegeder, I., A. Schmidtko, E. Niederberger, P. Ruth & G. Geisslinger (2002) Dual effects of spinally 
delivered 8-bromo-cyclic guanosine monophosphate (8-bromo-cGMP) in formalin-induced 
nociception in rats. Neuroscience Letters, 332, 146-150. 
Thom, S. R., V. M. Bhopale, D. J. Mancini & T. N. Milovanova (2008) Actin S-nitrosylation inhibits 
neutrophil beta2 integrin function. J Biol Chem, 283, 10822-34. 
Tian, J., S. F. Kim, L. Hester & S. H. Snyder (2008) S-nitrosylation/activation of COX-2 mediates NMDA 
neurotoxicity. Proc Natl Acad Sci U S A, 105, 10537-40. 
Torrance, N., B. H. Smith, M. I. Bennett & A. J. Lee (2006) The epidemiology of chronic pain of 
predominantly neuropathic origin. Results from a general population survey. Journal of Pain, 7, 
281-289. 
Torta, F., V. Usuelli, A. Malgaroli & A. Bachi (2008) Proteomic analysis of protein S-nitrosylation. 
Proteomics, 8, 4484-4494. 
Tsang, A. H. K., Y. I. Lee, H. S. Ko, J. M. Savitt, O. Pletnikova, J. C. Troncoso, V. L. Dawson, T. M. Dawson & 
K. K. K. Chung (2009) S-nitrosylation of XIAP compromises neuronal survival in Parkinson's 






Uehara, T., T. Nakamura, D. D. Yao, Z. Q. Shi, Z. Z. Gu, Y. L. Ma, E. Masliah, Y. Nomura & S. A. Lipton 
(2006) S-Nitrosylated protein-disulphide isomerase links protein misfolding to 
neurodegeneration. Nature, 441, 513-517. 
Walker, A. K., M. A. Farg, C. R. Bye, C. A. McLean, M. K. Horne & J. D. Atkin (2010) Protein disulphide 
isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral 
sclerosis. Brain, 133, 105-116. 
Westermann, B. (2009) Nitric oxide links mitochondrial fission to Alzheimer's disease. Sci Signal, 2, pe29. 
Whalen, E. J., M. W. Foster, A. Matsumoto, K. Ozawa, J. D. Violin, L. G. Que, C. D. Nelson, M. Benhar, J. R. 
Keys, H. A. Rockman, W. J. Koch, Y. Daaka, R. J. Lefkowitz & J. S. Stamler (2007) Regulation of 
beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. 
Cell, 129, 511-522. 
Windebank, A. J. & W. G. Grisold (2008) Chemotherapy-induced neuropathy. Journal of the Peripheral 
Nervous System, 13, 27-46. 
Windheim, M., M. Peggle & P. Cohen (2008) Two different classes of E2 ubiquitin-conjugating enzymes 
are required for the mono-ubiquitination of proteins and elongation by polyubiquitin chains with 
a specific topology. Biochemical Journal, 409, 723-729. 
Xue, Y., Z. X. Liu, X. J. Gao, C. J. Jin, L. P. Wen, X. B. Yao & J. A. Ren (2010) GPS-SNO: Computational 
Prediction of Protein S-Nitrosylation Sites with a Modified GPS Algorithm. Plos One, 5, 7. 
Yavuzer, U., G. C. M. Smith, T. Bliss, D. Werner & S. P. Jackson (1998) DNA end-independent activation of 
DNA-PK mediated via association with the DNA-binding protein C1D. Genes & Development, 12, 
2188-2199. 
Yoshida, T., R. Inoue, T. Morii, N. Takahashi, S. Yamamoto, Y. Hara, M. Tominaga, S. Shimizu, Y. Sato & Y. 
Mori (2006) Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nature Chemical 
Biology, 2, 596-607. 
Yu, H. M., J. Xu, C. Li, C. Zhou, F. Zhang, D. Han & G. Y. Zhang (2008) Coupling between neuronal nitric 
oxide synthase and glutamate receptor 6-mediated c-Jun N-terminal kinase signaling pathway via 
S-nitrosylation contributes to ischemia neuronal death. Neuroscience, 155, 1120-1132. 
Zhang, L., J. Yu, H. Pan, P. Hu, Y. Hao, W. Cai, H. Zhu, A. D. Yu, X. Xie, D. Ma & J. Yuan (2007) Small 
molecule regulators of autophagy identified by an image-based high-throughput screen. 
Proceedings of the National Academy of Sciences of the United States of America, 104, 19023-
19028. 
Zhang, X., V. Verge, Z. Wiesenfeld-Hallin, G. Ju, D. Bredt, S. H. Synder & T. Hokfelt (1993) Nitric oxide 
synthase-like immunoreactivity in lumbar dorsal root ganglia and spinal cord of rat and monkey 
and effect of peripheral axotomy. J Comp Neurol, 335, 563-75. 
Zhu, H. N., S. Q. Pan, S. Gu, E. M. Bradbury & X. Chen (2002) Amino acid residue specific stable isotope 
labeling for quantitative proteomics. Rapid Communications in Mass Spectrometry, 16, 2115-
2123. 
Zhuang, W., B. Li, L. Long, L. Chen, Q. Huang & Z.-q. Liang (2011) Knockdown of the DNA-dependent 
protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. 








9.1 Appendix I - Acknowledgements 
My thanks to Prof. Dr. Irmgard Tegeder for giving me the opportunity to work on this project and whose 
guidance and mentorship was instrumental in the success of this work. 
Thanks to Prof. Dr. Jochen Klein for his co-supervision and participation as the primary supervisor. 
Thanks to Prof. Dr. Dr. Geisslinger for providing me with the job and working place at the Institut für 
Klinische Pharmakologie as well as the excellent working conditions. 
Many thanks to Annett Häussler, Thekla Myrczek, and Max Mattil for their excellent technical assistance 
and invaluable help. 
I thank Dr. Ilka Wittig for her priceless advice and guidance on all things “proteomics” as well as excellent 
companionship. Thanks also to Dr. Heinrich Heide and Mirco Steger for their help with the mass 
spectrometry analysis of my samples. 
My thanks to my working group AG Tegeder: Annett, Boris, Geetha, Hee-young, Katja, Maike, Philipp, 
and Thekla, thanks for all the fun we´ve had. And extra thanks to Dr. Hee-Young Lim for her help with all 
things molecular biology and cloning, Boris Albuquerque for his help with behavioral experiments and 
translations, and Maike Kanngießer for help with translations. 
On a more personal note I would like extend special thanks to Kristin Helgadóttir for joining me on this 
wonderful adventure to Germany and all her ceaseless support and motivation.  Also I would like to give 
special thanks to my parents whose support and encouragement for my education and welfare through 
the years has been priceless.  






9.2 Appendix II – Publications resulting from this work 
Publications 
Scheving R, Wittig I, Heide H, Albuquerque B, Steger M, Brandt U, Tegeder I, Protein S-nitrosylation in 
autophagy. (In preparation) 
 
Scheving R, Wittig I, Heide H, Albuquerque B, Steger M, Brandt U, Tegeder I, Protein S-nitrosylation and 
denitrosylation in the mouse spinal cord upon injury of the sciatic nerve. (Journal of Proteomics, May 
2012) 
 
Tegeder I; Scheving R, Wittig I, Geisslinger G. SNO-ing at the Nociceptive Synapse? Pharmacological 
Reviews, Jun 2011 
 
Presentations  
Scheving R, Wittig I, Heide H, Albuquerque B, Steger M, Brandt U, Tegeder I, Protein S-nitrosylation and 
denitrosylation in the mouse spinal cord upon injury of the sciatic nerve. Poster presentation at the 
European Proteomics Association Proteomics meeting Glasgow, Scotland, 9-12 July 2012. 
 
Scheving R, Wittig I, Heide H, Steger M, Brandt U, Tegeder I, Protein S-nitrosylation and denitrosylation 
in the mouse spinal cord upon injury of the sciatic nerve. Poster presentation at the Deutsche 
Gesellschaft für experimentelle und klinische Pharmakologie (DGPT) 77th annual meeting, Frankfurt am 






9.3 Appendix III – Curriculum Vitae 
Personal information  
 Reynir Scheving 
Letzter Hasenpfad 13 
60598 Frankfurt am Main 
Germany 
Born in Reykjavik, Iceland 
Education  
Since September 2009 J.W. Goethe University Hospital 
• Institute of Clinical Pharmacology 
• PhD Student of Prof. Dr. Irmgard Tegeder 
2002 to 2007 University of Iceland 
• Master of Science in Pharmacy 
• Master’s thesis: Optimization of the physical properties of 
silicone as a drug delivery system. 
1995 – 1999 Menntaskólinn við Hamrahlíð  
• High school degree in Natural Sciences. 
Employment  
2007 to 2009   Actavis, Iceland 
• Research Scientist in Analytical Development 
1999 - 2002  Securitas, Iceland 






9.4 Appendix IV - Effects of L-NAME treatment 
Spot UniProt ID2 Gene 
Name 








    TTEST Ratio TTEST Ratio     
1 MATR3_MOUSE matr3 Matrin-3 0.0115 -1.18 0.0138 -1.29 94.6 6.25 May play a role in transcription or may 
interact with other nuclear matrix proteins 
to form the internal fibrogranular network 
 2 DYN1_MOUSE dnm1 Dynamin-1 0.3365 1.09 0.8963 -1.01 97.7 7.74 Microtubule-associated force-producing 
protein involved in producing microtubule 
bundles and able to bind and hydrolyze 
GTP.  
 3 DYN1_MOUSE dnm1 Dynamin-1 0.3249 -1.15 0.0498 -1.62 97.7 7.74 (see above) 
 4 UBP5_MOUSE usp5 Ubiquitin carboxyl-terminal 
hydrolase 5 
0.6382 1.05 0.3796 -1.10 95.8 5.01 Involved in unanchored 'Lys-48'-linked 
polyubiquitin disassembly. 
 5 K6PP_MOUSE pfkp 6-phosphofructokinase type C 0.1585 -1.05 0.0220 -1.12 85.4 7.11 Catalytic activity: ATP + D-fructose 6-
phosphate = ADP + D-fructose 1,6-
bisphosphate. 
 6 GAS6_MOUSE gas6 Growth arrest-specific protein 6 0.6728 -1.03 0.0072 -1.23 74.6 5.52 Ligand for tyrosine-protein kinase 
receptors AXL, TYRO3 and MER whose 
signaling is implicated in cell growth and 
survival, cell adhesion and cell migration  
 7 DYN1_MOUSE dnm1 Dynamin-1 0.1581 1.07 0.0004 -1.32 97.7 7.74  
 8 ACON_MOUSE aco2 Aconitate hydratase, mitochondrial 0.0520 1.15 0.1471 -1.12 85.4 7.93 Catalyzes the isomerization of citrate to 
isocitrate via cis-aconitat 
126, 448, 
451 
9 NSF_MOUSE nsf Vesicle-fusing ATPase 0.0482 -1.14 0.0597 1.10 82.6 6.95 Required for vesicle-mediated transport.  11, 21, 
599 
10 NSF_MOUSE nsf Vesicle-fusing ATPase 0.0995 -1.16 0.8249 1.02 82.6 6.95  11, 21, 
599 
11 NDUS1_MOUSE ndufs1 NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial 
0.0158 -1.10 0.0001 -1.50 79.7 5.72 Core subunit of the mitochondrial 
membrane respiratory chain NADH 
dehydrogenase (Complex I). 
 12 NDUS1_MOUSE ndufs1 NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial 
0.0118 -1.12 0.0660 -1.10 79.7 5.72 (see above) 
 13 NDUS1_MOUSE ndufs1 NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial 
0.1530 -1.15 0.0438 1.35 79.7 5.72 (see above) 
 14 MCCA_MOUSE mccc1 Methylcrotonoyl-CoA carboxylase 
subunit alpha, mitochondrial 
0.7789 -1.02 0.0828 1.19 79.3 7.83 Catalytic activity: ATP + 3-methylcrotonoyl-
CoA + HCO3- = ADP + phosphate + 3-
methylglutaconyl-CoA. 






Spot UniProt ID2 Gene 
Name 








assembly of multimeric protein complexes 
inside the ER. 
16 SYG_MOUSE gars Glycyl-tRNA synthetase 0.0286 1.49 0.0015 1.60 81.8 6.65 Catalyzes the attachment of glycine to 
tRNA(Gly).  
 17 VATA_MOUSE atp6v1a V-type proton ATPase catalytic 
subunit A 
0.4758 -1.02 0.0347 -1.14 68.3 5.58 V-ATPase vacuolar ATPase is responsible 
for acidifying a variety of intracellular 
compartments in eukaryotic cells. 
 18 SPTB2_MOUSE spnb2 Spectrin beta chain, brain 1 0.6780 1.04 0.0655 -1.22 274.1 5.58 Interacts with calmodulin in a calcium-
dependent manner and is thus candidate 
for the calcium-dependent movement of 
the cytoskeleton at the membrane. 
 19 HSP7C_MOUSE hspa8 Heat shock cognate 71 kDa protein 0.1600 1.48 0.3320 -1.28 70.8 5.52 Chaperone. 
 20 GPDM_MOUSE gpd2 Glycerol-3-phosphate 
dehydrogenase, mitochondrial 
0.0058 -1.24 0.0117 -1.77 80.9 6.61 Catalytic activity: sn-glycerol 3-phosphate + 
a quinone = glycerone phosphate + a 
quinol. 
21 GPDM_MOUSE gpd2 Glycerol-3-phosphate 
dehydrogenase, mitochondrial 
0.8122 1.01 0.0013 1.58 80.9 6.61 Catalytic activity: sn-glycerol 3-phosphate + 
a quinone = glycerone phosphate + a 
quinol. 
 22 LMNB1_MOUSE lmnb1 Lamin-B1 0.0549 -1.24 0.0017 -1.26 66.7 5.16 Lamins are components of the nuclear 
lamina, a fibrous layer on the 
nucleoplasmic side of the inner nuclear 
membrane 
 23 TKT_MOUSE tkt Transketolase 0.5558 -1.03 0.1893 1.08 67.6 7.50 Sedoheptulose 7-phosphate + D-
glyceraldehyde 3-phosphate = D-ribose 5-
phosphate + D-xylulose 5-phosphate. 
 24 STXB1_MOUSE stxbp1 Syntaxin-binding protein 1 0.1303 -1.15 0.4313 1.08 67.5 6.96 May participate in the regulation of 
synaptic vesicle docking and fusion, 
possibly through interaction with GTP-
binding proteins.  
 25 NFL_MOUSE nefl Neurofilament light polypeptide  -1.10  2.03 61.5 4.64 Involved in the maintenance of neuronal 
caliber. 
 26 TCPG_MOUSE cct3 T-complex protein 1 subunit gamma 0.6839 1.02 0.0504 1.26 60.6 6.70 Molecular chaperone 
 27 KPYM_MOUSE pkm2 Pyruvate kinase isozymes M1/M2 0.0128 -1.12 0.0197 1.10 57.8 7.47 Glycolytic enzyme that catalyzes the 
transfer of a phosphoryl group from 
phosphoenolpyruvate (PEP) to ADP, 
generating ATP. 49, 152 
28 KPYM_MOUSE pkm2 Pyruvate kinase isozymes M1/M2 0.0032 1.24 0.0427 -1.16 57.8 7.47 (see above) 49, 152 
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30 SYDC_MOUSE dars Aspartyl-tRNA synthetase, 
cytoplasmic 
0.0495 -1.06 0.0351 -1.27 57.1 6.49 Catalyzes the specific attachment of an 
amino acid to its cognate tRNA. 
 31 AMPL_MOUSE lap3 Cytosol aminopeptidase 0.6623 -1.03 0.0175 -1.32 56.1 7.72 Presumably involved in the processing and 
regular turnover of intracellular proteins. 
 32 DHE3_MOUSE glud1 Glutamate dehydrogenase 1, 
mitochondrial 
0.0168 1.11 0.3585 -1.04 61.3 8.00 May be involved in learning and memory 
reactions by increasing the turnover of the 
excitatory neurotransmitter glutamate (By 
similarity). 327, 376 
33 ATPA_MOUSE atp5a1 ATP synthase subunit alpha, 
mitochondrial 
0.1241 -1.13 0.0034 -1.29 59.7 9.19 Produces ATP from ADP in the presence of 
a proton gradient across the membrane 
which is generated by electron transport 
complexes of the respiratory chain.  
 34 DHE3_MOUSE glud1 Glutamate dehydrogenase 1, 
mitochondrial 
0.1063 -1.12 0.0028 -1.30 61.3 8.00 May be involved in learning and memory 
reactions by increasing the turnover of the 
excitatory neurotransmitter glutamate  327, 376 
35 DHE3_MOUSE glud1 Glutamate dehydrogenase 1, 
mitochondrial 
0.0016 -1.24 0.0034 -1.27 61.3 8.00  
327, 376 
36 SSDH_MOUSE aldh5a1 Succinate-semialdehyde 
dehydrogenase, mitochondrial 
0.0232 -1.34 0.0184 -1.13 55.9 8.25 Catalyzes one step in the degradation of 
the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA)  
 37 AL9A1_MOUSE aldh9a1 4-trimethylaminobutyraldehyde 
dehydrogenase 
0.0332 -1.07 0.5331 -1.01 53.5 6.98 Converts gamma-
trimethylaminobutyraldehyde into gamma-
butyrobetaine  
 38 SSDH_MOUSE aldh5a1 Succinate-semialdehyde 
dehydrogenase, mitochondrial 
0.0216 -1.11 0.4499 1.03 55.9 8.25 (see above) 
 39 NDUV1_MOUSE ndufv1 NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
0.0010 -1.20 0.4293 -1.05 50.8 8.21 Core subunit of the mitochondrial 
membrane respiratory chain NADH 
dehydrogenase (Complex I). 187 
40 ARP3_MOUSE actr3 Actin-related protein 3 0.0235 1.75 0.9286 -1.01 47.3 5.88 Functions as ATP-binding component of 
the Arp2/3 complex 
 41 DNJA1_MOUSE dnaja1 DnaJ homolog subfamily A member 
1 
0.7302 1.02 0.0119 1.14 44.8 7.08 Co-chaperone of Hsc70.  
 42 KCRU_MOUSE ckmt1 Creatine kinase, ubiquitous 
mitochondrial 
0.0804 -1.13 0.0284 -1.32 47.0 8.16 Reversibly catalyzes the transfer of 
phosphate between ATP and various 
phosphogens. 90, 317 
43 KCRU_MOUSE ckmt1 Creatine kinase, ubiquitous 
mitochondrial 
0.0426 -1.11 0.9355 -1.00 47.0 8.16 (see above) 
90, 317 
44 KCRB_MOUSE ckb Creatine kinase B-type 0.9585 1.00 0.0080 1.13 42.7 5.67 Reversibly catalyzes the transfer of 






Spot UniProt ID2 Gene 
Name 








45 ODPA_MOUSE pdha1 Pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial 
0.0892 -1.12 0.2639 1.05 43.2 8.19 Catalyzes the overall conversion of 
pyruvate to acetyl-CoA and CO(2).  
218, 222 
46 KCRU_MOUSE ckmt1 Creatine kinase, ubiquitous 
mitochondrial 
0.1008 -1.14 0.0029 -1.23 47.0 8.16 (see above) 
90, 317 
47 MK03_MOUSE mapk3 Mitogen-activated protein kinase 3 0.0242 1.09 0.6723 -1.01 43.0 6.61 Involved in both the initiation and 
regulation of meiosis, mitosis, and 
postmitotic functions in differentiated cells 
by phosphorylating transcription factors . 
 48 MPI_MOUSE mpi Mannose-6-phosphate isomerase 0.3258 1.28 0.3299 -1.30 46.5 5.95 Involved in the synthesis of the GDP-
mannose and dolichol-phosphate-
mannose. 
 49 ALDOA_MOUSE aldoa Fructose-bisphosphate aldolase A 0.4874 1.03 0.0136 -1.13 39.3 8.09 Plays a key role in glycolysis and 
gluconeogenesis.  
 50 THIL_MOUSE acat1 Acetyl-CoA acetyltransferase, 
mitochondrial 
0.5437 -1.05 0.0077 -1.32 44.8 8.51 Plays a major role in ketone body 
metabolism  116 
51 ALDOC_MOUSE aldoc Fructose-bisphosphate aldolase C 0.5658 1.02 0.0082 1.12 39.4 7.12 Catalytic activity: D-fructose 1,6-
bisphosphate = glycerone phosphate + D-
glyceraldehyde 3-phosphate. 178 
52 ALDOA_MOUSE aldoa Fructose-bisphosphate aldolase A 0.0304 -1.10 0.1419 -1.07 39.3 8.09 Plays a key role in glycolysis and 
gluconeogenesis.  
53 SNAG_MOUSE napg Gamma-soluble NSF attachment 
protein 
0.5787 -1.06 0.0607 -1.51 34.7 5.41 Required for vesicular transport between 
the ER and Golgi. 
54 CNN3_MOUSE cnn3 Calponin-3 0.8599 1.01 0.0329 1.22 36.4 5.72 Implicated in the regulation and 
modulation of smooth muscle contraction.  
55 G3P_MOUSE gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 




56 G3P_MOUSE gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
0.9600 1.01 0.0221 -1.39 35.8 8.25 (see above) 150, 154, 
245 
57 MDHM_MOUSE mdh2 Malate dehydrogenase, 
mitochondrial 
0.0120 1.19 0.9942 -1.00 35.6 8.68 Catalytic activity: (S)-malate + NAD+ = 




58 FAHD2_MOUSE fahd2a Fumarylacetoacetate hydrolase 
domain-containing protein 2A 
0.1068 1.19 0.0435 1.27 34.7 8.16 May have hydrolase activity 
 59 CAH2_MOUSE car2 Carbonic anhydrase 2 0.0826 1.26 0.0116 1.13 29.0 7.01 Essential for bone resorption and 
osteoclast differentiation. Reversible 
hydration of carbon dioxide. 
 60 PGAM1_MOUSE pgam1 Phosphoglycerate mutase 1 0.0195 -1.11 0.0108 -1.14 28.8 7.18 Interconversion of 3- and 2-
phosphoglycerate with 2,3-





Spot UniProt ID2 Gene 
Name 









61 PSA7_MOUSE psma7 Proteasome subunit alpha type-7 0.0701 -1.30 0.8673 1.01 27.8 8.46 The proteasome is a multicatalytic 
proteinase complex which is characterized 
by its ability to cleave peptides with Arg, 
Phe, Tyr, Leu, and Glu adjacent to the 
leaving group at neutral or slightly basic 
pH.  
 62 RAN_MOUSE ran GTP-binding nuclear protein Ran 0.6796 -1.02 0.0067 -1.26 24.4 7.49 Involved in nucleocytoplasmic transport. 
Required for the import of protein into the 
nucleus and also for RNA export. I 112, 120 
63 KAD2_MOUSE ak2 Adenylate kinase 2, mitochondrial 0.1876 -1.09 0.0032 -1.72 26.5 7.39 Catalyzes the reversible transfer of the 
terminal phosphate group between ATP 
and AMP.  
 64 HSPB1_MOUSE hspb1 Heat shock protein beta-1 0.0269 1.28 0.0130 1.15 23.0 6.55 Involved in stress resistance and actin 
organization. 
 65 GSTA4_MOUSE gsta4 Glutathione S-transferase A4 0.0052 1.28 0.0328 1.26 25.5 7.39 Conjugation of reduced glutathione to a 
wide number of exogenous and 
endogenous hydrophobic electrophiles. 
 66 SODM_MOUSE sod2 Superoxide dismutase [Mn], 
mitochondrial 
0.0744 1.12 0.0161 1.18 24.6 8.62 Destroys radicals which are normally 
produced within the cells and which are 
toxic to biological systems. 
 67 TAGL3_MOUSE tagln3 Transgelin-3 0.3762 1.18 0.4628 -1.13 22.5 7.33  
 68 SODC_MOUSE sod1 Superoxide dismutase [Cu-Zn] 0.7658 -1.02 0.0029 1.59 15.9 6.51 (see above) 
 69 CYC_MOUSE cycs Cytochrome c, somatic 0.2205 -1.09 0.0022 1.42 11.6 9.58 Electron carrier protein.  
 S-nitrosylation in the dorsal horn of the L4/5 mouse spinal cord was assessed by 2D SNO-DIGE analysis and subsequent identification by electrospray ionization 
mass spectrometry (ESI-MS/MS). SNO Upregulation is shown in blue, SNO down regulation in red. Quadruple 2D gels of naïve and SNI operated mice and SNI 
operated with L-NAME treatment were analyzed and statistically compared by t-tests, P was set at 0.05. Identification of the modified cysteines was done with 








9.5 Appendix V - Effects of Sham operation 
Spot 
no. 
UniProt ID Gene 
Name 
Name Ratio T-test Mass pI Seq 
Cov 
Pept Functional description SNOSID Site Functional 
classification 
1 Q6P8X1 snx6 Sorting nexin-6 -1.39 0.010 46649 5.73 28.8% 13 Plays a role in retrograde protein transport from endosomes 
to the trans-Golgi network.  
  Vesicle 
trafficking 
2 Q9CZ13 uqcrc1 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
-1.38 0.022 52852 5.77 39.2% 32 This is a component of the ubiquinol-cytochrome c reductase 
complex (complex III or cytochrome b-c1 complex), which is 
part of the mitochondrial respiratory chain.  
  Energy 
metabolism 
3 P97807 fh Fumarate hydratase, 
mitochondrial 
-1.34 0.024 54357 9.46 23.9% 15 Catalytic activity: (S)-malate = fumarate + H2O.   Energy 
metabolism 
4 Q9CZ13 uqcrc1 Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
-1.37 0.024 52852 5.77 10.6% 2 This is a component of the ubiquinol-cytochrome c reductase 
complex (complex III or cytochrome b-c1 complex), which is 
part of the mitochondrial respiratory chain.  
  Energy 
metabolism 
5 P15105 glul Glutamate 
decarboxylase 
-1.31 0.035 42120 6.67 20.6% 9 This enzyme has 2 functions: it catalyzes the production of 
glutamine and GABA. 
99; 346; 359 Biosynthesis 
6 P15105 glul Glutamate 
decarboxylase 
-1.19 0.096 42120 6.67 55.7% 20 This enzyme has 2 functions: it catalyzes the production of 
glutamine and GABA. 
99; 346; 359 Biosynthesis 
7 P05063 aldoc Aldolase 3 -1.41 0.032 39395 6.73 38.7% 54 Catalytic activity: D-fructose 1,6-bisphosphate = glycerone 
phosphate + D-glyceraldehyde 3-phosphate. 
  Energy 
metabolism 
8 P16858 gapdh Glyceraldehyde-3-
phosphate 
dehydrogenase 
-1.44 0.036 35810 8.16 35.0% 12 Has both glyceraldehyde-3-phosphate dehydrogenase and 





9 Q9D6R2 idh3a Isocitric dehydrogenase 
subunit alpha 
-1.26 0.046 39639 6.29 47.3% 27 Catalytic activity: Isocitrate + NAD+ = 2-oxoglutarate + CO2 + 
NADH. 
  Energy 
metabolism 
10 P14152 mdh1 Cytosolic malate 
dehydrogenase 
-1.24 0.032 36511 6.16 44.4% 48 Catalytic activity: (S)-malate + NAD+ = oxaloacetate + NADH. 137; 154 Energy 
metabolism 
11 Q99LC5 etfa Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
1.62 0.025 35009 8.28 7.5% 15 Transfers the electrons to the main mitochondrial respiratory 
chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase) 
  Energy 
metabolism 
12 P14152 mdh1 Cytosolic malate 
dehydrogenase 
-1.51 0.022 36511 6.16 19.2% 1 Catalytic activity: (S)-malate + NAD+ = oxaloacetate + NADH. 137; 154 Energy 
metabolism 
13 P00920 car2 Carbonate dehydratase 
II 
1.65 0.007 29033 6.57 46.1% 5 Essential for bone resorption and osteoclast differentiation 
(By similarity). Reversible hydration of carbon dioxide. 
  Unknown 
14 Q9DBJ1 pgam1 Phosphoglycerate 
mutase 1 
-1.28 0.048 28832 6.79 17.7% 13 Interconversion of 3- and 2-phosphoglycerate with 2,3-
bisphosphoglycerate as the primer of the reaction. Can also 
catalyze the reaction of EC 5.4.2.4 (synthase) and EC 3.1.3.13 
(phosphatase), but with a reduced activity. 
153 Energy 
metabolism 
15 P16015 car3 Carbonate dehydratase 
III 
-1.60 0.029 29366 6.99 79.5% 8 Reversible hydration of carbon dioxide.   Unknown 







UniProt ID Gene 
Name 
Name Ratio T-test Mass pI Seq 
Cov 
Pept Functional description SNOSID Site Functional 
classification 
mutase 1 bisphosphoglycerate as the primer of the reaction.  metabolism 
17 Q8BVI4 qdpr Dihydropteridine 
reductase 
1.29 0.044 25570 7.63 76.3% 7 The product of this enzyme, tetrahydrobiopterin (BH-4), is an 
essential cofactor for phenylalanine, tyrosine, and tryptophan 
hydroxylases (By similarity). 
158 Biosynthesis 
18 Q9R0Y5 ak1 Adenylate kinase 
isoenzyme 1 
-1.32 0.045 21540 5.42 22.6% 29 Catalyzes the reversible transfer of the terminal phosphate 
group between ATP and AMP.  
  Energy 
metabolism 
19 Q64152 btf3 RNA polymerase B 
transcription factor 3 
-1.30 0.027 22031 10.06 28.8% 4 General transcription factor. BTF3 can form a stable complex 
with RNA polymerase II. Required for the initiation of 
transcription (By similarity). 
  Transcription 
 
S-nitrosylation in the dorsal horn of the L4/5 mouse spinal cord was assessed by 2D SNO-DIGE analysis and subsequent identification by electrospray ionization 
mass spectrometry (ESI-MS/MS). SNO Upregulation is shown in blue, SNO down regulation in red. Quadruple 2D gels of naïve and SNI-Sham operated mice were 
analyzed and statistically compared by t-tests, P was set at 0.05. Identification of the modified cysteines was done with the SNO site identification method 





9.6 Appendix VI - The complete list of SNOSID results 
Protein ID 
Gene 
Name Protein Name Cysteine # SNI 
SNI +  
L-NAME Control 
1433T_MOUSE ywhaq 14-3-3 protein theta 94 
  
X 
1433Z_MOUSE ywhaz 14-3-3 protein zeta/delta 94 X 
A2M_MOUSE a2m Alpha-2-macroglobulin 594 
  
X 
AATM_MOUSE got2 Aspartate aminotransferase, mitochondrial 106 X 
 
X 
AATM_MOUSE got2 Aspartate aminotransferase, mitochondrial 187 X 
 
X 
ACON_MOUSE aco2 Aconitate hydratase, mitochondrial 126 X 
  ACON_MOUSE aco2 Aconitate hydratase, mitochondrial 448 
  
X 
ACON_MOUSE aco2 Aconitate hydratase, mitochondrial 451 
  
X 
ADT1_MOUSE slc25a4 ADP/ATP translocase 1 129 
  
X 
AINX_MOUSE ina Alpha-internexin 54 X 
  ALBU_MOUSE alb Serum albumin 269 X X 
ALBU_MOUSE alb Serum albumin 270 X 
 
X 
ALBU_MOUSE alb Serum albumin 274 X 
 
X 
ALBU_MOUSE alb Serum albumin 277 X 
 
X 
ALBU_MOUSE alb Serum albumin 384 
  
X 
ALBU_MOUSE alb Serum albumin 385 
  
X 
ALBU_MOUSE alb Serum albumin 393 
  
X 
ALBU_MOUSE alb Serum albumin 472 
  
X 
ALBU_MOUSE alb Serum albumin 500 X 
 
X 
ALBU_MOUSE alb Serum albumin 501 X X 
ALBU_MOUSE alb Serum albumin 511 X X X 
ALBU_MOUSE alb Serum albumin 538 X 
 
X 
ALBU_MOUSE alb Serum albumin 591 X X X 
ALDOA_MOUSE aldoa Fructose-bisphosphate aldolase A 73 
  
X 
ALDOC_MOUSE aldoc Fructose-bisphosphate aldolase C 178 X 
 
X 
ANXA2_MOUSE anxa2 Annexin A2 133 X 
  AT1A1_MOUSE atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 249 X 
  AT1A1_MOUSE atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 374 X X X 
AT1A2_MOUSE atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 241 X X X 
AT1A2_MOUSE atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 247 X X X 
AT1A2_MOUSE atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 372 X X X 
AT1A2_MOUSE atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 553 X 
 
X 
AT1A2_MOUSE atp1a2 Sodium/potassium-transporting ATPase subunit alpha-2 702 X 
 
X 
AT1A3_MOUSE atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 239 X 
 
X 
AT1A3_MOUSE atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 364 X X X 
AT1A3_MOUSE atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 49 X X X 
AT1A3_MOUSE atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 546 X 
 
X 
AT1A3_MOUSE atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 695 X 
 
X 
AT1B1_MOUSE atp1b1 Sodium/potassium-transporting ATPase subunit beta-1 214 X X X 
AT1B2_MOUSE atp1b2 Sodium/potassium-transporting ATPase subunit beta-2 10 X 
AT1B2_MOUSE atp1b2 Sodium/potassium-transporting ATPase subunit beta-2 261 X 
  AT1B3_MOUSE atp1b3 Sodium/potassium-transporting ATPase subunit beta-3 191 
  
X 
AT2B2_MOUSE atp2b2 Plasma membrane calcium-transporting ATPase 2 526 X 
  ATP5H_MOUSE atp5h ATP synthase subunit d, mitochondrial 101 X 
 
X 
ATPO_MOUSE atp5o ATP synthase subunit O, mitochondrial 141 X 
 
X 
BASI_MOUSE bsg Basigin 203 X 
 
X 
CADM2_MOUSE cadm2 Cell adhesion molecule 2 248 X X X 
CADM3_MOUSE cadm3 Cell adhesion molecule 3 207 
  
X 
CADM4_MOUSE cadm4 Cell adhesion molecule 4 145 X X 
CADM4_MOUSE cadm4 Cell adhesion molecule 4 245 
  
X 
CATB_MOUSE ctsb Cathepsin B 93 X 
 
X 









Name Protein Name Cysteine # SNI 
SNI +  
L-NAME Control 
CD81_MOUSE cd81 CD81 antigen 156 X X X 
CD81_MOUSE cd81 CD81 antigen 157 X X X 
CD82_MOUSE cd82 CD82 antigen 174 
  
X 
CD82_MOUSE cd82 CD82 antigen 176 
  
X 
CH60_MOUSE hspd1 60 kDa heat shock protein, mitochondrial 442 X X X 
CLCB_MOUSE cltb Clathrin light chain B 199 X 
  CLH_MOUSE cltc Clathrin heavy chain 1 151 
  
X 
CLH_MOUSE cltc Clathrin heavy chain 1 491 X 
 
X 
CLH_MOUSE cltc Clathrin heavy chain 1 926 
  
X 
CLH_MOUSE cltc Clathrin heavy chain 1 934 
  
X 
CN37_MOUSE cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase 111 X 
 
X 
CN37_MOUSE cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase 334 X 
 
X 
COF1_MOUSE cfl1 Cofilin-1 139 X X 
CSRP1_MOUSE csrp1 Cysteine and glycine-rich protein 1 167 
  
X 
CTL1_MOUSE slc44a1 Choline transporter-like protein 1 68 X 
 
X 
CX6B1_MOUSE cox6b1 Cytochrome c oxidase subunit 6B1 30 X 
 
X 
CX6B1_MOUSE cox6b1 Cytochrome c oxidase subunit 6B1 54 X 
 
X 
CX6B1_MOUSE cox6b1 Cytochrome c oxidase subunit 6B1 65 X X X 
CY1_MOUSE cyc1 Cytochrome c1, heme protein, mitochondrial 139 X 
 
X 
DHE3_MOUSE glud1 Glutamate dehydrogenase 1, mitochondrial 376 
  
X 
DHPR_MOUSE qdpr Dihydropteridine reductase 158 X 
 
X 
DHSA_MOUSE sdha Succinate dehydrogenase [ubiquinone] flavoprotein  89 X 
DLDH_MOUSE dld Dihydrolipoyl dehydrogenase, mitochondrial 484 
  
X 
DOPD_MOUSE ddt D-dopachrome decarboxylase 24 
  
X 
DPP6_MOUSE dpp6 Dipeptidyl aminopeptidase-like protein 6 674 
  
X 
DPYL1_MOUSE crmp1 Dihydropyrimidinase-related protein 1 248 
  
X 
DPYL2_MOUSE dpysl2 Dihydropyrimidinase-related protein 2 248 X X X 
DPYL2_MOUSE dpysl2 Dihydropyrimidinase-related protein 2 504 X 
 
X 
DPYL3_MOUSE dpysl3 Dihydropyrimidinase-related protein 3 248 X X X 
DPYL3_MOUSE dpysl3 Dihydropyrimidinase-related protein 3 471 
  
X 
EAA2_MOUSE slc1a2 Excitatory amino acid transporter 2 561 X X 
EF2_MOUSE eef2 Elongation factor 2 290 
  
X 
ENDD1_MOUSE endod1 Endonuclease domain-containing 1 protein 34 
  
X 
ENOA_MOUSE eno1 Alpha-enolase 357 X X X 
ENOG_MOUSE eno2 Gamma-enolase 357 X X X 
FBX2_MOUSE fbxo2 F-box only protein 2 75 X 
 
X 
G3P_MOUSE gapdh Glyceraldehyde-3-phosphate dehydrogenase 150 X X X 
G3P_MOUSE gapdh Glyceraldehyde-3-phosphate dehydrogenase 154 X X X 
G3P_MOUSE gapdh Glyceraldehyde-3-phosphate dehydrogenase 245 X 
 
X 
GABT_MOUSE abat 4-aminobutyrate aminotransferase, mitochondrial 440 X 
GBB1_MOUSE gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 148 X 
  GBB1_MOUSE gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  149 X 
GBB1_MOUSE gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  25 X 
 
X 
GBB1_MOUSE gnb1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  294 X 
 
X 
GBB2_MOUSE gnb2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  148 
  
X 
GBB2_MOUSE gnb2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  149 
  
X 
GBB2_MOUSE gnb2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)  204 X 
 
X 
GBB2_MOUSE gnb2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 25 X 
  GDIA_MOUSE gdi1 Rab GDP dissociation inhibitor alpha 202 X 
 
X 
GDIA_MOUSE gdi1 Rab GDP dissociation inhibitor alpha 282 X 
 
X 
GDIA_MOUSE gdi1 Rab GDP dissociation inhibitor alpha 317 X 
GFAP_MOUSE gfap Glial fibrillary acidic protein 291 X X X 
GLNA_MOUSE glul Glutamine synthetase 346 X 
 
X 







Name Protein Name Cysteine # SNI 
SNI +  
L-NAME Control 
GLRX5_MOUSE glrx5 Glutaredoxin-related protein 5, mitochondrial 63 
  
X 
GNAO_MOUSE gnao1 Guanine nucleotide-binding protein G(o) subunit alpha 140 X X 
GPM6A_MOUSE gpm6a Neuronal membrane glycoprotein M6-a 192 
  
X 
GPM6B_MOUSE gpm6b Neuronal membrane glycoprotein M6-b 226 
  
X 
GSLG1_MOUSE glg1 Golgi apparatus protein 1 503 
  
X 
GSLG1_MOUSE glg1 Golgi apparatus protein 1 511 
  
X 
HBA_MOUSE hba Hemoglobin subunit alpha 105 X 
 
X 
HBB1_MOUSE hbb-b1 Hemoglobin subunit beta-1 94 X X X 
HEMO_MOUSE hpx Hemopexin 255 X 
  HNRPL_MOUSE hnrnpl Heterogeneous nuclear ribonucleoprotein L 257 
  
X 
HNRPL_MOUSE hnrnpl Heterogeneous nuclear ribonucleoprotein L 258 
  
X 
HPLN2_MOUSE hapln2 Hyaluronan and proteoglycan link protein 2 291 X 
 
X 
HPLN4_MOUSE hapln4 Hyaluronan and proteoglycan link protein 4 210 X 
HPLN4_MOUSE hapln4 Hyaluronan and proteoglycan link protein 4 264 
  
X 
HS74L_MOUSE hspa4l Heat shock 70 kDa protein 4L 376 X X X 
HS74L_MOUSE hspa4l Heat shock 70 kDa protein 4L 380 X X X 
KCRB_MOUSE ckb Creatine kinase B-type 254 X 
 
X 
KCRS_MOUSE ckmt2 Creatine kinase S-type, mitochondrial 317 
  
X 
KCRU_MOUSE ckmt1 Creatine kinase U-type, mitochondrial 317 X X 
 KCRU_MOUSE ckmt1 Creatine kinase U-type, mitochondrial 90 X 
  KPYM_MOUSE pkm2 Pyruvate kinase isozymes M1/M2 152 X 
  KPYM_MOUSE pkm2 Pyruvate kinase isozymes M1/M2 49 X X X 
LSAMP_MOUSE lsamp Limbic system-associated membrane protein 111 
  
X 
MDHC_MOUSE mdh1 Malate dehydrogenase, cytoplasmic 137 X X X 
MDHC_MOUSE mdh1 Malate dehydrogenase, cytoplasmic 154 X 
 
X 
MDHM_MOUSE mdh2 Malate dehydrogenase, mitochondrial 212 X X X 
MDHM_MOUSE mdh2 Malate dehydrogenase, mitochondrial 275 X 
 
X 
MDHM_MOUSE mdh2 Malate dehydrogenase, mitochondrial 285 X X X 
MDHM_MOUSE mdh2 Malate dehydrogenase, mitochondrial 89 X 
 
X 
MDHM_MOUSE mdh2 Malate dehydrogenase, mitochondrial 93 X 
 
X 
MIF_MOUSE mif Macrophage migration inhibitory factor 81 X X 
MOG_MOUSE mog Myelin-oligodendrocyte glycoprotein 126 X 
 
X 
MOG_MOUSE mog Myelin-oligodendrocyte glycoprotein 52 X X X 
MT3_MOUSE mt3 Metallothionein-3 34 X 
 
X 
MT3_MOUSE mt3 Metallothionein-3 35 X 
 
X 
MT3_MOUSE mt3 Metallothionein-3 37 X 
 
X 
MT3_MOUSE mt3 Metallothionein-3 38 X 
 
X 
MT3_MOUSE mt3 Metallothionein-3 42 X 
 
X 
MYPR_MOUSE plp1 Myelin proteolipid protein 201 X X X 
NCAM1_MOUSE ncam1 Neural cell adhesion molecule 1 288 X 
NCAM1_MOUSE ncam1 Neural cell adhesion molecule 1 41 X 
 
X 
NCDN_MOUSE ncdn Neurochondrin 415 X 
NDUA8_MOUSE ndufa8 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 8 66 X X X 
NDUAA_MOUSE ndufa10 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 10, mitochondrial 67 X 
NDUAB_MOUSE ndufa11 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 11 18 X 
NDUAB_MOUSE ndufa11 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 11 95 X 
NDUS5_MOUSE ndufs5 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 43 
  
X 
NDUS5_MOUSE ndufs5 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 66 X X X 
NDUS8_MOUSE ndufs8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8,  119 X 








Name Protein Name Cysteine # SNI 
SNI +  
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NDUV1_MOUSE ndufv1 NADH dehydrogenase [ubiquinone] flavoprotein 1,  142 
  
X 
NFASC_MOUSE nfasc Neurofascin 452 X X 
NFH_MOUSE nefh Neurofilament heavy polypeptide 225 X 
 
X 
NPTN_MOUSE nptn Neuroplastin 217 X 
 
X 




Dihydrolipoyllysine-residue acetyltransferase component 
of pyruvate dehydrogenase complex, mitochondrial 290 X 
 
X 
ODPA_MOUSE pdha1 Pyruvate dehydrogenase E1 component subunit alpha 218 X X X 
ODPA_MOUSE pdha1 Pyruvate dehydrogenase E1 component subunit alpha 222 X X X 
PARK7_MOUSE park7 Protein DJ-1 46 
  
X 
PGAM1_MOUSE pgam1 Phosphoglycerate mutase 1 153 X 
 
X 
PGCB_MOUSE bcan Brevican core protein 178 
  
X 
PGCB_MOUSE bcan Brevican core protein 834 X 
 
X 
PGCB_MOUSE bcan Brevican core protein 847 X 
 
X 
PGK1_MOUSE pgk1 Phosphoglycerate kinase 1 367 X X 
PGK1_MOUSE pgk1 Phosphoglycerate kinase 1 379 X 
 
X 
PGK1_MOUSE pgk1 Phosphoglycerate kinase 1 380 X 
 
X 
PPIA_MOUSE ppia Peptidyl-prolyl cis-trans isomerase A 161 X 
 
X 
PRDX1_MOUSE prdx1 Peroxiredoxin-1 173 X 
 
X 
PRDX3_MOUSE prdx3 Thioredoxin-dependent peroxide reductase, mitochondrial 230 
  
X 
PRDX5_MOUSE prdx5 Peroxiredoxin-5, mitochondrial 200 
  
X 
PRDX5_MOUSE prdx5 Peroxiredoxin-5, mitochondrial 96 X X X 
PRDX6_MOUSE prdx6 Peroxiredoxin-6 47 X 
 
X 
QCR2_MOUSE uqcrc2 Cytochrome b-c1 complex subunit 2, mitochondrial 192 X X 
QCR6_MOUSE uqcrh Cytochrome b-c1 complex subunit 6, mitochondrial 65 X 
 
X 
RAB3A_MOUSE rab3a Ras-related protein Rab-3A 184 X 
  RAC2_MOUSE rac2 Ras-related C3 botulinum toxin substrate 2 157 X 
 
X 
RAN_MOUSE ran GTP-binding nuclear protein Ran 112 X 
 
X 
RAN_MOUSE ran GTP-binding nuclear protein Ran 120 X 
 
X 
RASK_MOUSE kras GTPase KRas 80 
  
X 
ROMO1_MOUSE romo1 Reactive oxygen species modulator 1 15 
  
X 
RP3A_MOUSE rph3a Rabphilin-3A 641 X 
 
X 
SAHH3_MOUSE ahcyl2 Putative adenosylhomocysteinase 3 400 X X 
SC6A5_MOUSE slc6a5 Sodium- and chloride-dependent glycine transporter 2 333 X 
 
X 
SNAB_MOUSE napb Beta-soluble NSF attachment protein 66 
  
X 
SPRL1_MOUSE sparcl1 SPARC-like protein 1 501 
  
X 
STIP1_MOUSE stip1 Stress-induced-phosphoprotein 1 26 
  
X 
STXB1_MOUSE stxbp1 Syntaxin-binding protein 1 180 X 
 
X 
SUCA_MOUSE suclg1 Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha,  172 X 
 
X 
SUCA_MOUSE suclg1 Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha,  181 X 
 
X 
SUCB1_MOUSE sucla2 Succinyl-CoA ligase [ADP-forming] subunit beta,  152 X 
  SUCB1_MOUSE sucla2 Succinyl-CoA ligase [ADP-forming] subunit beta,  158 X 
  SUCB1_MOUSE sucla2 Succinyl-CoA ligase [ADP-forming] subunit beta,  430 X 
  SUSD2_MOUSE susd2 Sushi domain-containing protein 2 748 
  
X 
SUSD2_MOUSE susd2 Sushi domain-containing protein 2 762 
  
X 
SYPH_MOUSE syp Synaptophysin 87 X X X 
TBA1A_MOUSE tuba1a Tubulin alpha-1A chain 347 X 
 
X 
TBA1B_MOUSE tuba1b Tubulin alpha-1B chain 347 X X X 
TBA1C_MOUSE tuba1c Tubulin alpha-1C chain 347 X X X 
TBA4A_MOUSE tuba4a Tubulin alpha-4A chain 347 X X X 
TBA4A_MOUSE tuba4a Tubulin alpha-4A chain 54 X 
 
X 
TBB2A_MOUSE tubb2a Tubulin beta-2A chain 12 X 
 
X 
TBB2A_MOUSE tubb2a Tubulin beta-2A chain 354 X X 









Name Protein Name Cysteine # SNI 
SNI +  
L-NAME Control 
TBB2C_MOUSE tubb2c Tubulin beta-2C chain 354 
  
X 
TBB3_MOUSE tubb3 Tubulin beta-3 chain 12 X X X 
TBB3_MOUSE tubb3 Tubulin beta-3 chain 354 X 
 
X 
TBB4_MOUSE tubb4 Tubulin beta-4 chain 12 X X X 
TBB5_MOUSE tubb5 Tubulin beta-5 chain 12 X X X 
TBB5_MOUSE tubb5 Tubulin beta-5 chain 354 
  
X 
TERA_MOUSE vcp Transitional endoplasmic reticulum ATPase 535 X 
 
X 
THIL_MOUSE acat1 Acetyl-CoA acetyltransferase, mitochondrial 116 X 
 
X 
THY1_MOUSE thy1 Thy-1 membrane glycoprotein 28 X 
 
X 
TPIS_MOUSE tpi1 Triosephosphate isomerase 127 X 
 
X 
TPIS_MOUSE tpi1 Triosephosphate isomerase 218 X 
 
X 
UCHL1_MOUSE uchl1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 152 X X X 
UCHL1_MOUSE uchl1 Ubiquitin carboxyl-terminal hydrolase isozyme L1 220 X X 
VATB2_MOUSE atp6v1b2 V-type proton ATPase subunit B, brain isoform 289 X 
 
X 
VDAC1_MOUSE vdac1 Voltage-dependent anion-selective channel protein 1 245 X 
 
X 
VDAC2_MOUSE vdac2 Voltage-dependent anion-selective channel protein 2 77 X 
 
X 
VISL1_MOUSE vsnl1 Visinin-like protein 1 187 X 
 
X 








9.7 Appendix VII - Full list of proteins identified with the SILAC method 

















CH10_HUMAN 10 kDa heat shock protein, mitochondrial 0,79 0,68 1,33 0,90 0,003 0,014 0,052 0,229 
U5S1_HUMAN 116 kDa U5 small nuclear ribonucleoprotein component 0,96 0,97 1,33 1,29 0,403 0,434 0,036 0,104 
1433E_HUMAN 14-3-3 protein epsilon 0,01 0,26 0,04 0,01 0,183 0,251 0,184 0,250 
1433G_HUMAN 14-3-3 protein gamma 0,98 0,85 1,07 0,90 0,453 0,280 0,373 0,167 
1433T_HUMAN 14-3-3 protein theta 0,77 0,86 1,17 1,01 0,224 0,305 0,265 0,492 
1433Z_HUMAN 14-3-3 protein zeta/delta 1,16 0,90 0,81 0,73 0,373 0,357 0,116 0,141 
PLCE_HUMAN 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon 1,07 0,96 1,00 0,96 0,155 0,399 0,499 0,450 
PSMD1_HUMAN 26S proteasome non-ATPase regulatory subunit 1 0,74 1,92 0,64 1,22 0,143 0,297 0,312 0,353 
PSD12_HUMAN 26S proteasome non-ATPase regulatory subunit 12 0,72 0,77 0,90 0,69 0,015 0,011 0,170 0,011 
PSMD3_HUMAN 26S proteasome non-ATPase regulatory subunit 3 1,01 1,68 0,70 1,17 0,270 
PSMD6_HUMAN 26S proteasome non-ATPase regulatory subunit 6 0,81 0,73 1,06 0,77 0,073 0,031 0,305 0,040 
RM12_HUMAN 39S ribosomal protein L12, mitochondrial 0,80 0,77 1,59 1,23 0,033 0,041 0,095 0,286 
HCD2_HUMAN 3-hydroxyacyl-CoA dehydrogenase type-2 0,60 0,76 1,23 0,93 0,003 0,088 0,089 0,088 
THIM_HUMAN 3-ketoacyl-CoA thiolase, mitochondrial 0,79 1,14 1,17 1,33 
  
0,085 
 RS10_HUMAN 40S ribosomal protein S10 0,63 0,91 0,65 0,59 
  
0,004 
 RS12_HUMAN 40S ribosomal protein S12 
        RS13_HUMAN 40S ribosomal protein S13 1,03 0,91 1,33 1,22 0,142 
RS14_HUMAN 40S ribosomal protein S14 1,24 1,28 1,13 1,44 0,302 0,272 0,278 0,253 
RS16_HUMAN 40S ribosomal protein S16 0,78 0,84 1,09 0,92 0,083 0,038 0,153 0,222 
RS17L_HUMAN 40S ribosomal protein S17-like 0,83 0,90 0,69 0,63 0,103 
RS18_HUMAN 40S ribosomal protein S18 
  
0,86 
   
0,361 
 RS19_HUMAN 40S ribosomal protein S19 0,39 0,47 0,83 0,38 0,159 0,192 0,286 0,208 
RS20_HUMAN 40S ribosomal protein S20 0,97 0,84 1,22 1,02 0,429 0,167 0,092 0,449 
RS23_HUMAN 40S ribosomal protein S23 0,83 0,72 1,56 1,12 0,226 0,088 0,135 0,427 
RS24_HUMAN 40S ribosomal protein S24 1,52 1,38 1,37 1,90 
  
0,040 
 RS25_HUMAN 40S ribosomal protein S25 0,86 0,86 1,10 0,94 0,265 0,287 0,340 0,187 
RS3_HUMAN 40S ribosomal protein S3 1,47 1,22 1,21 1,47 0,185 0,308 0,015 0,155 
RS3A_HUMAN 40S ribosomal protein S3a 0,83 0,72 1,16 0,84 0,108 0,029 0,099 0,086 
RS4X_HUMAN 40S ribosomal protein S4, X isoform 1,27 1,36 0,57 0,77 
  
0,002 
 RS6_HUMAN 40S ribosomal protein S6 0,84 0,73 1,19 0,87 0,183 0,056 0,106 0,120 
RS8_HUMAN 40S ribosomal protein S8 0,89 0,92 0,97 0,89 0,233 0,334 0,402 0,132 
RSSA_HUMAN 40S ribosomal protein SA 0,80 0,91 1,05 0,95 0,022 0,168 0,329 0,270 
CH60_HUMAN 60 kDa heat shock protein, mitochondrial 0,99 0,98 0,98 0,96 0,450 0,450 0,437 0,253 
RLA0_HUMAN 60S acidic ribosomal protein P0 1,09 0,89 1,05 0,94 0,334 0,263 0,393 0,289 
RLA1_HUMAN 60S acidic ribosomal protein P1 1,18 0,73 1,26 0,93 0,273 
RLA2_HUMAN 60S acidic ribosomal protein P2 0,66 0,73 1,42 1,03 0,028 0,011 0,126 0,463 
RL10_HUMAN 60S ribosomal protein L10 0,69 0,70 1,36 0,95 0,087 0,052 0,044 0,390 
RL10A_HUMAN 60S ribosomal protein L10a 1,42 0,76 1,90 1,44 0,286 0,365 0,054 0,350 
RL11_HUMAN 60S ribosomal protein L11 0,88 0,86 1,25 1,08 0,061 0,166 0,110 0,362 
RL12_HUMAN 60S ribosomal protein L12 1,08 0,99 1,12 1,11 0,302 0,455 0,222 0,257 






















RL17_HUMAN 60S ribosomal protein L17 0,99 0,94 1,17 1,10 0,482 0,339 0,090 0,438 
RL18_HUMAN 60S ribosomal protein L18 0,92 0,67 1,31 0,88 0,221 0,102 0,120 0,145 
RL19_HUMAN 60S ribosomal protein L19 0,98 0,99 0,98 0,97 0,154 0,334 0,313 0,238 
RL22_HUMAN 60S ribosomal protein L22 0,93 0,92 1,07 0,98 0,135 0,319 0,328 0,235 
RL23_HUMAN 60S ribosomal protein L23 0,85 0,67 0,57 0,38 
 
0,067 
  RL23A_HUMAN 60S ribosomal protein L23a 0,97 0,95 1,01 0,96 0,402 0,413 0,484 0,268 
RL26_HUMAN 60S ribosomal protein L26 0,86 0,61 1,63 0,99 
  
0,200 
 RL27A_HUMAN 60S ribosomal protein L27a 0,84 0,81 1,03 0,84 0,054 0,135 0,433 0,075 
RL29_HUMAN 60S ribosomal protein L29 1,00 1,14 0,85 0,96 
 
0,329 0,324 
 RL30_HUMAN 60S ribosomal protein L30 1,49 0,81 46,78 37,92 0,152 0,189 
RL37A_HUMAN 60S ribosomal protein L37a 1,02 0,97 1,16 1,12 
  
0,187 
 RL4_HUMAN 60S ribosomal protein L4 1,13 1,49 1,02 1,53 0,274 0,024 0,443 0,038 
RL5_HUMAN 60S ribosomal protein L5 1,14 1,14 0,84 0,95 0,222 0,244 0,099 0,270 
RL7_HUMAN 60S ribosomal protein L7 0,72 0,80 1,36 1,09 0,114 0,206 0,169 0,148 
RL7A_HUMAN 60S ribosomal protein L7a 1,03 1,08 0,97 1,05 0,415 0,290 0,402 0,314 
RL8_HUMAN 60S ribosomal protein L8 1,08 1,10 0,85 0,93 0,208 0,159 0,036 0,296 
RL9_HUMAN 60S ribosomal protein L9 1,38 1,47 0,97 1,42 0,021 0,044 0,438 0,095 
GRP78_HUMAN 78 kDa glucose-regulated protein 1,27 1,20 1,06 1,27 0,107 0,182 0,157 0,177 
ACTB_HUMAN Actin, cytoplasmic 1 1,43 1,32 1,00 1,33 0,176 0,239 0,486 0,238 
TCP4_HUMAN Activated RNA polymerase II transcriptional coactivator p15 0,97 1,10 0,72 0,79 0,311 0,210 0,012 0,007 
ADNP_HUMAN Activity-dependent neuroprotector homeobox protein 1,08 0,92 1,13 1,05 0,371 
SAHH_HUMAN Adenosylhomocysteinase 1,00 0,90 0,79 0,71 0,494 
  
0,161 
KAD2_HUMAN Adenylate kinase 2, mitochondrial 0,84 0,52 2,58 1,35 0,242 0,071 0,143 0,485 
APMAP_HUMAN Adipocyte plasma membrane-associated protein 0,85 0,74 1,52 1,13 0,046 
ADT2_HUMAN ADP/ATP translocase 2 1,28 1,23 1,12 1,37 0,272 0,312 0,078 0,287 
ADT3_HUMAN ADP/ATP translocase 3 0,88 0,93 1,28 1,20 0,294 0,286 0,006 0,071 
AKAP8_HUMAN A-kinase anchor protein 8 0,85 0,89 1,33 1,19 0,224 0,269 0,034 0,103 
ADAS_HUMAN Alkyldihydroxyacetonephosphate synthase, peroxisomal 1,01 1,36 1,24 1,69 0,412 0,068 0,072 0,010 
ACTN1_HUMAN Alpha-actinin-1 1,07 1,33 0,86 1,14 0,353 0,022 0,144 0,186 
ACTN4_HUMAN Alpha-actinin-4 0,81 0,93 0,99 0,92 0,267 0,410 0,479 0,096 
ENOA_HUMAN Alpha-enolase 0,32 0,37 0,58 0,21 0,180 0,201 0,205 0,206 
AINX_HUMAN Alpha-internexin 1,09 1,19 1,18 1,40 0,268 0,007 0,184 0,116 
AIMP1_HUMAN Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 0,94 0,83 0,49 0,41 0,396 
  
0,074 
SYRC_HUMAN Arginine--tRNA ligase, cytoplasmic 0,85 0,77 0,62 0,47 0,374 0,290 0,078 0,155 
SYDC_HUMAN Aspartate--tRNA ligase, cytoplasmic 1,01 0,93 0,99 0,92 0,444 0,413 
ATPA_HUMAN ATP synthase subunit alpha, mitochondrial 0,94 0,87 1,12 0,98 0,129 0,098 0,181 0,339 
AT5F1_HUMAN ATP synthase subunit b, mitochondrial 
  
1,24 
   
0,157 
 ATPB_HUMAN ATP synthase subunit beta, mitochondrial 1,26 1,21 1,11 1,35 0,293 0,328 0,058 0,280 
ATP5H_HUMAN ATP synthase subunit d, mitochondrial 0,52 0,42 1,96 0,83 0,045 0,037 0,008 0,138 
ATP5L_HUMAN ATP synthase subunit g, mitochondrial 0,59 0,68 1,12 0,76 
  
0,238 
 ATPG_HUMAN ATP synthase subunit gamma, mitochondrial 0,71 0,53 1,96 1,05 
 
0,059 
  ATPO_HUMAN ATP synthase subunit O, mitochondrial 0,74 0,75 1,06 0,80 0,026 0,020 0,263 0,010 

























ABCF1_HUMAN ATP-binding cassette sub-family F member 1 1,46 1,13 0,47 0,53 0,114 0,320 0,041 0,066 
DHX9_HUMAN ATP-dependent RNA helicase A 0,81 0,91 1,27 1,15 0,211 0,134 0,104 0,346 
ARI1A_HUMAN AT-rich interactive domain-containing protein 1A 1,37 1,67 1,31 2,19 0,058 0,032 0,342 0,190 
BCLF1_HUMAN Bcl-2-associated transcription factor 1 0,92 1,02 1,68 1,72 0,264 0,439 0,006 0,014 
SYEP_HUMAN Bifunctional glutamate/proline--tRNA ligase 0,89 0,88 0,92 0,81 0,330 0,318 0,284 0,219 
BASP1_HUMAN Brain acid soluble protein 1 0,60 0,90 3,19 2,86 0,001 0,385 0,064 0,068 
FACE1_HUMAN CAAX prenyl protease 1 homolog 0,89 0,78 1,33 1,04 0,158 0,065 0,047 0,314 
CMC2_HUMAN Calcium-binding mitochondrial carrier protein Aralar2 0,78 0,75 1,24 0,93 0,163 0,155 0,223 0,332 
CALD1_HUMAN Caldesmon 2,43 2,38 0,81 1,93 
  
0,163 
 CALM_HUMAN Calmodulin 0,70 1,12 2,00 2,25 0,024 0,310 0,144 0,182 
CALX_HUMAN Calnexin 0,92 0,85 1,00 0,86 0,066 0,030 0,498 0,042 
CALR_HUMAN Calreticulin 0,96 0,94 1,34 1,25 0,385 0,345 0,010 0,042 
CALU_HUMAN Calumenin 0,81 0,93 1,30 1,21 0,209 0,328 0,085 0,379 
CAPR1_HUMAN Caprin-1 1,11 0,92 0,85 0,78 0,297 0,089 0,020 0,003 
CPT2_HUMAN Carnitine O-palmitoyltransferase 2, mitochondrial 
  
0,88 
   
0,347 
 CTNA1_HUMAN Catenin alpha-1 0,74 0,85 1,15 0,97 0,027 0,202 0,132 0,385 
CD166_HUMAN CD166 antigen 1,34 1,57 1,41 2,21 0,251 0,153 0,011 0,031 
CDC5L_HUMAN Cell division cycle 5-like protein 0,91 1,04 1,10 1,15 0,308 0,114 0,244 0,304 
ZW10_HUMAN Centromere/kinetochore protein zw10 homolog 0,41 0,36 1,13 0,41 
  
0,330 
 CBX3_HUMAN Chromobox protein homolog 3 0,73 0,75 1,38 1,03 0,037 0,053 0,029 0,396 
CBX5_HUMAN Chromobox protein homolog 5 0,83 1,23 0,94 1,15 0,389 0,360 0,370 0,370 
CHD4_HUMAN Chromodomain-helicase-DNA-binding protein 4 0,68 0,70 1,06 0,75 0,298 0,348 0,438 0,400 
CHD7_HUMAN Chromodomain-helicase-DNA-binding protein 7 1,02 0,91 1,31 1,19 0,405 
   CMGA_HUMAN Chromogranin-A 0,84 1,14 1,66 1,90 0,162 0,325 0,046 0,046 
CISY_HUMAN Citrate synthase, mitochondrial 1,01 0,91 1,14 1,04 0,453 0,160 0,161 0,484 
CLH1_HUMAN Clathrin heavy chain 1 1,11 0,77 1,13 0,87 0,290 0,272 0,365 0,188 
CPSF7_HUMAN Cleavage and polyadenylation specificity factor subunit 7 1,08 
  
0,76 0,469 
   COF1_HUMAN Cofilin-1 0,98 0,96 0,80 0,77 0,440 0,351 0,035 0,056 
CHCH3_HUMAN Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial 0,88 0,89 1,14 1,02 0,124 0,234 0,157 0,376 
C1QBP_HUMAN Complement component 1 Q subcomponent-binding protein, mitochondrial 0,93 0,90 1,22 1,09 0,239 0,037 0,020 0,164 
CNTN1_HUMAN Contactin-1 0,85 0,66 1,60 1,05 0,049 
H2AY_HUMAN Core histone macro-H2A.1 0,75 0,86 1,39 1,20 0,152 0,017 0,005 0,057 
H2AW_HUMAN Core histone macro-H2A.2 0,74 0,79 1,57 1,23 0,054 0,076 0,029 0,153 
CELF1_HUMAN CUGBP Elav-like family member 1 0,94 0,93 1,59 1,47 
  
0,007 
 QCR2_HUMAN Cytochrome b-c1 complex subunit 2, mitochondrial 1,04 1,14 1,04 1,19 0,408 0,197 0,340 0,211 
UCRI_HUMAN Cytochrome b-c1 complex subunit Rieske, mitochondrial 0,87 0,87 1,13 0,99 0,244 0,308 0,260 0,279 
COX2_HUMAN Cytochrome c oxidase subunit 2 0,89 1,02 1,00 1,03 0,286 0,456 0,492 0,273 
COX41_HUMAN Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 0,71 0,95 1,03 0,97 0,172 0,162 0,345 0,494 
COX5B_HUMAN Cytochrome c oxidase subunit 5B, mitochondrial 0,62 0,82 1,25 1,02 0,071 0,062 0,011 0,430 
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 0,51 0,41 1,21 0,49 0,210 0,229 0,101 0,264 
DC1I2_HUMAN Cytoplasmic dynein 1 intermediate chain 2 0,86 0,83 1,09 0,91 
 
0,017 0,155 0,166 
CKAP4_HUMAN Cytoskeleton-associated protein 4 0,83 1,13 1,04 1,17 0,143 0,350 0,436 0,186 






















DCA13_HUMAN DDB1- and CUL4-associated factor 13 1,08 1,32 1,26 1,66 0,250 
  
0,084 
DPYL3_HUMAN Dihydropyrimidinase-related protein 3 0,83 4,08 0,46 1,86 
  
0,287 
 DDB1_HUMAN DNA damage-binding protein 1 1,11 1,06 1,17 1,23 0,152 0,348 0,248 
TOP1_HUMAN DNA topoisomerase 1 1,13 1,34 1,25 1,67 0,407 0,143 0,202 0,056 
TOP2B_HUMAN DNA topoisomerase 2-beta 0,05 0,04 1,82 0,08 0,184 0,183 0,149 0,189 
APEX1_HUMAN DNA-(apurinic or apyrimidinic site) lyase 2,68 0,88 0,54 0,48 0,262 0,422 0,146 0,408 
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit 0,98 1,01 0,90 0,92 0,461 0,471 0,073 0,468 
RPB1_HUMAN DNA-directed RNA polymerase II subunit RPB1 1,22 1,23 0,92 1,12 
 
0,001 0,365 0,341 
DJB11_HUMAN DnaJ homolog subfamily B member 11 0,67 0,67 1,58 1,06 0,127 0,022 0,069 0,419 
DPM1_HUMAN Dolichol-phosphate mannosyltransferase 0,83 0,78 1,36 1,07 0,210 0,164 0,066 0,316 
OST48_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit 0,76 0,69 1,31 0,91 
  
0,019 
 RPN1_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 1,11 1,00 1,17 1,17 0,002 0,494 0,030 0,005 
RPN2_HUMAN Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 1,11 0,99 1,56 1,55 0,335 0,493 0,069 0,298 
DOPO_HUMAN Dopamine beta-hydroxylase 0,77 0,84 1,14 0,96 0,176 0,141 0,202 0,441 
DSRAD_HUMAN Double-stranded RNA-specific adenosine deaminase 2,11 1,73 1,03 1,78 0,080 0,165 0,464 0,043 
DREB_HUMAN Drebrin 0,83 1,09 1,20 1,31 0,101 0,380 0,165 0,016 
DYL1_HUMAN Dynein light chain 1, cytoplasmic 1,16 1,28 1,24 1,59 0,110 0,031 0,005 
RBP2_HUMAN E3 SUMO-protein ligase RanBP2 3,92 2,14 0,94 2,02 
  
0,458 
 UBR4_HUMAN E3 ubiquitin-protein ligase UBR4 0,85 0,82 1,04 0,85 0,168 0,116 0,390 
 ELAV1_HUMAN ELAV-like protein 1 0,87 0,88 1,06 0,94 0,383 0,390 0,435 0,353 
ELAV3_HUMAN ELAV-like protein 3 1,70 1,88 0,63 1,18 0,074 
ELMD2_HUMAN ELMO domain-containing protein 2 1,57 1,73 
  
0,064 
   EF1A1_HUMAN Elongation factor 1-alpha 1 0,92 0,92 0,85 0,79 0,384 0,317 0,147 0,007 
EF1B_HUMAN Elongation factor 1-beta 0,76 0,90 1,20 1,07 0,064 0,309 0,117 0,292 
EF1D_HUMAN Elongation factor 1-delta 1,00 1,03 1,00 1,03 0,476 0,439 0,490 0,360 
EF2_HUMAN Elongation factor 2 1,37 1,38 0,42 0,57 0,239 0,177 0,007 0,153 
EFTU_HUMAN Elongation factor Tu, mitochondrial 0,83 0,65 1,19 0,77 0,182 0,112 0,250 0,081 
ERP29_HUMAN Endoplasmic reticulum resident protein 29 0,84 0,83 1,52 1,26 0,245 0,267 0,050 0,121 
ENPL_HUMAN Endoplasmin 1,38 1,44 1,02 1,47 0,230 0,202 0,359 0,206 
ERH_HUMAN Enhancer of rudimentary homolog 0,75 0,77 1,65 1,28 
  
0,133 
 ERLN1_HUMAN Erlin-1 0,93 0,96 1,26 1,22 0,265 0,253 0,004 0,039 
DHB12_HUMAN Estradiol 17-beta-dehydrogenase 12 0,71 0,75 1,05 0,78 0,076 0,069 0,271 0,084 
IF4A1_HUMAN Eukaryotic initiation factor 4A-I 0,73 0,78 0,98 0,77 
 
0,185 0,448 0,195 
IF4A3_HUMAN Eukaryotic initiation factor 4A-III 0,97 1,26 1,29 1,63 0,457 0,256 0,096 0,058 
IF2G_HUMAN Eukaryotic translation initiation factor 2 subunit 3 0,93 1,31 1,06 1,39 0,251 0,452 0,272 
IF4E_HUMAN Eukaryotic translation initiation factor 4E 1,30 1,03 0,51 0,52 
 
0,464 
  IF6_HUMAN Eukaryotic translation initiation factor 6 
  
0,97 
   
0,473 
 SP16H_HUMAN FACT complex subunit SPT16 1,21 1,49 0,62 0,92 0,347 0,247 0,165 0,287 
SSRP1_HUMAN FACT complex subunit SSRP1 0,97 0,97 0,83 0,81 0,375 0,394 0,287 0,262 
CAZA1_HUMAN F-actin-capping protein subunit alpha-1 1,59 1,04 0,88 0,91 0,236 0,465 0,342 0,395 
FUBP1_HUMAN Far upstream element-binding protein 1 0,98 0,98 1,17 1,15 0,483 0,487 0,274 0,391 
FUBP2_HUMAN Far upstream element-binding protein 2 1,10 1,04 1,74 1,80 0,236 0,388 0,153 0,244 
























FLNA_HUMAN Filamin-A 0,04 0,04 0,88 0,04 0,187 0,188 0,234 0,189 
FLOT2_HUMAN Flotillin-2 0,78 
   
0,122 
   FIZ1_HUMAN Flt3-interacting zinc finger protein 1 1,29 0,092 
FXR1_HUMAN Fragile X mental retardation syndrome-related protein 1 1,07 1,38 0,80 1,10 0,402 0,260 0,272 0,154 
FXR2_HUMAN Fragile X mental retardation syndrome-related protein 2 0,87 0,80 1,19 0,95 0,217 0,081 0,105 0,263 
FUMH_HUMAN Fumarate hydratase, mitochondrial 1,66 0,051 
LEG1_HUMAN Galectin-1 0,94 0,97 1,17 1,13 0,338 0,431 0,202 0,403 
GDAP1_HUMAN Ganglioside-induced differentiation-associated protein 1 0,68 0,63 1,07 0,68 
  
0,414 
 TF3C3_HUMAN General transcription factor 3C polypeptide 3 0,85 1,12 1,33 1,49 
  
0,063 
 GTF2I_HUMAN General transcription factor II-I 0,74 1,02 0,89 0,91 0,240 0,445 0,218 0,453 
G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase 0,45 0,52 0,87 0,45 0,073 0,041 0,165 0,028 
G6PI_HUMAN Glucose-6-phosphate isomerase 0,85 0,54 0,39 0,21 0,370 0,109 0,096 0,030 
GLU2B_HUMAN Glucosidase 2 subunit beta 0,84 0,94 1,14 1,07 0,279 0,366 0,174 0,460 
DHE3_HUMAN Glutamate dehydrogenase 1, mitochondrial 0,81 0,149 
SYQ_HUMAN Glutamine--tRNA ligase 1,75 1,74 0,82 1,42 0,076 0,124 0,260 0,124 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 1,06 1,00 0,97 0,97 0,427 0,488 0,396 0,493 
GPAT4_HUMAN Glycerol-3-phosphate acyltransferase 4 0,96 1,00 0,99 0,99 0,481 
NMT1_HUMAN Glycylpeptide N-tetradecanoyltransferase 1 0,75 0,65 1,23 0,80 0,236 0,097 0,198 0,097 
RAN_HUMAN GTP-binding nuclear protein Ran 0,87 0,77 1,03 0,79 0,143 0,035 0,361 0,015 
GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 1,46 2,33 0,29 0,67 0,200 0,089 0,049 0,248 
GNAI3_HUMAN Guanine nucleotide-binding protein G(k) subunit alpha 1,31 1,72 1,15 1,98 0,222 0,142 0,230 0,029 
GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit alpha isoforms short 1,00 1,11 
  
0,498 
   GNAS1_HUMAN Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas 
  
0,99 
   
0,482 
 NHP2_HUMAN H/ACA ribonucleoprotein complex subunit 2 1,97 1,57 0,05 0,08 0,255 0,390 0,215 
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B 1,10 1,03 1,01 1,04 0,384 0,468 0,466 0,452 
HSP74_HUMAN Heat shock 70 kDa protein 4 0,26 0,22 0,76 0,17 0,195 0,186 0,105 0,169 
HSP7C_HUMAN Heat shock cognate 71 kDa protein 0,94 0,90 0,99 0,89 0,123 0,056 0,432 0,040 
HS105_HUMAN Heat shock protein 105 kDa 0,35 0,30 1,14 0,34 0,232 0,241 
HSPB1_HUMAN Heat shock protein beta-1 1,07 0,82 1,06 0,88 0,384 0,154 0,388 0,219 
HS90A_HUMAN Heat shock protein HSP 90-alpha 0,90 0,91 0,88 0,80 0,267 0,225 0,069 0,076 
HS90B_HUMAN Heat shock protein HSP 90-beta 1,52 1,43 0,91 1,30 0,135 0,144 0,146 0,187 
HDGR2_HUMAN Hepatoma-derived growth factor-related protein 2 1,02 1,06 0,89 0,94 0,245 0,002 0,050 0,246 
HP1B3_HUMAN Heterochromatin protein 1-binding protein 3 1,14 1,26 0,78 0,98 0,212 0,059 0,088 
 ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1 0,82 0,85 1,45 1,23 0,056 0,025 0,003 0,036 
ROA3_HUMAN Heterogeneous nuclear ribonucleoprotein A3 1,07 1,10 0,96 1,06 0,313 0,270 0,377 0,400 
HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 0,96 1,03 0,97 1,00 0,330 0,356 0,357 0,385 
HNRDL_HUMAN Heterogeneous nuclear ribonucleoprotein D-like 0,77 0,86 1,18 1,01 0,032 0,011 0,003 0,361 
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F 0,61 0,68 1,14 0,78 0,007 0,087 0,225 0,038 
HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H 0,84 0,93 1,08 1,01 0,199 0,370 0,397 0,367 
HNRH3_HUMAN Heterogeneous nuclear ribonucleoprotein H3 0,61 0,64 1,62 1,04 0,096 0,078 0,059 0,335 
HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K 0,82 0,88 1,08 0,95 0,105 0,168 0,248 0,190 
HNRPL_HUMAN Heterogeneous nuclear ribonucleoprotein L 0,50 0,51 1,57 0,80 0,116 0,115 0,001 0,299 






















HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q 1,61 0,97 1,15 1,11 0,113 0,471 0,292 0,315 
HNRPR_HUMAN Heterogeneous nuclear ribonucleoprotein R 0,68 0,70 1,57 1,10 0,009 0,004 0,000 0,052 
HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U 0,10 0,10 1,26 0,13 0,180 0,182 0,023 0,189 
HNRL2_HUMAN Heterogeneous nuclear ribonucleoprotein U-like protein 2 0,82 0,78 1,70 1,32 0,146 0,164 0,019 0,058 
ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 1,35 1,39 1,11 1,55 0,259 0,239 0,230 0,230 
HNRPC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 0,74 0,76 1,49 1,13 0,009 0,020 0,014 0,188 
HXK1_HUMAN Hexokinase-1 1,25 1,20 1,17 1,40 0,288 0,362 0,096 0,220 
HMGB1_HUMAN High mobility group protein B1 0,64 0,67 1,16 0,78 0,016 0,075 0,238 0,049 
HMGB2_HUMAN High mobility group protein B2 0,63 0,99 1,43 1,42 0,160 0,489 0,235 0,215 
HMGA1_HUMAN High mobility group protein HMG-I/HMG-Y 1,00 1,00 1,59 1,59 0,495 0,497 0,052 0,268 
SYHC_HUMAN Histidine--tRNA ligase, cytoplasmic 0,94 0,63 1,26 0,80 0,467 
   HDAC2_HUMAN Histone deacetylase 2 0,98 1,13 1,31 1,48 0,460 0,222 0,088 0,162 
H10_HUMAN Histone H1.0 0,57 0,70 1,08 0,76 0,316 
H12_HUMAN Histone H1.2 0,68 0,92 1,14 1,05 0,183 
H15_HUMAN Histone H1.5 1,29 1,43 1,35 1,92 0,287 0,207 0,030 0,067 
H1X_HUMAN Histone H1x 0,75 0,95 1,09 1,04 0,004 0,323 0,229 0,363 
H2A1H_HUMAN Histone H2A type 1-H 1,13 1,22 1,37 1,67 0,392 0,326 0,013 0,103 
H2B1K_HUMAN Histone H2B type 1-K 0,95 1,05 1,02 1,07 0,410 0,387 0,325 0,343 
H31_HUMAN Histone H3.1 0,93 0,92 1,47 1,36 0,309 0,232 0,010 0,031 
H4_HUMAN Histone H4 1,13 1,31 1,35 1,76 0,403 0,279 0,050 0,104 
RBBP4_HUMAN Histone-binding protein RBBP4 0,91 0,79 1,07 0,84 0,429 
HYOU1_HUMAN Hypoxia up-regulated protein 1 0,99 1,07 1,29 1,38 0,486 0,318 0,028 0,007 
IMA2_HUMAN Importin subunit alpha-2 1,18 0,90 0,82 0,74 0,117 0,243 0,123 0,036 
IMA4_HUMAN Importin subunit alpha-4 1,48 1,62 0,53 0,86 0,154 0,150 0,051 
IMB1_HUMAN Importin subunit beta-1 0,96 0,90 1,16 1,05 0,408 0,312 0,187 0,430 
IPYR_HUMAN Inorganic pyrophosphatase 2,74 2,31 0,69 1,59 0,005 0,001 0,153 0,202 
ITB1_HUMAN Integrin beta-1 0,67 0,96 1,20 1,15 0,070 0,457 0,335 0,268 
ILF2_HUMAN Interleukin enhancer-binding factor 2 0,76 0,79 1,52 1,20 0,011 0,033 0,012 0,112 
ILF3_HUMAN Interleukin enhancer-binding factor 3 1,11 1,11 1,31 1,45 0,316 0,311 0,010 0,055 
IDHP_HUMAN Isocitrate dehydrogenase [NADP, mitochondrial 1,76 0,88 3,09 2,72 
  
0,050 
 NADAP_HUMAN Kanadaptin 0,82 1,16 0,85 0,99 0,370 0,335 
KTN1_HUMAN Kinectin 1,02 0,95 1,16 1,11 0,430 0,315 0,077 0,368 
LAP2B_HUMAN Lamina-associated polypeptide 2, isoforms beta/gamma 0,80 0,57 1,94 1,10 0,044 0,129 0,041 0,018 
LMNB1_HUMAN Lamin-B1 1,04 1,16 1,30 1,52 0,428 0,262 0,041 0,047 
LMNB2_HUMAN Lamin-B2 0,12 0,12 1,59 0,20 0,169 0,170 0,012 0,189 
LAMB1_HUMAN Laminin subunit beta-1 0,69 0,86 1,14 0,98 0,068 0,035 0,200 0,428 
LAMC1_HUMAN Laminin subunit gamma-1 0,95 1,12 0,86 0,97 0,428 0,284 0,207 0,327 
LARP7_HUMAN La-related protein 7 1,07 1,14 1,02 1,16 0,010 
LETM1_HUMAN LETM1 and EF-hand domain-containing protein 1, mitochondrial 1,20 1,22 0,83 1,01 0,208 0,260 0,228 0,226 
LPPRC_HUMAN Leucine-rich PPR motif-containing protein, mitochondrial 1,08 1,14 1,24 1,42 0,184 0,072 0,044 0,035 
LRC59_HUMAN Leucine-rich repeat-containing protein 59 0,81 0,84 1,10 0,93 0,068 0,113 0,179 0,142 
LMF2_HUMAN Lipase maturation factor 2 1,33 0,086 






















LDHB_HUMAN L-lactate dehydrogenase B chain 0,82 2,73 0,27 0,73 0,285 0,222 0,190 0,222 
S27A3_HUMAN Long-chain fatty acid transport protein 3 0,90 1,04 1,25 1,30 0,277 
  
0,035 
ACSL3_HUMAN Long-chain-fatty-acid--CoA ligase 3 1,23 1,37 1,42 1,94 0,053 0,038 0,098 0,045 




   
0,263 
 MRP_HUMAN MARCKS-related protein 1,71 1,59 1,01 1,61 0,006 0,030 0,475 0,042 
MATR3_HUMAN Matrin-3 0,95 0,97 1,31 1,28 0,294 0,378 0,013 0,054 
PGRC1_HUMAN Membrane-associated progesterone receptor component 1 0,75 0,57 1,74 1,00 0,216 0,087 0,083 0,425 
MAP1B_HUMAN Microtubule-associated protein 1B 1,13 1,20 1,08 1,29 0,209 0,146 0,258 0,073 
MAP4_HUMAN Microtubule-associated protein 4 2,10 1,24 0,76 0,94 0,131 0,201 0,100 0,335 
MTCH2_HUMAN Mitochondrial carrier homolog 2 0,87 0,82 1,54 1,26 0,064 0,021 0,001 0,015 
TOM70_HUMAN Mitochondrial import receptor subunit TOM70 0,99 0,97 1,90 1,83 
 
0,471 0,029 0,128 
IMMT_HUMAN Mitochondrial inner membrane protein 0,92 0,82 1,35 1,11 0,267 0,220 0,071 0,347 
BUB3_HUMAN Mitotic checkpoint protein BUB3 1,20 1,19 1,27 1,52 0,041 
MOT1_HUMAN Monocarboxylate transporter 1 0,70 0,74 2,50 1,84 0,042 
  
0,006 
MDR1_HUMAN Multidrug resistance protein 1 1,16 0,88 1,72 1,52 
 
0,362 0,081 
 MRP1_HUMAN Multidrug resistance-associated protein 1 1,78 1,36 0,244 
PUR6_HUMAN Multifunctional protein ADE2 0,91 0,75 1,09 0,81 0,327 0,063 0,265 0,118 
MBB1A_HUMAN Myb-binding protein 1A 0,74 1,01 1,68 1,71 0,280 0,482 0,140 0,257 





MYADM_HUMAN Myeloid-associated differentiation marker 0,80 1,21 0,97 1,17 0,252 0,300 0,424 0,221 
ML12A_HUMAN Myosin regulatory light chain 12A 1,80 1,25 0,60 0,75 0,193 
  
0,086 
MYH10_HUMAN Myosin-10 0,88 0,91 0,83 0,75 0,270 0,407 0,297 0,085 
MYH9_HUMAN Myosin-9 1,61 1,33 1,07 1,42 0,057 0,286 0,415 0,388 
MARCS_HUMAN Myristoylated alanine-rich C-kinase substrate 1,13 1,18 1,56 1,84 0,369 0,329 0,002 0,048 
NNTM_HUMAN NAD(P) transhydrogenase, mitochondrial 0,98 0,92 1,06 0,97 0,474 0,374 0,387 0,238 
NDUA7_HUMAN NADH dehydrogenase [ubiquinone 1 alpha subcomplex subunit 7 0,74 0,82 1,43 1,17 0,032 0,000 0,005 0,034 
NDUS3_HUMAN NADH dehydrogenase [ubiquinone iron-sulfur protein 3, mitochondrial 0,70 0,82 1,16 0,95 0,015 
NDUS1_HUMAN NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 1,23 0,71 3,48 2,47 0,395 0,027 0,013 0,022 
NACA_HUMAN Nascent polypeptide-associated complex subunit alpha 0,91 0,91 0,82 0,75 0,199 0,089 0,103 0,060 
NEST_HUMAN Nestin 1,86 1,27 1,24 1,58 0,071 0,326 0,269 0,232 
NCAM1_HUMAN Neural cell adhesion molecule 1 0,89 1,83 1,62 2,96 0,222 0,239 0,175 0,144 
VGF_HUMAN Neurosecretory protein VGF 1,18 1,78 1,21 2,16 0,162 0,049 0,236 0,058 
GANAB_HUMAN Neutral alpha-glucosidase AB 0,90 0,90 1,08 0,97 0,288 0,275 0,237 0,327 
AAAT_HUMAN Neutral amino acid transporter B(0) 2,19 0,009 
NH2L1_HUMAN NHP2-like protein 1 1,89 1,71 1,21 2,07 0,037 0,092 0,299 0,063 
HMGN1_HUMAN Non-histone chromosomal protein HMG-14 0,45 0,63 2,18 1,37 0,029 0,037 0,002 0,019 
NONO_HUMAN Non-POU domain-containing octamer-binding protein 1,08 1,17 1,25 1,47 0,316 0,119 0,050 0,031 
NLTP_HUMAN Non-specific lipid-transfer protein 0,70 0,93 0,96 0,90 0,082 0,339 0,406 0,446 
NASP_HUMAN Nuclear autoantigenic sperm protein 0,09 0,10 0,98 0,10 0,184 0,185 0,398 0,186 
NUMA1_HUMAN Nuclear mitotic apparatus protein 1 0,82 1,39 0,66 0,92 0,357 0,330 0,271 0,261 
NU107_HUMAN Nuclear pore complex protein Nup107 1,13 1,10 1,75 1,92 0,062 






















NUP50_HUMAN Nuclear pore complex protein Nup50 1,07 0,97 1,59 1,54 0,311 
  
0,030 
NUP88_HUMAN Nuclear pore complex protein Nup88 
  
1,28 
   
0,218 
 NUP93_HUMAN Nuclear pore complex protein Nup93 0,98 0,89 1,41 1,25 0,456 0,218 0,018 0,066 
NUP62_HUMAN Nuclear pore glycoprotein p62 
  
2,54 
   
0,190 
 YBOX1_HUMAN Nuclease-sensitive element-binding protein 1 0,58 0,75 1,34 1,00 0,006 0,085 0,267 0,497 
NOC3L_HUMAN Nucleolar complex protein 3 homolog 1,40 1,34 0,90 1,20 0,344 
NOP56_HUMAN Nucleolar protein 56 1,30 1,44 0,85 1,22 0,264 0,284 0,390 0,258 
NOP58_HUMAN Nucleolar protein 58 1,30 1,24 1,36 1,68 0,026 0,254 0,124 0,003 
DDX21_HUMAN Nucleolar RNA helicase 2 0,61 0,72 1,74 1,26 0,024 0,063 0,003 0,050 
NUCL_HUMAN Nucleolin 0,97 1,01 1,01 1,02 0,275 0,459 0,461 0,306 
NPM_HUMAN Nucleophosmin 1,01 0,98 1,29 1,26 0,477 0,457 0,055 0,302 
TPR_HUMAN Nucleoprotein TPR 0,75 0,76 1,45 1,10 0,105 0,025 0,011 0,179 
NDKA_HUMAN Nucleoside diphosphate kinase A 0,83 0,93 1,00 0,93 0,026 0,204 0,493 0,101 
BPTF_HUMAN Nucleosome-remodeling factor subunit BPTF 0,64 0,82 1,20 0,99 0,055 0,239 0,130 0,400 
PALM_HUMAN Paralemmin-1 0,78 0,99 1,37 1,36 0,112 0,484 0,053 0,250 
PSIP1_HUMAN PC4 and SFRS1-interacting protein 1,20 1,23 1,36 1,66 0,212 0,192 0,045 0,032 
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A 0,70 0,70 0,50 0,35 0,334 0,320 0,073 0,178 
PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B 0,75 0,87 1,35 1,17 0,078 0,123 0,035 0,194 
FKBP8_HUMAN Peptidyl-prolyl cis-trans isomerase FKBP8 0,52 0,47 2,21 1,05 
 
0,004 0,052 0,431 
PRDX1_HUMAN Peroxiredoxin-1 0,99 0,85 1,06 0,90 0,472 0,091 0,269 0,052 
PRDX5_HUMAN Peroxiredoxin-5, mitochondrial 0,55 0,49 1,16 0,57 0,317 0,246 0,283 0,227 
DHB4_HUMAN Peroxisomal multifunctional enzyme type 2 1,19 1,05 0,75 0,79 0,179 0,360 0,014 0,090 
PHF6_HUMAN PHD finger protein 6 0,65 0,77 1,10 0,85 
  
0,379 
 MPCP_HUMAN Phosphate carrier protein, mitochondrial 0,80 0,87 1,15 1,00 0,070 0,156 0,236 0,420 
PGAM1_HUMAN Phosphoglycerate mutase 1 0,09 0,21 0,47 0,10 0,145 0,248 0,292 0,243 
PININ_HUMAN Pinin 0,98 0,96 1,40 1,35 0,419 0,410 0,080 0,413 
PLEC_HUMAN Plectin 1,11 1,16 1,26 1,46 
 
0,188 0,057 0,221 
POGZ_HUMAN Pogo transposable element with ZNF domain 0,89 0,94 1,44 1,36 0,082 0,293 0,011 0,012 
PARP1_HUMAN Poly [ADP-ribose polymerase 1 1,03 0,99 0,96 0,96 0,421 0,476 0,380 0,460 
PCBP1_HUMAN Poly(rC)-binding protein 1 0,59 0,67 0,86 0,58 0,150 0,177 0,251 0,176 
PUF60_HUMAN Poly(U)-binding-splicing factor PUF60 0,56 0,03 1,40 0,04 0,354 0,246 0,234 0,249 
PABP1_HUMAN Polyadenylate-binding protein 1 1,15 1,06 1,11 1,18 0,335 0,414 0,218 0,176 
PABP2_HUMAN Polyadenylate-binding protein 2 
 
1,29 0,86 1,11 
 
0,405 0,422 0,373 
PTBP1_HUMAN Polypyrimidine tract-binding protein 1 1,00 0,85 1,42 1,20 0,496 0,284 0,063 0,462 
UBC_HUMAN Polyubiquitin-C 0,56 0,68 1,15 0,78 0,045 
LMNA_HUMAN Prelamin-A/C 0,89 0,98 1,31 1,29 0,049 0,421 0,027 0,053 
PRP19_HUMAN Pre-mRNA-processing factor 19 1,16 1,27 0,90 1,15 0,131 0,004 0,121 0,127 
PRP6_HUMAN Pre-mRNA-processing factor 6 0,84 1,47 1,24 0,098 
PRP8_HUMAN Pre-mRNA-processing-splicing factor 8 0,97 0,98 1,33 1,30 0,345 0,444 0,038 0,052 
DDX17_HUMAN Probable ATP-dependent RNA helicase DDX17 0,72 0,73 1,03 0,76 0,046 0,151 0,463 0,108 
DDX5_HUMAN Probable ATP-dependent RNA helicase DDX5 0,76 0,92 1,42 1,30 0,221 0,229 0,016 0,046 
AT131_HUMAN Probable cation-transporting ATPase 13A1 1,06 0,69 1,45 1,00 0,420 0,077 0,008 0,494 






















PHB_HUMAN Prohibitin 0,80 0,86 1,13 0,98 0,172 0,214 0,245 0,256 
PHB2_HUMAN Prohibitin-2 0,95 0,92 0,96 0,88 0,394 0,366 0,422 0,247 
PA2G4_HUMAN Proliferation-associated protein 2G4 1,27 1,33 1,00 1,33 0,483 
P4HA1_HUMAN Prolyl 4-hydroxylase subunit alpha-1 1,07 0,98 0,91 0,89 0,317 0,475 0,343 0,225 
PSME1_HUMAN Proteasome activator complex subunit 1 0,76 1,08 0,45 0,49 0,336 0,433 0,103 0,416 
PSA1_HUMAN Proteasome subunit alpha type-1 0,85 0,90 0,81 0,72 0,062 0,029 0,129 0,055 
PSA5_HUMAN Proteasome subunit alpha type-5 1,11 1,11 0,88 0,98 0,265 0,272 0,186 0,446 
PSA7_HUMAN Proteasome subunit alpha type-7 0,79 0,75 1,05 0,79 
  
0,280 
 ANM1_HUMAN Protein arginine N-methyltransferase 1 2,90 2,01 0,32 0,65 0,077 0,004 0,004 0,107 
CNPY2_HUMAN Protein canopy homolog 2 0,72 0,77 1,33 1,02 0,120 0,042 0,055 0,413 
DEK_HUMAN Protein DEK 1,89 1,77 1,28 2,26 
  
0,356 
 PDIA1_HUMAN Protein disulfide-isomerase 1,20 1,15 1,43 1,63 0,089 0,057 0,002 0,005 
PDIA3_HUMAN Protein disulfide-isomerase A3 1,02 1,08 1,17 1,27 0,476 0,393 0,021 0,202 
PDIA4_HUMAN Protein disulfide-isomerase A4 0,65 0,54 1,34 0,73 0,143 0,092 0,020 0,195 
PDIA6_HUMAN Protein disulfide-isomerase A6 0,38 0,47 1,39 0,66 0,172 0,208 0,017 0,294 
TMX3_HUMAN Protein disulfide-isomerase TMX3 0,63 0,83 1,36 1,13 0,038 0,207 0,048 0,161 
LMAN1_HUMAN Protein ERGIC-53 1,46 1,01 1,46 0,491 
K1967_HUMAN Protein KIAA1967 0,88 0,94 1,43 1,35 0,186 0,335 0,077 0,305 
LYRIC_HUMAN Protein LYRIC 0,95 0,64 1,23 0,79 0,220 0,187 0,307 0,133 
SCAFB_HUMAN Protein SCAF11 
 
0,66 0,97 0,64 
 
0,014 
  SON_HUMAN Protein SON 1,86 2,12 1,40 2,96 0,027 
DHX15_HUMAN Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 1,04 0,84 1,37 1,15 0,350 0,237 0,077 0,337 
RAB1C_HUMAN Putative Ras-related protein Rab-1C 1,03 0,84 1,76 1,47 
  
0,024 
 NOP2_HUMAN Putative ribosomal RNA methyltransferase NOP2 0,72 0,63 1,77 1,11 0,049 0,060 0,038 0,330 
LC7L2_HUMAN Putative RNA-binding protein Luc7-like 2 1,31 0,81 0,76 0,61 
  
0,361 
 RRMJ3_HUMAN Putative rRNA methyltransferase 3 1,02 0,97 1,21 1,17 0,424 0,453 0,182 0,469 
P5CR2_HUMAN Pyrroline-5-carboxylate reductase 2 
  
1,37 
   
0,084 
 ODPB_HUMAN Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 0,87 0,80 1,10 0,88 0,116 0,061 0,367 0,247 
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 0,60 1,25 0,71 0,89 0,123 0,356 0,293 0,315 
GDIB_HUMAN Rab GDP dissociation inhibitor beta 0,45 1,15 0,24 0,28 
 
0,427 0,179 0,133 
RANB3_HUMAN Ran-binding protein 3 0,56 0,14 0,207 
RAB14_HUMAN Ras-related protein Rab-14 0,96 0,60 1,48 0,89 0,412 0,103 0,112 0,360 
RAB1A_HUMAN Ras-related protein Rab-1A 0,34 0,59 1,72 1,02 
  
0,229 
 RAB2A_HUMAN Ras-related protein Rab-2A 8,53 1,34 0,77 1,03 0,246 0,291 0,261 0,241 
RAB2B_HUMAN Ras-related protein Rab-2B 1,16 1,16 0,92 1,06 0,030 0,238 0,285 0,168 
RAB3A_HUMAN Ras-related protein Rab-3A 1,00 1,14 1,08 1,23 0,488 0,136 0,233 0,061 
RAB5C_HUMAN Ras-related protein Rab-5C 1,24 1,12 1,01 1,13 0,019 0,131 0,477 0,263 
RAB7A_HUMAN Ras-related protein Rab-7a 0,80 0,99 0,90 0,88 0,114 0,473 0,312 0,447 
F213A_HUMAN Redox-regulatory protein FAM213A 0,91 0,99 1,38 1,36 
  
0,057 
 RSF1_HUMAN Remodeling and spacing factor 1 0,83 0,91 1,12 1,03 0,173 0,146 0,092 0,457 
RTN4_HUMAN Reticulon-4 4,35 2,35 1,87 4,39 
 
0,286 0,271 0,227 
RTL1_HUMAN Retrotransposon-like protein 1 0,90 0,73 0,96 0,70 0,347 0,116 0,425 0,193 























RL1D1_HUMAN Ribosomal L1 domain-containing protein 1 1,27 1,21 1,11 1,33 0,280 0,245 0,353 0,090 
BOP1_HUMAN Ribosome biogenesis protein BOP1 0,87 0,84 1,90 1,60 
  
0,020 
 RRBP1_HUMAN Ribosome-binding protein 1 0,75 0,151 
RCL1_HUMAN RNA 3'-terminal phosphate cyclase-like protein 
  
1,21 
   
0,071 
 RBMX_HUMAN RNA-binding motif protein, X chromosome 0,81 0,88 1,19 1,06 0,075 
  
0,474 
RBM14_HUMAN RNA-binding protein 14 0,87 0,95 1,08 1,03 0,127 0,260 0,340 0,398 
RBM25_HUMAN RNA-binding protein 25 1,02 1,01 1,21 1,22 0,418 0,465 0,189 0,319 
RBM39_HUMAN RNA-binding protein 39 0,78 0,84 1,61 1,36 
  
0,012 
 RBM4_HUMAN RNA-binding protein 4 0,74 0,77 1,20 0,93 0,011 
  
0,268 
RBM8A_HUMAN RNA-binding protein 8A 0,77 0,87 1,10 0,96 0,129 0,182 0,341 0,424 
FUS_HUMAN RNA-binding protein FUS 0,67 0,79 1,16 0,92 0,000 0,045 0,080 0,074 
RALY_HUMAN RNA-binding protein Raly 0,92 0,74 1,65 1,23 0,392 0,233 0,070 0,456 
FBRL_HUMAN rRNA 2'-O-methyltransferase fibrillarin 0,27 0,29 1,22 0,36 0,220 0,225 0,048 0,169 
RUVB1_HUMAN RuvB-like 1 0,09 0,12 0,51 0,06 0,233 0,239 0,070 0,164 
RUVB2_HUMAN RuvB-like 2 1,07 0,72 0,87 0,62 0,412 
   SARNP_HUMAN SAP domain-containing ribonucleoprotein 0,78 1,03 0,90 0,92 0,058 0,457 0,298 0,199 
AT2A2_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 1,30 1,03 1,24 1,28 0,210 0,454 0,028 0,156 
SAFB1_HUMAN Scaffold attachment factor B1 0,77 0,58 1,71 1,00 0,077 0,004 0,058 0,495 
SCFD1_HUMAN Sec1 family domain-containing protein 1 
  
1,20 
   
0,174 
 SCAM1_HUMAN Secretory carrier-associated membrane protein 1 
  
0,87 
   
0,216 
 SCAM3_HUMAN Secretory carrier-associated membrane protein 3 1,57 1,40 0,81 1,13 0,055 0,102 0,267 0,140 
SEPT2_HUMAN Septin-2 0,69 0,76 1,28 0,97 0,138 0,210 0,059 0,453 
SEPT6_HUMAN Septin-6 0,93 1,05 0,94 0,99 0,432 0,451 0,410 0,437 
SEPT7_HUMAN Septin-7 0,95 0,94 1,03 0,97 0,298 0,260 0,467 0,353 
SEPT9_HUMAN Septin-9 1,15 0,85 1,03 0,88 0,141 0,220 0,422 0,070 
SRRM1_HUMAN Serine/arginine repetitive matrix protein 1 0,98 1,17 1,14 1,33 
  
0,296 
 SRRM2_HUMAN Serine/arginine repetitive matrix protein 2 0,88 0,95 0,86 0,82 0,117 0,297 0,182 0,110 
SRSF1_HUMAN Serine/arginine-rich splicing factor 1 0,99 1,13 0,86 0,98 0,479 0,336 0,215 0,462 
SRSF7_HUMAN Serine/arginine-rich splicing factor 7 1,54 1,30 1,13 1,47 0,258 
   
2AAA_HUMAN 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha 
isoform 0,44 0,67 1,54 1,03 0,032 0,185 0,096 0,432 
PP1A_HUMAN Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 1,19 1,14 1,33 1,52 0,428 0,448 0,270 0,333 
STRAP_HUMAN Serine-threonine kinase receptor-associated protein 3,16 2,74 0,96 2,64 
  
0,467 
 SERPH_HUMAN Serpin H1 0,75 0,82 1,22 0,99 0,068 0,163 0,229 0,369 
SRRT_HUMAN Serrate RNA effector molecule homolog 0,75 1,17 0,101 0,441 
SFXN1_HUMAN Sideroflexin-1 1,11 0,93 1,23 1,14 0,288 0,274 0,148 0,301 
SPCS3_HUMAN Signal peptidase complex subunit 3 0,86 1,01 1,19 1,20 0,331 0,489 0,117 
 SRP14_HUMAN Signal recognition particle 14 kDa protein 3,25 3,35 1,58 5,27 0,024 0,017 0,201 0,049 
SRP09_HUMAN Signal recognition particle 9 kDa protein 1,34 0,98 0,88 0,86 0,323 0,366 0,302 0,325 
SRPRB_HUMAN Signal recognition particle receptor subunit beta 1,02 0,97 1,17 1,14 0,415 0,405 0,175 0,322 
SSBP_HUMAN Single-stranded DNA-binding protein, mitochondrial 0,81 0,75 1,09 0,82 0,104 0,159 0,369 0,144 
PDS5A_HUMAN Sister chromatid cohesion protein PDS5 homolog A 0,62 0,71 0,86 0,61 0,135 0,142 

























SMD1_HUMAN Small nuclear ribonucleoprotein Sm D1 0,33 0,47 1,12 0,53 0,198 0,242 0,102 0,180 
SMD2_HUMAN Small nuclear ribonucleoprotein Sm D2 0,60 0,96 0,75 0,72 0,137 0,418 0,190 0,385 
SMD3_HUMAN Small nuclear ribonucleoprotein Sm D3 0,78 0,85 1,31 1,11 0,147 0,188 0,257 0,461 
SUMO2_HUMAN Small ubiquitin-related modifier 2 
 
0,70 1,32 0,93 
  
0,078 
 AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1 0,79 0,83 1,30 1,07 0,017 0,156 0,057 0,175 
SPTA2_HUMAN Spectrin alpha chain, brain 0,68 0,76 1,48 1,12 0,146 0,214 0,012 0,337 
SPTB2_HUMAN Spectrin beta chain, brain 1 0,98 1,08 1,49 1,62 0,395 0,322 0,012 0,006 
SKP1_HUMAN S-phase kinase-associated protein 1 0,79 0,93 1,19 1,10 
  
0,105 
 SGPL1_HUMAN Sphingosine-1-phosphate lyase 1 0,91 0,92 0,98 0,91 0,068 0,066 0,356 
 SF3A1_HUMAN Splicing factor 3A subunit 1 0,75 0,76 1,30 0,99 0,138 0,082 0,105 0,353 
SF3B1_HUMAN Splicing factor 3B subunit 1 0,73 0,59 1,73 1,02 0,173 0,145 0,049 0,473 
SF3B2_HUMAN Splicing factor 3B subunit 2 0,79 0,77 1,41 1,08 0,129 0,105 0,057 0,433 
SF3B3_HUMAN Splicing factor 3B subunit 3 1,36 0,96 1,06 1,01 0,231 0,382 0,373 0,471 
SF3B5_HUMAN Splicing factor 3B subunit 5 0,71 0,87 1,45 1,26 0,097 0,325 0,193 0,136 
U2AF2_HUMAN Splicing factor U2AF 65 kDa subunit 0,70 0,79 1,15 0,91 0,094 0,083 0,200 0,280 
SFPQ_HUMAN Splicing factor, proline- and glutamine-rich 1,20 1,21 1,19 1,45 0,346 0,334 0,050 0,269 
SRC8_HUMAN Src substrate cortactin 0,98 1,05 1,23 1,29 0,296 
SND1_HUMAN Staphylococcal nuclease domain-containing protein 1 0,86 0,84 0,95 0,80 0,001 0,016 0,317 0,070 
STMN1_HUMAN Stathmin 0,40 0,46 1,64 0,76 0,002 
  
0,035 
STML2_HUMAN Stomatin-like protein 2 1,16 1,01 1,08 1,09 0,212 0,477 0,351 0,446 
GRP75_HUMAN Stress-70 protein, mitochondrial 0,96 0,92 1,32 1,22 0,270 0,186 0,019 0,094 
STIP1_HUMAN Stress-induced-phosphoprotein 1 5,99 3,53 0,36 1,27 
 
0,206 0,157 0,361 
SMC1A_HUMAN Structural maintenance of chromosomes protein 1A 1,12 1,16 0,93 1,08 0,168 
   SMRC1_HUMAN SWI/SNF complex subunit SMARCC1 0,79 0,89 1,32 1,18 0,239 0,136 0,373 





SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 0,81 0,87 1,56 1,35 0,115 0,120 0,033 0,116 
SMRD1_HUMAN 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily D member 1 0,74 0,81 1,30 1,06 0,065 0,118 0,049 0,257 
SMCA5_HUMAN 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily A member 5 1,02 0,97 1,37 1,33 0,477 0,463 0,092 0,394 
VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog 1,40 1,04 1,11 1,15 0,339 0,479 0,306 0,434 
SYNP2_HUMAN Synaptopodin-2 1,09 1,13 0,91 1,03 0,322 0,297 0,321 0,119 
TADBP_HUMAN TAR DNA-binding protein 43 1,01 1,03 1,17 1,20 0,473 0,438 0,189 0,351 
TCPA_HUMAN T-complex protein 1 subunit alpha 1,06 1,61 0,60 0,97 0,453 0,107 0,079 0,290 
TCPB_HUMAN T-complex protein 1 subunit beta 1,16 0,78 1,01 0,79 0,310 0,026 0,459 0,022 
TCPD_HUMAN T-complex protein 1 subunit delta 0,53 0,39 0,64 0,25 0,307 0,255 0,182 0,218 
TCPZ_HUMAN T-complex protein 1 subunit zeta 0,92 1,11 0,34 0,37 0,428 0,432 0,069 0,378 
THIO_HUMAN Thioredoxin 1,33 1,20 0,51 0,62 0,314 0,352 0,164 
TXD12_HUMAN Thioredoxin domain-containing protein 12 0,52 0,46 1,86 0,85 0,051 0,077 0,043 0,141 
TXND5_HUMAN Thioredoxin domain-containing protein 5 1,10 0,78 1,65 1,28 
  
0,097 
 PRDX3_HUMAN Thioredoxin-dependent peroxide reductase, mitochondrial 0,85 0,86 1,20 1,03 0,038 0,033 0,139 0,427 
TMX1_HUMAN Thioredoxin-related transmembrane protein 1 0,96 0,438 
























THOC2_HUMAN THO complex subunit 2 0,98 0,99 1,15 1,14 0,410 0,462 0,139 0,183 
THOC4_HUMAN THO complex subunit 4 0,83 0,86 1,19 1,02 0,107 0,242 0,228 0,397 
TR150_HUMAN Thyroid hormone receptor-associated protein 3 0,96 1,16 1,11 1,29 0,389 0,102 0,102 0,029 
TOIP1_HUMAN Torsin-1A-interacting protein 1 0,92 1,02 1,40 1,43 0,332 0,474 0,043 0,077 
TIF1B_HUMAN Transcription intermediary factor 1-beta 0,43 0,71 0,74 0,53 0,001 0,162 0,221 0,025 
ATRX_HUMAN Transcriptional regulator ATRX 0,91 0,68 1,15 0,79 0,352 
TFR1_HUMAN Transferrin receptor protein 1 1,12 1,11 1,01 1,13 0,273 0,355 0,473 0,481 





TERA_HUMAN Transitional endoplasmic reticulum ATPase 13,31 1,56 0,59 0,92 0,237 0,031 0,007 0,094 
TMED9_HUMAN Transmembrane emp24 domain-containing protein 9 0,70 0,80 1,25 1,00 0,052 0,153 0,087 0,211 
TCOF_HUMAN Treacle protein 0,81 0,87 1,04 0,91 
 
0,210 0,423 0,276 
ECHA_HUMAN Trifunctional enzyme subunit alpha, mitochondrial 1,15 1,36 1,30 1,78 0,110 0,054 0,058 0,062 
ECHB_HUMAN Trifunctional enzyme subunit beta, mitochondrial 0,99 1,47 1,22 1,80 0,411 0,134 0,168 0,008 
TPIS_HUMAN Triosephosphate isomerase 3,04 1,52 0,10 0,15 0,200 0,325 0,081 0,474 
TPM3_HUMAN Tropomyosin alpha-3 chain 0,85 0,93 0,89 0,82 0,169 
   TPM4_HUMAN Tropomyosin alpha-4 chain 0,98 22,10 0,05 1,12 
 
0,211 0,137 0,247 
TBA1B_HUMAN Tubulin alpha-1B chain 1,27 0,81 1,03 0,040 
TBB5_HUMAN Tubulin beta chain 0,71 0,71 1,08 0,77 0,096 0,147 0,363 0,151 
TBB2B_HUMAN Tubulin beta-2B chain 1,04 1,53 0,91 1,38 0,452 0,189 0,404 0,160 
TBB3_HUMAN Tubulin beta-3 chain 0,77 1,03 0,69 0,72 
  
0,163 
 TPD54_HUMAN Tumor protein D54 0,73 0,76 0,92 0,69 0,131 0,123 0,326 0,121 
TP53B_HUMAN Tumor suppressor p53-binding protein 1 
  
0,83 
   
0,145 
 BAZ1B_HUMAN Tyrosine-protein kinase BAZ1B 1,04 1,20 0,85 1,02 0,165 0,148 0,211 
 RU2A_HUMAN U2 small nuclear ribonucleoprotein A' 0,96 1,22 0,83 1,02 0,437 0,148 0,208 0,400 
SR140_HUMAN U2 snRNP-associated SURP motif-containing protein 0,54 0,61 1,97 1,20 0,107 
   U520_HUMAN U5 small nuclear ribonucleoprotein 200 kDa helicase 0,84 0,86 1,10 0,94 0,088 0,118 0,273 0,331 
LSM2_HUMAN U6 snRNA-associated Sm-like protein LSm2 
  
1,24 
   
0,011 
 COQ6_HUMAN Ubiquinone biosynthesis monooxygenase COQ6 0,74 0,79 0,91 0,72 0,142 0,167 0,176 
UCHL1_HUMAN Ubiquitin carboxyl-terminal hydrolase isozyme L1 1,24 1,55 0,33 0,51 0,339 0,083 0,002 0,031 
MYO1B_HUMAN Unconventional myosin-Ib 0,98 1,15 1,47 1,70 0,374 0,230 0,029 0,008 
USMG5_HUMAN Up-regulated during skeletal muscle growth protein 5 0,78 0,85 1,07 0,91 0,405 
SYVC_HUMAN Valine--tRNA ligase 
  
0,67 
   
0,309 
 VAPB_HUMAN Vesicle-associated membrane protein-associated protein B/C 0,79 1,29 0,94 1,21 0,156 0,343 0,443 0,141 
SC22B_HUMAN Vesicle-trafficking protein SEC22b 1,31 1,42 0,96 1,36 0,121 
  
0,058 
VIME_HUMAN Vimentin 1,21 1,01 1,06 1,08 0,171 0,479 0,371 0,457 
VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 0,79 0,78 1,28 1,00 0,008 0,013 0,007 0,488 
VDAC2_HUMAN Voltage-dependent anion-selective channel protein 2 0,79 0,81 1,24 1,00 0,087 0,077 0,071 0,296 
VDAC3_HUMAN Voltage-dependent anion-selective channel protein 3 0,94 0,61 3,04 1,87 0,376 0,070 0,150 0,144 
CA2D1_HUMAN Voltage-dependent calcium channel subunit alpha-2/delta-1 1,44 1,06 1,44 1,54 0,128 0,439 0,118 0,347 
XRCC5_HUMAN X-ray repair cross-complementing protein 5 1,50 1,69 0,84 1,43 0,141 0,087 0,083 0,171 
XRCC6_HUMAN X-ray repair cross-complementing protein 6 0,98 1,14 0,89 1,01 0,469 0,283 0,264 0,367 
YLPM1_HUMAN YLP motif-containing protein 1 0,67 0,61 2,01 1,23 0,012 
























ZN384_HUMAN Zinc finger protein 384 0,84 0,90 1,02 0,92 0,296 0,219 0,406 0,179 
ZRAB2_HUMAN Zinc finger Ran-binding domain-containing protein 2 0,88 0,86 1,09 0,94 0,274 0,301 0,079 0,410 
 
 
